CCDR
CANADA
COMMUNICABLE
DISEASE REPORT
canada.ca/ccdr
December 2021 - Volume 47-12
SOCIAL MEDIA RESPONSES
TO COVID-19
OVERVIEW
Hepatitis C epidemic in
Canada
IMPLEMENTATION SCIENCE
QUALITATIVE STUDY
505
Social media responses to
COVID-19
524
Clinical performance of ID NOW 534
with compatible SARS-CoV-2
symptoms
CCDR
CANADA
COMMUNICABLE
DISEASE REPORT
The Canada Communicable Disease Report (CCDR)
is a bilingual, peer-reviewed, open-access, online scientific journal
published by the Public Health Agency of Canada (PHAC). It
provides timely, authoritative and practical information on infectious
diseases to clinicians, public health professionals, and policy-makers
to inform policy, program development and practice.
The CCDR Editorial Board is composed of members based in
Canada, United States of America, European Union and Australia.
Board members are internationally renowned and active experts in
the fields of infectious disease, public health and clinical research.
They meet four times a year, and provide advice and guidance to the
Editor-in-Chief.
Editorial Team
Editor-in-Chief
Michel Deilgat, CD, BA, MD, MPA,
MEd, MIS (c), CCPE
CCDR Editorial Board
Members
First Nations & Indigenous
Advisor
Sarah Funnell, BSc, MD, MPH, CCFP,
FRCPC
Executive Editor
Alejandra Dubois, BSND, MSc, PhD
Junior Editor
Associate Scientific Editor
Lucie Péléja, (Honours) BSc (Psy),
MSc (Health Systems) (c)
(University of Ottawa)
Rukshanda Ahmad, MBBS, MHA
Julie Thériault, RN, BscN, MSc(PH)
Peter Uhthoff, BASc, MSc, MD
Production Editor
Wendy Patterson
Editorial Coordinator
Laura Rojas Higuera
Web Content Manager
Daniel Beck
Copy Editors
Joanna Odrowaz-Pieniazek
Pascale Salvatore, BA (Trad.)
Laura Stewart-Davis, PhD
Communications Advisor
Maya Bugorski, BA, BSocSc
Indexed
in PubMed, Directory of Open Access
(DOAJ)/Medicus
Available
in PubMed Central (full text)
Contact the Editorial
Office
ccdr-rmtc@phac-aspc.gc.ca
613.301.9930
Photo credit
The cover photo represents
SARS-CoV-2 and the response from
the social media. Image from Adobe
Stock adapted by Wendy Patterson
(https://stock.adobe.com/ca/search/
images?load_type=search&native_
visual_search=&similar_content_
id=&is_recent_search=&search_
type=usertyped&k=COVID&asset_
id=332085478).
CCDR • December 2021 • Vol. 47 No. 12
Heather Deehan, RN, BScN, MHSc
Vaccine Distribution and Logistics,
Public Health Agency of Canada,
Ottawa, Canada
Jacqueline J Gindler, MD
Centers for Disease Control and
Prevention, Atlanta, United States
Rahul Jain, MD, CCFP, MScCH
Department of Family and Community
Medicine, University of Toronto and
Sunnybrook Health Sciences Centre
Toronto, Canada
Jennifer LeMessurier, MD, MPH
Public Health and Preventive
Medicine, University of Ottawa,
Ottawa, Canada
Caroline Quach, MD, MSc, FRCPC,
FSHEA
Pediatric Infectious Diseases and
Medical Microbiologist, Centre
hospitalier universitaire Sainte-Justine,
Université de Montréal, Canada
Kenneth Scott, CD, MD, FRCPC
Internal Medicine and Adult Infectious
Diseases
Canadian Forces Health Services
Group (Retired), Ottawa, Canada
Public Health Agency of Canada
(Retired), Ottawa, Canada
ISSN SN 1481-8531 / Cat. HP3-1E-PDF / Pub. 200434
CCDR
CANADA
COMMUNICABLE
DISEASE REPORT
SOCIAL MEDIA
RESPONSES TO
COVID-19
TABLE OF CONTENTS
OVERVIEW
The hepatitis C epidemic in Canada: An overview of
recent trends in surveillance, injection drug use, harm
reduction and treatment
505
L Lourenço, M Kelly, J Tarasuk, K Stairs, M Bryson, N Popovic, J Aho
RAPID COMMUNICATION
Impact of school closures and re-openings on COVID-19
transmission
515
M El Jaouhari, R Edjoc, L Waddell, P Huston, N Atchessi, M Striha,
S Bonti-Ankomah
QUALITATIVE STUDY
Among sheeples and antivaxxers: Social media responses
to COVID-19 vaccine news posted by Canadian news
organizations, and recommendations to counter vaccine
hesitancy
524
L Tang, S Douglas, A Laila
IMPLEMENTATION SCIENCE
The PRONTO study: Clinical performance of ID NOW in
individuals with compatible SARS-CoV-2 symptoms in
walk-in centres—accelerated turnaround time for contact
tracing
534
I Goupil-Sormany, J Longtin, J Dumaresq, M Jacob-Wagner,
F Bouchard, L Romero, J Harvey, J Bestman-Smith, M Provençal,
S Beauchemin, V Richard, A-C Labbé
OUTBREAK
COVID-19 outbreak in a long-term care facility in
Kelowna, British Columbia after rollout of COVID-19
vaccine in March 2021
F Sabet, B Gauthier, M Siddiqui, A Wilmer, N Prystajecky, P Rydings,
M Andrews, S Pollock
CCDR • December 2021 • Vol. 47 No. 12
543
OVERVIEW
The hepatitis C epidemic in Canada: An overview
of recent trends in surveillance, injection drug
use, harm reduction and treatment
Lillian Lourenço1*, Marian Kelly1, Jill Tarasuk1, Kyla Stairs1, Maggie Bryson1, Nashira Popovic1,
Josephine Aho1
This work is licensed under a Creative
Commons Attribution 4.0 International
License.
Abstract
Hepatitis C continues to be a significant public health concern in Canada, with the hepatitis C
virus (HCV) responsible for more life-years lost than all other infectious diseases in Canada. An
increase in reported hepatitis C infections was observed between 2014 and 2018. Here, we
present changing epidemiological trends and discuss risk factors for hepatitis C acquisition in
Canada that may have contributed to this increase in reported hepatitis C infections, focusing
on injection drug use. We describe a decrease in the use of borrowed needles or syringes
coupled with an increase in using other used injection drug use equipment. Also, an increased
prevalence of injection drug use and use of prescription opioid and methamphetamine injection
by people who inject drugs (PWID) may be increasing the risk of HCV acquisition. At the same
time, while harm reduction coverage appears to have increased in Canada in recent years, gaps
in access and coverage remain. We also consider how direct-acting antiviral (DAA) eligibility
expansion may have affected hepatitis C rates from 2014 to 2018. Finally, we present new
surveillance trends observed in 2019 and discuss how the coronavirus disease 2019 (COVID-19)
pandemic may affect hepatitis C case counts from 2020 onwards. Continual efforts to i) enhance
hepatitis C surveillance and ii) strengthen the reach, effectiveness, and adoption of hepatitis C
prevention and treatment services across Canada are vital to reducing HCV transmission among
PWID and achieving Canada’s HCV elimination targets by 2030.
Affiliation
Public Health Agency of Canada,
Centre for Communicable
Diseases and Infection Control,
Ottawa, ON
1
*Correspondence:
lillian.lourenco@phac-aspc.gc.ca
Suggested citation: Lourenço L, Kelly M, Tarasuk J, Stairs K, Bryson M, Popovic N, Aho J. The hepatitis C
epidemic in Canada: an overview of recent trends in surveillance, injection drug use, harm reduction and
treatment. Can Commun Dis Rep 2021;47(12):561–70. https://doi.org/10.14745/ccdr.v47i12a01
Keywords: HCV, epidemiology, people who inject drugs, PWID, needle-and-syringe programs, supervised
consumption, Canadian Drugs and Substances Strategy, substance use
Introduction
Hepatitis C is a preventable and, in almost all cases, curable
liver infection. Despite this, hepatitis C is responsible for more
life-years lost than any other infectious disease in Canada (1–3).
Researchers estimate that, in 2017, at least one person was
infected with the hepatitis C virus (HCV) every hour in Canada,
and 194,500 Canadians were living with chronic hepatitis C (4).
In June 2018, the federal, provincial and territorial ministers
of health released the Pan-Canadian Sexually Transmitted and
Blood-borne Infections Framework for Action (5). The Framework
endorses the World Health Organization’s target to eliminate
viral hepatitis as a public health threat by 2030, including
achieving a 90% reduction in new cases of chronic hepatitis C
infections by 2030 (5).
Hepatitis C is a nationally notifiable disease monitored by the
Public Health Agency of Canada (PHAC). The Agency reports
annually on trends in reported hepatitis C cases overall and by
Page 505
CCDR • December 2021 • Vol. 47 No. 12
age, sex and province or territory. Surveillance data show a 14%
increase in the reported national hepatitis C rate, from 29.4 per
100,000 people in 2014 to 33.6 per 100,000 people in 2018 (6),
representing a total of acute, chronic and unspecified hepatitis C
cases. In addition, from 2014 to 2018, the reported hepatitis C
rates increased faster for females than for males (20% vs 10%
increase) (6).
This article summarizes several trends and factors that may have
influenced the rising hepatitis C rates between 2014 and 2018.
While several factors are associated with the risk of hepatitis C
acquisition, injection drug use is the most common risk factor
for new infections in Canada (7–9). In this overview, we describe
changes in injection drug use patterns and practices as well
as in harm reduction services and practices. We also consider
the impact—recent and potential—of expanding direct-acting
antiviral (DAA) eligibility on hepatitis C rates. Finally, we discuss
OVERVIEW
surveillance trends from 2018 to 2019 and the potential impact
of the coronavirus disease 2019 (COVID-19) pandemic on the
hepatitis C epidemic in Canada.
A changing landscape: Injection drug
use on the rise
An estimated 1% of Canada’s population have ever injected
drugs (10) and about 0.3% were using injection drugs in
2014 (11). PHAC estimated that people who inject drugs
(PWID) made up almost half of those who ever had a hepatitis
C infection in 2017 (4). Based on data from 2000 to 2016, PWID
make up between 60% and 85% of all new HCV infections
in Canada (7–9). The sharing of needles, syringes and other
injection equipment appears to be the primary driver of HCV
transmission in Canada today (7–9). A modelling study estimated
that the PWID population in Canada increased by 32% between
2011 and 2016 (11).
Injection drug use, social determinants of
health and key populations
Injection drug use is associated with a history of trauma
and family instability (12,13), transactional sex (12,13),
food insecurity (14,15), incarceration (12,16), insecure
housing (12,17–23), low income (12,17,20,24), lower levels
of education (12), systemic discrimination (12,24) and
unemployment (21,23,25).
Indigenous peoples bear a disproportionate burden of
substance use disorders and associated harms in Canada, a
situation that is associated with structural injustices rooted
in colonization. Available evidence suggests Indigenous
peoples are overrepresented among PWID in several regions
in Canada (12,26–29). Estimates show that Indigenous youth
(aged 24 years and younger) make up between 70% and 80% of
new HCV infections among young PWID in Canada (30–32).
Gay, bisexual and other men who have sex with men (gbMSM)
are an emerging population at risk for hepatitis C (33,34). An
estimated 5% of gbMSM have a past or current HCV infection
(35). Injection drug use appears to be the leading risk factor
for hepatitis C in this population in Canada (33), though sexual
transmission in the context of certain sexual practices associated
with a risk of exposure via blood has also been known to occur,
particularly among gbMSM living with HIV (36–38).
Understanding evolving behaviours related to HCV acquisition
is essential to understanding the evolving hepatitis C epidemic
among PWID.
Increased prevalence of prescription opioid
injection and methamphetamine use among
people who inject drugs
Substance use patterns in North America have been described
in terms of “twin epidemics,” comprising the opioid crisis,
which has been responsible for a significant burden of morbidity
and mortality among PWID in Canada over the past two
decades (39), and an apparent resurgence of psychostimulant
use and related harms since 2017 (40). In the most recent
bio-behavioural Tracks survey of PWID in Canada (Phase 4:
2017–2019), the five most frequently reported injected drugs
(in the six months before the survey) were cocaine (60.0%),
hydromorphone (50.1%), methamphetamine (43.5%), morphine
(41.6%) and heroin (32.4%). Of note, hydromorphone, morphine
and heroin are all opioids (12).
Although national prevalence estimates are not available,
non-medical use of prescription opioids has become increasingly
common among PWID in Canada over the past 15 years (41–43).
One study from Montréal found that in a prospective cohort of
PWID, the proportion reporting prescription opioid injection
increased from 21% in 2004 to 75% in 2009. PWID who reported
prescription opioid injection were more likely than PWID who
were non-prescription opioid injection drug users to acquire
hepatitis C (41). This increased risk may be in part due to more
frequent injections and increased opportunities for sharing used
injection equipment (42,44) among those who use prescription
opioids, a cohort that tends to be younger and less experienced
with injection drug use (41).
The prescription opioid epidemic may be accelerating the
transition to injection drug use among younger people who use
drugs (45). Several studies from the United States have found an
association between the increasing use of injection prescription
opioids and increased rates of hepatitis C infections, particularly
among younger adults (<30 years old) and reproductive-aged
females (46–48).
There has also been a reported increase in the prevalence
of methamphetamine use in Canada over the past 15 years
(12,49,50). In the Tracks survey of PWID in Canada, the
proportion of participants injecting methamphetamine
increased from 6.8% in Phase 1 (2003–2005) to 43.5% in Phase 4
(2017–2019) (12). Methamphetamine use has been associated
with HCV transmission in Canadian studies (51,52) and linked
to increased frequency of syringe sharing (53) and increased
injection frequency (54). Rates of methamphetamine use vary
widely across the country (50). The most pronounced increases
appear to be in Western and Central Canada (50,55,56). In 2016,
the Winnipeg region declared a hepatitis C outbreak linked to a
dramatic increase in the use of methamphetamine (57–59).
CCDR • December 2021 • Vol. 47 No. 12
Page 506
OVERVIEW
Injection drug use equipment sharing practices
are changing
Hepatitis C rates among females in Canada are
on the rise
The proportion of Tracks survey participants who reported
borrowing used needles or syringes decreased from 20.2% in
Phase 1 (2003–2005) to 11.6% in Phase 4 (2017–2019) (12). In
contrast, the proportion of participants who reported borrowing
other used injection equipment (water, filters, cookers, spoons,
tourniquets, ties, swabs and acidifiers) increased by almost
one-third between Phase 1 and 4 (from 29.8% to 38.0%) (12).
This finding is a concern as the risk of HCV acquisition from
sharing drug-preparation equipment is similar to that associated
with syringe sharing (60) and persists in the absence of needle
or syringe sharing (61). Some studies have linked prescription
opioid injection use to increased sharing of other used injection
equipment, specifically, the sharing of “washes” (the residue
found on used filters and cookers) (42,61–63).
From 2014 to 2018, reported hepatitis C rates increased for both
females and males (6). However, while rates were consistently
higher among males, rates for females in 2018 were 20% higher
than those in 2014; while rates for males were 10% higher. Also,
women aged 25 to 39 years old showed the largest hepatitis C
rate increases in Manitoba, Ontario, Québec, New Brunswick and
Yukon during this time. Similarly, during the same period, higher
rate increases of other sexually transmitted and bloodborne
infections (STBBI), such as syphilis and HIV, were reported among
females compared to males in several jurisdictions (69,70).
Several studies from the United States have also reported an
increase in hepatitis C rates among reproductive-age females
in recent years, a trend that has been linked to the opioid
crisis (46–48).
Harm reduction coverage across Canada is
increasing, but gaps remain
While the bio-behavioural surveillance data from Phase 4 of
the Tracks survey of PWID found that the proportion who
self-reported borrowing other used injecting equipment in the
past six months was 45.9% for cisgender females versus 33.7%
for cisgender males (12), understanding what is driving these
increasing rates among females is challenging for three main
reasons: i) national routine surveillance data do not include
risk factor data; ii) no testing volume data are available; and iii)
Canadian research to contextualize this trend is limited.
In 2016, the federal minister of health announced an updated
drug strategy for Canada, the Canadian Drugs and Substances
Strategy (CDSS) (64,65). The CDSS puts an increased emphasis
on public health in the Government of Canada’s response to
substance use, with harm reduction included as one of the
pillars of the strategy in addition to prevention, treatment and
enforcement (64,65). Increased federal action and investments
to address substance use, overdose prevention, addictions,
harm reduction and drug treatment followed the launch of the
CDSS. In 2017, PHAC created the Harm Reduction Fund, one of
the CDSS initiatives (66), to support community-based projects
across Canada that help reduce HIV and hepatitis C acquisition
and transmission among people who share injection and
inhalation drug use equipment. Evidence-based harm reduction
strategies, such as needle-and-syringe programs, opioid agonist
therapy and supervised consumption services are essential to
reducing the risk of HCV transmission and reinfection among
PWID (67,68). The Phase 4 (2017–2019) Tracks survey of PWID
found that 90.1% of participants reported using a needle-andsyringe distribution program, 47.3% used some form of opioid
agonist therapy and 13.5% used a supervised consumption
service in the 12 months before the survey (12).
One Canadian modelling study found that between 2011 and
2016, needle-and-syringe coverage increased from 193 to 291
needles and syringes per PWID (11). Opioid-agonist-therapy
coverage increased from 55 to 66 recipients per 100 PWID,
despite increasing injection drug use over this period (11).
Based on these preliminary data, Canada appears to be meeting
the World Health Organization’s needle-and-syringe-program
and opioid-agonist-therapy provision targets overall. However,
coverage and access vary across provinces and territories (11,33).
Page 507
CCDR • December 2021 • Vol. 47 No. 12
Low hepatitis C treatment rates, expansion of
direct-acting antivirals and its potential impact
on future hepatitis C rates among the people
who inject drugs community
According to the 2017–2019 PWID Tracks survey, 10.6% of
PWID who were aware of their hepatitis C infection had ever
taken hepatitis C treatment and 3.8% were currently receiving
treatment (12). Low treatment rates are of concern for the health
of the individual living with hepatitis C and the potential risk for
HCV transmission.
There is substantial evidence demonstrating that PWID, including
those with ongoing substance use, can be successfully treated
for hepatitis C (71–73) particularly when treatment is delivered
in a low-barrier setting and paired with wrap-around social
and harm reduction supports (74–77). Moreover, Canadian
modelling studies show that treatment can act as prevention
in high-prevalence groups, such as PWID, especially when
combined with opioid agonist therapy and high-coverage
needle-and-syringe programs (78,79).
From 2014 to early 2018, Canadian hepatitis C treatment
guidelines limited second-generation DAAs (with cure rates
above 95% against the main HCV genotypes) to people with
advanced liver fibrosis or cirrhosis (80). In June 2018, the
OVERVIEW
Canadian guidelines removed all disease-stage restrictions on
DAA eligibility, making DAAs eligible for all people with chronic
hepatitis C (81). However, the rollout of lifting disease-stage
restrictions differed by province and territory, and other
non-disease-stage restrictions remain and differ by province
and territory (82,83). Although it is likely that expanded DAA
eligibility may have contributed to an increase in hepatitis C
testing across Canada from 2014 to 2018, there is, unfortunately,
a lack of Canadian scientific evidence to support this hypothesis.
A study by Saeed et al. found that while hepatitis C treatment
uptake increased dramatically among PWID after treatment
restrictions were lifted in British Columbia, Ontario and Québec,
uptake rates declined a year later (83). This was thought to
reflect a “warehousing effect,” as physicians began clearing
the initial backlog of treatment-eligible individuals engaged
in care who had been deferring treatment until DAAs became
available (83). To this end, we need innovative and tailored
programs and policies to successfully engage PWID in care and
facilitate increased levels of treatment initiation (33,83–87).
The advent of DAAs has raised concerns about a potentially
higher risk of reinfection in high-risk populations, such as PWID
and HIV-positive gbMSM (88,89). However, concurrent harm
reduction strategies and behavioural and structural interventions
appear to reduce the risk of reinfection (72,74,77,90,91). The
impact of DAA on treatment uptake and reinfection risk are both
areas that warrant further scholarly attention and surveillance.
Anticipating the impact of the COVID-19
pandemic on hepatitis C in Canada
Evidence is already emerging that the COVID-19 pandemic and
public health mitigation measures have adversely impacted the
delivery of and demand for STBBI prevention, testing, treatment
and harm reduction services in Canada (92). According to a 2020
PHAC survey of how the COVID-19 pandemic impacted the
delivery of STBBI and harm reduction services in Canada, 21%
of service providers providing support and treatment services
for people living with HIV, hepatitis C or both experienced a
decreased demand for and ability to deliver their services (92).
In addition, 44% of STBBI prevention, testing and treatment
service providers experienced a decrease in their ability to
provide their services. Concurrently, 40% of harm reduction
and drug treatment service providers reported an increase in
demand for their services, although 63% reported no change or
only a slight change in their ability to deliver their services (92).
Given decreased access to HCV testing, this will likely impact
the number of HCV diagnoses in 2020 and 2021, generating in
underestimating the rate of newly reported hepatitis C cases.
This would occur in the context of changing drug use practices
generating from the pandemic’s impact on harm reduction
service availability and the quality and quantity of the drug
supply, and COVID-related isolation requirements (93–97).
Conversely, the COVID-19 pandemic may generate in
new opportunities for engagement in hepatitis C care.
The same survey noted that 81% of STBBI-related service
providers provided remote services since the beginning of
the pandemic. Of these, 66% created new remote services
during this period (92). The recent expansion of virtual care,
if sustained, may present opportunities to improve access to
hepatitis C care in the future, particularly for rural and remote
populations (92,93,98), and could reduce wait times for accessing
specialty care (99), enabling faster treatment scale-up. However,
future monitoring and research will be needed to determine
whether such virtual services have high uptake among PWID.
At the time of going to press, the latest available hepatitis C
surveillance data showed the national reported hepatitis C rate
had declined by 10% from 2018 to 2019 (100). Furthermore,
all but two provinces and territories showed declining
reported hepatitis C rates, of between −4% and −40%
(Prince Edward Island’s hepatitis C rates increased by 15% since
2018, and Nova Scotia’s remained stable). Unfortunately, due
to the impacts of the COVID-19 pandemic, it will be difficult
to determine if the rate drop from 2018 to 2019 should be
interpreted as a blip or a new trend.
Discussion
This overview article summarized several changing trends and
risk factors associated with hepatitis C, with a strong focus on
injection drug use practices. These trends and risk factors may
partially explain the rising reported hepatitis C rates observed
in Canada between 2014 and 2018. We also discussed how the
staggered expansion of DAA eligibility across Canada may have
contributed to an increase in hepatitis C testing and how this and
the COVID-19 pandemic might influence future rates of reported
hepatitis cases.
Limitations
This overview has several limitations: first, national surveillance
data are limited to reported cases by age, sex and province or
territory. It does not provide any risk factor data or differentiate
between acute, chronic or reinfection cases. While injection drug
use is the most commonly cited risk factor for hepatitis C, and
thus the focus of this overview, there are other risk factors such
as having received care in an hepatitis C–endemic area, other
non-injection drug use, needle-stick injury among healthcare
workers, having had a blood transfusion before 1992, sex
practices that lead to blood exposure, and mother to child
transmission (101). Changes associated with any of these risk
factors may have also contributed to the observed increase in
rates of reported cases from 2014 to 2018. However, there was
insufficient literature to determine this.
CCDR • December 2021 • Vol. 47 No. 12
Page 508
OVERVIEW
Second, Canadian surveillance data do not include the number
of people testing for hepatitis C, which would inform changes
in testing practices over time. Finally, the surveys and papers
reviewed used varying time points, and each came with its own
set of limitations. For example, the Tracks surveys are crosssectional and descriptive (12).
4.
Public Health Agency of Canada. Infographic: people living
with hepatitis C (HCV), Canada, 2017. Ottawa (ON): PHAC;
2020 (accessed 2021-08-25). https://www.canada.ca/en/
public-health/services/publications/diseases-conditions/
infographic-people-living-with-hepatitis-c-2017.html
5.
Public Health Agency of Canada. Reducing the health
impact of sexually transmitted and blood-borne infections
in Canada by 2030: a pan-Canadian STBBI framework for
action. Ottawa (ON): PHAC; 2018 (accessed 2021-04-20).
https://www.canada.ca/en/public-health/services/infectiousdiseases/sexual-health-sexually-transmitted-infections/
reports-publications/sexually-transmitted-blood-borneinfections-action-framework.html
6.
Public Health Agency of Canada. Report on hepatitis B and
C in Canada: 2018. Ottawa (ON): PHAC; 2021 (accessed
2021-06-28). https://www.canada.ca/en/public-health/
services/publications/diseases-conditions/report-hepatitis-bc-canada-2018.html
7.
Health Canada. Fifth Report on Human Biomonitoring of
Environmental Chemicals in Canada: Results of the Canadian
Health Measures Survey Cycle 5 (2016–2017). Ottawa (ON):
HC; 2019 (accessed 2021-06-28). https://www.canada.ca/
en/health-canada/services/environmental-workplace-health/
reports-publications/environmental-contaminants/fifthreport-human-biomonitoring.html
8.
Yang Q, Ogunnaike-Cooke S, Halverson J, Yan P, Zhang
F, Tomas K, Schanzer D, Archibald CP. Estimated national
HIV incidence rates among key subpopulations in Canada,
2014. Presented at 25th Annual Canadian Conference on
HIV/AIDS Research (CAHR), 12–15 May 2016, Winnipeg,
Canada. Abstract EPH3.5; 2016. https://www.cahr-acrv.ca/
wp-content/uploads/2015/10/CAHR16-Abstracts-for-webFinal.pdf
9.
Remis R. Modelling the incidence and prevalence of
hepatitis C infection and its sequelae in Canada, 2007: final
report. Ottawa (ON): Public Health Agency of Canada; 2009.
https://www.phac-aspc.gc.ca/sti-its-surv-epi/model/pdf/
model07-eng.pdf
Conclusion
The continuous routine and enhanced bio-behavioural
surveillance of hepatitis C are crucial for monitoring Canada’s
hepatitis C epidemic. Improvements to national surveillance
data, including collecting risk factor and sociodemographic
data and differentiating hepatitis C cases by infection status
using standardized national definitions, would improve our
understanding of the structural and behavioural risk factors
driving HCV transmission in Canada. At the time of developing
this overview, PHAC was reviewing the hepatitis C case definition
in collaboration with provinces and territories and considering
the feasibility of adding a reinfection case definition.
Furthermore, ongoing efforts to strengthen the reach,
effectiveness and adoption of evidence-based hepatitis C
prevention and treatment services across Canada are vital to
reducing HCV transmission among high-risk PWID and achieving
Canada’s HCV elimination targets by 2030.
Authors’ statement
LL — Conceptualization, research, writing, original draft, final
draft, review, editing, supervision
MK— Conceptualization, research, writing, original draft, editing
JT — Editing, research
KS — Research, editing, reference management
MB — Review, editing
JA — Conceptualization, review, editing, supervision
Competing interests
None.
References
1.
Myers RP, Liu M, Shaheen AA. The burden of hepatitis C
virus infection is growing: a Canadian population-based
study of hospitalizations from 1994 to 2004. Can J
Gastroenterol 2008;22(4):381–7. DOI PubMed
2.
Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P,
Peltekian K, Ramji A, Estes C, Razavi H, Sherman M. Burden
of disease and cost of chronic hepatitis C infection in
Canada. Can J Gastroenterol Hepatol 2014;28(5):243–50.
DOI PubMed
3.
Schanzer DL, Paquette D, Lix LM. Historical trends and
projected hospital admissions for chronic hepatitis C
infection in Canada: a birth cohort analysis. CMAJ Open
2014;2(3):E139–44. DOI PubMed
Page 509
CCDR • December 2021 • Vol. 47 No. 12
10. Public Health Agency of Canada. Epidemiology of acute
hepatitis C infection in Canada. Results from the Enhanced
Hepatitis Strain Surveillance System (EHSSS). Ottawa
(ON): PHAC; 2009. https://publications.gc.ca/collections/
collection_2011/aspc-phac/HP40-41-2010-eng.pdf
11. Jacka B, Larney S, Degenhardt L, Janjua N, Høj S,
Krajden M, Grebely J, Bruneau J. Prevalence of injecting
drug use and coverage of interventions to prevent HIV and
hepatitis C virus infection among people who inject drugs in
Canada. Am J Public Health 2020;110(1):45–50.
DOI PubMed
12. Tarasuk J, Zhang J, Lemyre A, Cholette F, Bryson M,
Paquette D. National findings from the Tracks survey of
people who inject drugs in Canada, Phase 4, 2017–2019.
Can Commun Dis Rep 2020;46(5):138–48. DOI
13. McNeil R, Shannon K, Shaver L, Kerr T, Small W. Negotiating
place and gendered violence in Canada’s largest open drug
scene. Int J Drug Policy 2014;25(3):608–15. DOI PubMed
OVERVIEW
14. Strike C, Rudzinski K, Patterson J, Millson M. Frequent
food insecurity among injection drug users: correlates and
concerns. BMC Public Health 2012;12:1058. DOI PubMed
15. Schmitz J, Kral AH, Chu D, Wenger LD, Bluthenthal RN.
Food insecurity among people who inject drugs in
Los Angeles and San Francisco. Public Health Nutr
2016;19(12):2204–12. DOI PubMed
16. Kouyoumdjian F, Schuler A, Matheson FI, Hwang SW. Health
status of prisoners in Canada: narrative review. Can Fam
Physician 2016;62(3):215–22. PubMed
17. Galea S, Vlahov D. Social determinants and the health
of drug users: socioeconomic status, homelessness, and
incarceration. Public Health Rep 2002;117 Suppl 1:S135–45.
PubMed
18. Arum C, Fraser H, Artenie AA, Bivegete S, Trickey A,
Alary M, Astemborski J, Iversen J, Lim AG, MacGregor L,
Morris M, Ong JJ, Platt L, Sack-Davis R, van Santen DK,
Solomon SS, Sypsa V, Valencia J, Van Den Boom W,
Walker JG, Ward Z, Stone J, Vickerman P; Homelessness,
HIV, and HCV Review Collaborative Group. Homelessness,
unstable housing, and risk of HIV and hepatitis C
virus acquisition among people who inject drugs: a
systematic review and meta-analysis. Lancet Public Health
2021;6(5):e309–23. DOI PubMed
19. Morris MD, Yen IH, Shiboski S, Evans JL, Page K. Housing
stability and hepatitis C Infection for young adults who
inject drugs: examining the relationship of consistent and
intermittent housing status on HCV infection risk. J Urban
Health 2020;97(6):831–44. DOI PubMed
20. Artenie AA, Fortier E, Sylvestre MP, Høj SB, Minoyan N,
Gauvin L, Jutras-Aswad D, Bruneau J. Socioeconomic
stability is associated with lower injection frequency among
people with distinct trajectories of injection drug use. Int J
Drug Policy 2021;94:103205. DOI PubMed
21. Hadland SE, DeBeck K, Kerr T, Feng C, Montaner JS,
Wood E. Prescription opioid injection and risk of hepatitis
C in relation to traditional drugs of misuse in a prospective
cohort of street youth. BMJ Open 2014;4(7):e005419.
DOI PubMed
22. Kim C, Kerr T, Li K, Zhang R, Tyndall MW, Montaner JS,
Wood E. Unstable housing and hepatitis C incidence among
injection drug users in a Canadian setting. BMC Public
Health 2009;9:270. DOI PubMed
23. Richardson L, DeBeck K, Feng C, Kerr T, Wood E.
Employment and risk of injection drug use initiation among
street involved youth in Canadian setting. Prev Med
2014;66:56–9. DOI PubMed
24. Fischer B, Haydon E, Rehm J, Krajden M, Reimer J. Injection
drug use and the hepatitis C virus: considerations for a
targeted treatment approach--the case study of Canada.
J Urban Health 2004;81(3):428–47. DOI PubMed
26. Jongbloed K, Pearce ME, Pooyak S, Zamar D, Thomas V,
Demerais L, Christian WM, Henderson E, Sharma R, Blair AH,
Yoshida EM, Schechter MT, Spittal PM; Cedar Project
Partnership. The Cedar Project: mortality among young
Indigenous people who use drugs in British Columbia. CMAJ
2017;189(44):E1352–9. DOI PubMed
27. Craib KJ, Spittal PM, Patel SH, Christian WM,
Moniruzzaman A, Pearce ME, Demerais L, Sherlock C,
Schechter MT; Cedar Project Partnership. Prevalence and
incidence of hepatitis C virus infection among Aboriginal
young people who use drugs: results from the Cedar Project.
Open Med 2009;3(4):e220–7. PubMed
28. Spittal PM, Pearce ME, Chavoshi N, Christian WM,
Moniruzzaman A, Teegee M, Schechter MT. The Cedar
Project: high incidence of HCV infections in a longitudinal
study of young Aboriginal people who use drugs in two
Canadian cities. BMC Public Health 2012;12(1):632.
DOI PubMed
29. Gordon J, Bocking N, Pouteau K, Farrell T, Ryan G,
Kelly L. First Nations hepatitis C virus infections: six-year
retrospective study of on-reserve rates of newly reported
infections in northwestern Ontario. Can Fam Physician
2017;63(11):e488–94. PubMed
30. Public Health Agency of Canada. Hepatitis C in Canada:
2005-2010 Surveillance report. Ottawa (ON): PHAC; 2011
(accessed 2020-10-27). https://www.catie.ca/sites/default/
files/1109-0139-Hep%20C%20Report-FR%20FINAL.pdf
31. Trubnikov M, Yan P, Archibald C. Estimated prevalence
of hepatitis C virus infection in Canada, 2011.
Can Commun Dis Rep 2014;40(19):429–36. DOI PubMed
32. Uhanova J, Tate RB, Tataryn DJ, Minuk GY. The
epidemiology of hepatitis C in a Canadian Indigenous
population. Can J Gastroenterol 2013;27(6):336–40.
DOI PubMed
33. The Canadian Network on Hepatitis C. Blueprint to inform
hepatitis C elimination efforts in Canada. Montréal (QC):
CanHepC; 2019 (accessed 2020-10-25). www.canhepc.ca/
en/blueprint/publication
34. Lanièce Delaunay C, Cox J, Klein M, Lambert G, Grace D,
Lachowsky NJ, Maheu-Giroux M. Trends in hepatitis C virus
seroprevalence and associated risk factors among men
who have sex with men in Montréal: results from three
cross-sectional studies (2005, 2009, 2018). Sex Transm Infect
2021;97(4):290–6. DOI PubMed
35. Public Health Agency of Canada. M-Track enhanced
surveillance of HIV, sexually transmitted and blood-borne
infections, and associated risk behaviours among men who
have sex with men in Canada. Ottawa (ON): PHAC; 2011.
http://librarypdf.catie.ca/ATI-20000s/26403.pdf
25. Tarasuk J, Ogunnaike-Cooke S, Archibald C, MacLean R,
Bennett R, Kim J, Malloch L; I-Track Principal
Investigators. Key findings from a national enhanced HIV
surveillance system: 2010 - 2012. Can Commun Dis Rep
2014;40(18):397–407. DOI PubMed
CCDR • December 2021 • Vol. 47 No. 12
Page 510
OVERVIEW
36. Lockart I, Matthews GV, Danta M. Sexually transmitted
hepatitis C infection: the evolving epidemic in
HIV-positive and HIV-negative MSM. Curr Opin Infect Dis
2019;32(1):31–7. DOI PubMed
47. Patrick SW, Bauer AM, Warren MD, Jones TF, Wester C.
Hepatitis C virus infection among women giving birth—
Tennessee and United States, 2009–2014. MMWR Morb
Mortal Wkly Rep 2017;66(18):470–3. DOI PubMed
37. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M,
Bhagani S, Vogel M, Baumgarten A, Chaix ML, Fisher M,
Gotz H, Matthews GV, Neifer S, White P, Rawlinson W,
Pol S, Rockstroh J, Coutinho R, Dore GJ, Dusheiko GM,
Danta M. Evidence of a large, international network of HCV
transmission in HIV-positive men who have sex with men.
Gastroenterology 2009;136(5):1609–17. DOI PubMed
48. Koneru A, Nelson N, Hariri S, Canary L, Sanders KJ,
Maxwell JF, Huang X, Leake JA, Ward JW, Vellozzi C.
Increased hepatitis C virus (HCV) detection in women of
childbearing age and potential risk for vertical transmission –
United States and Kentucky, 2011–2014. MMWR Morb
Mortal Wkly Rep 2016;65(28):705–10. DOI PubMed
38. Jordan AE, Perlman DC, Neurer J, Smith DJ, Des Jarlais DC,
Hagan H. Prevalence of hepatitis C virus infection among
HIV+ men who have sex with men: a systematic review and
meta-analysis. Int J STD AIDS 2017;28(2):145–59.
DOI PubMed
39. Gomes T, Greaves S, Tadrous M, Mamdani MM,
Paterson JM, Juurlink DN. Measuring the burden of
opioid-related mortality in Ontario, Canada. J Addict Med
2018;12(5):418–9. DOI PubMed
40. Fischer B, O’Keefe-Markman C, Lee AM, Daldegan-Bueno D.
‘Resurgent’, ‘twin’ or ‘silent’ epidemic? A select data
overview and observations on increasing psycho-stimulant
use and harms in North America. Subst Abuse Treat Prev
Policy 2021;16(1):17. DOI PubMed
41. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The
rising prevalence of prescription opioid injection and its
association with hepatitis C incidence among street-drug
users. Addiction 2012;107(7):1318–27. DOI PubMed
42. Roy É, Arruda N, Leclerc P, Morissette C, Blanchette C,
Blouin K, Alary M. Drug use practices among people who
inject drugs in a context of drug market changes: challenges
for optimal coverage of harm reduction programs.
Int J Drug Policy 2017;45:18–24. DOI PubMed
43. Bruneau J, Arruda N, Zang G, Jutras-Aswad D, Roy É.
The evolving drug epidemic of prescription opioid
injection and its association with HCV transmission among
people who inject drugs in Montréal, Canada. Addiction
2019;114(2):366–73. DOI PubMed
44. Roy E, Arruda N, Bourgois P. The growing popularity
of prescription opioid injection in downtown Montréal:
new challenges for harm reduction. Subst Use Misuse
2011;46(9):1142–50. DOI PubMed
45. Bluthenthal RN, Wenger L, Chu D, Bourgois P, Kral AH. Drug
use generations and patterns of injection drug use: birth
cohort differences among people who inject drugs in Los
Angeles and San Francisco, California. Drug Alcohol Depend
2017;175:210–8. DOI PubMed
46. Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K,
Ward JW, Holtzman D. Increases in acute hepatitis C
virus infection related to a growing opioid epidemic and
associated injection drug use, United States, 2004 to 2014.
Am J Public Health 2018;108(2):175–81. DOI PubMed
Page 511
CCDR • December 2021 • Vol. 47 No. 12
49. Canadian Centre on Substance Use and Addiction.
Methamphetamine. Ottawa (ON): CCSA; 2020 (accessed
2021-06-23). https://www.ccsa.ca/methamphetamine
50. Canadian Centre on Substance Use and Addiction.
CCENDU Bulletin: Changes in stimulant use and related
harms: focus on methamphetamine and cocaine. Ottawa
(ON): CCSA; 2019 (accessed 2021-06-23). https://www.
ccsa.ca/changes-stimulant-use-and-related-harms-focusmethamphetamine-and-cocaine-ccendu-bulletin?_cldee
=ZWFydGlnaWFAdW1kLmVkdQ%3D%3D&esid=84e16
ab9-8167-e911-a984-000d3af47939&recipientid=contact8ffdece4f1d1e6118105480fcfeaa931-d091dbe970d743fe9c200cc95b61d50d
51. Grebely J, Lima VD, Marshall BD, Milloy MJ, DeBeck K,
Montaner J, Simo A, Krajden M, Dore GJ, Kerr T, Wood E.
Declining incidence of hepatitis C virus infection among
people who inject drugs in a Canadian setting, 1996-2012.
PLoS One 2014;9(6):e97726. DOI PubMed
52. Cunningham EB, Jacka B, DeBeck K, Applegate TL,
Harrigan PR, Krajden M, Marshall BD, Montaner J,
Lima VD, Olmstead AD, Milloy MJ, Wood E, Grebely J.
Methamphetamine injecting is associated with
phylogenetic clustering of hepatitis C virus infection among
street-involved youth in Vancouver, Canada. Drug Alcohol
Depend 2015;152:272–6. DOI PubMed
53. Scheim AI, Bardwell G, Rachlis B, Mitra S, Kerr T. Syringe
sharing among people who inject drugs in London, Canada.
Can J Public Health 2018;109(2):174–82. DOI PubMed
54. Tyndall MW, Currie S, Spittal P, Li K, Wood E,
O’Shaughnessy MV, Schechter MT. Intensive injection
cocaine use as the primary risk factor in the Vancouver HIV-1
epidemic. AIDS 2003;17(6):887–93. DOI PubMed
55. Neufeld J. Plains speak on STBBIs, 2019: an emergent
challenge: an emergent challenge for the Prairies. Winnipeg
(MB): National Collaborating Centre for Infectious Diseases;
2019 (accessed 2021-05-02). https://nccid.ca/wp-content/
uploads/sites/2/2019/11/Final_Plains-Speak-on-STBBIs-2019Meeting-Proceedings.pdf
56. Drug and Alcohol Testing Association of Canada. Crystal
meth use on the rise in the Prairies. Barrie (ON): DATAC;
2018 (accessed 2021-05-05). https://datac.ca/crystal-methuse-on-the-increase-in-the-prairies/
OVERVIEW
57. Keele J. Report finds meth crisis contributing to increase
in blood-borne illnesses. CTV News (Winnipeg). Published:
2018-12-11 (accessed 2021-10-27). https://winnipeg.
ctvnews.ca/meth-crisis-contributing-to-increase-in-bloodborne-illnesses-report-1.4213562
58. Kusch L, Botelho-Urbanski J. Shared meth syringes drive
hepatitis outbreak. Winnipeg Free Press. Posted: 2018-1211. (accessed 2021-02-15). https://www.winnipegfreepress.
com/local/lack-of-provincial-leadership-has-exacerbatedcitys-meth-crisis-wrha-charges-in-document-502482181.html
59. Froese I. Meth use in Winnipeg causing outbreak of
blood-borne illnesses, new documents say. CBC News
(Manitoba). Posted: 2018-12-11 (accessed 2020-10-26).
https://www.cbc.ca/news/canada/manitoba/prairie-policemeth-health-disease-1.4941110
60. Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis
of hepatitis C seroconversion in relation to shared
syringes and drug preparation equipment. Addiction
2012;107(6):1057–65. DOI PubMed
68. Grebely J, Tran L, Degenhardt L, Dowell-Day A, Santo T,
Larney S, Hickman M, Vickerman P, French C, Butler K,
Gibbs D, Valerio H, Read P, Dore GJ, Hajarizadeh B.
Association between opioid agonist therapy and testing,
treatment uptake, and treatment outcomes for hepatitis C
infection among people who inject drugs: a systematic
review and meta-analysis. Clin Infect Dis 2021;73(1):e107–18.
DOI PubMed
69. Public Health Agency of Canada. Report on sexually
transmitted infections in Canada, 2018. Ottawa (ON): PHAC;
2021 (accessed 2021-06-28). https://www.canada.ca/en/
public-health/services/publications/diseases-conditions/
report-sexually-transmitted-infections-canada-2018.html
70. Haddad N, Weeks A, Robert A, Totten S. HIV in
Canada-surveillance report, 2019. Can Commun Dis Rep
2021;47(1):77–86. DOI PubMed
61. Ball LJ, Puka K, Speechley M, Wong R, Hallam B, Wiener JC,
Koivu S, Silverman MS. Sharing of injection drug preparation
equipment is associated with HIV infection: a cross-sectional
study. J Acquir Immune Defic Syndr 2019;81(4):e99–103.
DOI PubMed
71. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ,
Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B,
Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC,
Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E,
Robertson MN, Platt HL; C-EDGE CO-STAR Study Group.
C-EDGE CO-STAR Study Group. Elbasvir-grazoprevir to
treat hepatitis C virus infection in persons receiving opioid
agonist therapy: a randomized trial. Ann Intern Med
2016;165(9):625–34. DOI PubMed
62. Zibbell JE, Hart-Malloy R, Barry J, Fan L, Flanigan C. Risk
factors for HCV infection among young adults in rural New
York who inject prescription opioid analgesics. Am J Public
Health 2014;104(11):2226–32. DOI PubMed
72. Hajarizadeh B, Grebely J, Matthews GV, Martinello M,
Dore GJ. Uptake of direct-acting antiviral treatment
for chronic hepatitis C in Australia. J Viral Hepat
2018;25(6):640–8. DOI PubMed
63. Ball LJ, Venner C, Tirona RG, Arts E, Gupta K, Wiener
JC, Koivu S, Silverman MS. Heating injection drug
preparation equipment used for opioid injection may
reduce HIV transmission associated with sharing equipment.
J Acquir Immune Defic Syndr 2019;81(4):e127–34.
DOI PubMed
73. Grebely J, Dalgard O, Conway B, Cunningham EB,
Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M,
Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL,
Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV,
Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I,
Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E,
Dore GJ; SIMPLIFY Study Group. Sofosbuvir and velpatasvir
for hepatitis C virus infection in people with recent
injection drug use (SIMPLIFY): an open-label, single-arm,
phase 4, multicentre trial. Lancet Gastroenterol Hepatol
2018;3(3):153–61. DOI PubMed
64. Health Canada. Canadian Drugs and Substances Strategy.
Ottawa (ON): HC; 2019 (accessed 2021-06-28).
https://www.canada.ca/en/health-canada/services/
substance-use/canadian-drugs-substances-strategy.html
65. Health Canada. Canadian Drugs and Substance Strategy.
Ottawa (ON): HC; 2016 (accessed 2021-06-28).
https://www.canada.ca/content/dam/hc-sc/healthycanadians/migration/publications/healthy-living-vie-saine/
drugs-substances-strategy-2016-strategie-drogues-autresubstances/alt/pub-eng.pdf
74. Alimohammadi A, Holeksa J, Thiam A, Truong D, Conway B.
Real-world efficacy of direct-acting antiviral therapy for
HCV infection affecting people who inject drugs delivered
in a multidisciplinary setting. Open Forum Infect Dis
2018;5(6):ofy120. DOI PubMed
66. Public Health Agency of Canada. Applying for funding under
the Harm Reduction Fund (HRF). Ottawa (ON): PHAC; 2021
(accessed 2021-06-28). https://www.canada.ca/en/publichealth/services/funding-opportunities/sexually-transmittedblood-borne-infections/applying-funding-harm-reductionfund.html
75. Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, Matelski J,
Sockalingam S, Altenberg J, Powis J. Understanding
real-world adherence in the directly acting antiviral era: A
prospective evaluation of adherence among people with
a history of drug use at a community-based program in
Toronto, Canada. Int J Drug Policy 2017;47:202–8.
DOI PubMed
67. Socías ME, Ti L, Wood E, Nosova E, Hull M, Hayashi K,
Debeck K, Milloy MJ. Disparities in uptake of direct-acting
antiviral therapy for hepatitis C among people who inject
drugs in a Canadian setting. Liver Int 2019;39(8):1400–7.
DOI PubMed
76. Read P, Lothian R, Chronister K, Gilliver R, Kearley J,
Dore GJ, van Beek I. Delivering direct acting antiviral
therapy for hepatitis C to highly marginalised and current
drug injecting populations in a targeted primary health care
setting. Int J Drug Policy 2017;47:209–15. DOI PubMed
CCDR • December 2021 • Vol. 47 No. 12
Page 512
OVERVIEW
77. Wilton J, Wong S, Yu A, Ramji A, Cook D, Butt ZA,
Alvarez M, Binka M, Darvishian M, Jeong D, Bartlett SR,
Pearce ME, Adu PA, Yoshida EM, Krajden M, Janjua NZ.
Real-world effectiveness of sofosbuvir/velpatasvir for
treatment of chronic hepatitis C in British Columbia, Canada:
a population-based cohort study. Open Forum Infect Dis
2020;7(3):ofaa055. DOI
78. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ,
Vickerman P. Combination interventions to prevent HCV
transmission among people who inject drugs: modeling the
impact of antiviral treatment, needle and syringe programs,
and opiate substitution therapy. Clin Infect Dis 2013;57
Suppl 2:S39–45. DOI PubMed
79. Cousien A, Leclerc P, Morissette C, Bruneau J, Roy É,
Tran VC, Yazdanpanah Y, Cox J. The need for treatment
scale-up to impact HCV transmission in people who inject
drugs in Montréal, Canada: a modelling study. BMC Infect
Dis 2017;17(1):162. DOI PubMed
80. Schanzer D, Pogany L, Aho J, Tomas K, Gale-Rowe M,
Kwong JC, Janjua NZ, Feld J. Impact of availability
of direct-acting antivirals for hepatitis C on Canadian
hospitalization rates, 2012-2016. Can Commun Dis Rep
2018;44(7-8):150–6. DOI PubMed
81. Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji
A, Smyth D, Feld JJ; Canadian Association for the Study
of the Liver. The management of chronic hepatitis C: 2018
guideline update from the Canadian Association for the
Study of the Liver. CMAJ 2018;190(22):E677–87.
DOI PubMed
82. Bartlett S, Gennip J, Marshall AD, Bonn M, Fuchs D,
Yetman G, Butler-McPhee J, Cooper CL, Gallagher L,
Kronfli N, Williams S, Bruneau J, Feld JJ, Janjua N, Klein M,
Grebely J. Policies for reimbursement of direct-acting
antiviral treatment for hepatitis C virus infection in Canada:
"A Patchwork Of Obstruction." In: Canadian Liver Meeting
2021; 2021 May 12–15 (accessed 2021-06-28).
https://www.actionhepatitiscanada.ca/
uploads/8/3/3/9/83398604/clm_2021-poster_bartlett_v2.pdf
83. Saeed S, Strumpf E, Moodie EE, Wong L, Cox J, Walmsley S,
Tyndall M, Cooper C, Conway B, Hull M, Martel-Laferriere V,
Gill J, Wong A, Vachon ML, Klein MB; Canadian Coinfection
Cohort Study Investigators. Eliminating structural barriers:
the impact of unrestricted access on hepatitis C treatment
uptake among people living with human immunodeficiency
virus. Clin Infect Dis 2020;71(2):363–71. DOI PubMed
84. Bartlett SR, Yu A, Chapinal N, Rossi C, Butt Z, Wong S,
Darvishian M, Gilbert M, Wong J, Binka M, Alvarez M,
Tyndall M, Krajden M, Janjua NZ. The population level
care cascade for hepatitis C in British Columbia, Canada
as of 2018: impact of direct acting antivirals. Liver Int
2019;39(12):2261–72. DOI PubMed
85. Binka M, Janjua NZ, Grebely J, Estes C, Schanzer D,
Kwon JA, Shoukry NH, Kwong JC, Razavi H, Feld JJ,
Krajden M. Assessment of treatment strategies to achieve
hepatitis C elimination in Canada using a validated model.
JAMA Netw Open 2020;3(5):e204192. DOI PubMed
Page 513
CCDR • December 2021 • Vol. 47 No. 12
86. Jacob J, Ti L, Knight R. Will peer-based interventions
improve hepatitis C virus treatment uptake among
young people who inject drugs? Can J Public Health
2021;112(3):460–3. DOI PubMed
87. Goodyear T, Ti L, Carrieri P, Small W, Knight R. "Everybody
living with a chronic disease is entitled to be cured":
challenges and opportunities in scaling up access to
direct-acting antiviral hepatitis C virus treatment among
people who inject drugs. Int J Drug Policy 2020;81:102766.
DOI PubMed
88. Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd
AR, Dore GJ. Hepatitis C treatment as prevention: evidence,
feasibility, and challenges. Lancet Gastroenterol Hepatol
2016;1(4):317–27. DOI PubMed
89. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk
of late relapse or reinfection with hepatitis C virus after
achieving a sustained virological response: a systematic
review and meta-analysis. Clin Infect Dis 2016;62(6):683–94.
DOI PubMed
90. Rossi C, Butt ZA, Wong S, Buxton JA, Islam N, Yu A,
Darvishian M, Gilbert M, Wong J, Chapinal N, Binka M,
Alvarez M, Tyndall MW, Krajden M, Janjua NZ; BC
Hepatitis Testers Cohort Team. Hepatitis C virus reinfection
after successful treatment with direct-acting antiviral
therapy in a large population-based cohort. J Hepatol
2018;69(5):1007–14. DOI PubMed
91. Hajarizadeh B, Cunningham EB, Valerio H, Martinello M,
Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J,
Hickman M, Bruneau J, Dore GJ, Grebely J. Hepatitis
C reinfection after successful antiviral treatment among
people who inject drugs: A meta-analysis. J Hepatol
2020;72(4):643–57. DOI PubMed
92. Public Health Agency of Canada. How has COVID-19
Impacts on the delivery of STBBI-related services, including
harm reduction services. Ottawa (ON): PHAC; 2021
(accessed 2021-05-05). https://health-infobase.canada.ca/
datalab/covid-19-impact-stbbi-services.html
93. Canadian Centre on Substance Use and Addiction.
Impacts of the COVID-19 pandemic on substance use
treatment capacity in Canada. Ottawa (ON): CCSA;
2020 (accessed 2021-06-23). https://www.ccsa.ca/sites/
default/files/2020-12/CCSA-COVID-19-Impacts-PandemicSubstance-Use-Treatment-Capacity-Canada-2020-en.pdf
94. Canadian Centre on Substance Use and Addiction.
Impacts of the COVID-19 pandemic on people who use
substances: what we heard. Ottawa (ON): CCSA; 2020
(accessed 2021-06-23). https://www.ccsa.ca/sites/default/
files/2020-07/CCSA-COVID-19-Impacts-on-People-WhoUse-Substances-Report-2020-en.pdf
95. Canadian Centre on Substance Use and Addiction. CCENDU
Alert: Changes related to COVID-19 in the illegal drug
supply and access to services, and resulting health harms.
Ottawa (ON): CCSA; 2020 (accessed 2021-06-23).
https://www.ccsa.ca/sites/default/files/2020-05/CCSACOVID-19-CCENDU-Illegal-Drug-Supply-Alert-2020-en.pdf
OVERVIEW
96. Friesen EL, Kurdyak PA, Gomes T, Kolla G, Leece P, Zhu L,
Toombs E, O’Neill B, Stall NM, Jüni P, Mushquash CJ,
Mah L; Ontario COVID-19 Science Advisory Table and the
Mental Health Working Group. The impact of the COVID-19
pandemic on opioid-related harm in Ontario. Science Briefs
of the Ontario COVID-19 Science Advisory Table. 2021;2(42).
DOI
97. Reynolds C. Drug users at greater risk of dying as services
scale back in second wave of COVID-19. CTV News
(Ottawa). 2021 Jan 24 (accessed 2021-10-22).
https://www.ctvnews.ca/health/coronavirus/drug-users-atgreater-risk-of-dying-as-services-scale-back-in-second-waveof-covid-19-1.5279930
99. Lepage C, Garber G, Corrin R, Galanakis C, Leonard L,
Cooper C. Telemedicine successfully engages marginalized
rural hepatitis C patients in curative care. J Assoc Med
Microbiol Infect Dis Can 2020;5(2):87–97. DOI
100. Public Health Agency of Canada. Hepatitis C in Canada:
2019 surveillance data. Ottawa (ON): PHAC; 2021 (accessed
2021-07-05). https://www.canada.ca/en/public-health/
services/publications/diseases-conditions/hepatitis-c-2019surveillance-data.html
101. Centers for Disease Control and Prevention. Hepatitis C
questions and answers for the public (accessed 2021-10-19).
https://www.cdc.gov/hepatitis/hcv/cfaq.htm
98. Lanièce Delaunay C, Greenwald ZR, Minoyan N, Artenie AA,
Jeong D, Marathe G, Saeed YA, Kolla G, Kunden RD,
Okwor CI, Wallace HL, Mendlowitz A, Liu CH, Mazouz S,
D’souza S, Perciani CT, Rheault M, Palmer MA, Palayew A,
Abdelnabi MN, Cunningham EB. 2020-2021 trainees of
the Canadian Network on Hepatitis C. Striving towards
hepatitis C elimination in the era of COVID-19. Can Liver J
2021;4(1):4–7. DOI
Want to become
a peer reviewer?
CCDR
CANADA
COMMUNICABLE
DISEASE REPORT
Contact the CCDR editorial team:
ccdr-rmtc@phac-aspc.gc.ca
CCDR • December 2021 • Vol. 47 No. 12
Page 514
RAPID COMMUNICATION
Impact of school closures and re-openings on
COVID-19 transmission
Maryem El Jaouhari1, Rojiemiahd Edjoc1*, Lisa Waddell2, Patricia Huston3, Nicole Atchessi1,
Megan Striha1, Samuel Bonti-Ankomah1
This work is licensed under a Creative
Commons Attribution 4.0 International
License.
Abstract
Background: Globally, the education of students at primary and secondary schools has
been severely disrupted by the implementation of school closures to reduce the spread
of coronavirus disease 2019 (COVID-19). The effectiveness of school closures in reducing
transmission of COVID-19 and the impact of re-opening schools are unclear.
Methods: Research criteria for this rapid review included empirical studies, published or
pre-published worldwide before January 25, 2021, that assessed the effectiveness of school
closures in reducing the spread of COVID-19 and the impact of school re-openings on
COVID-19 transmission.
Affiliations
Health Security Regional
Operations Branch, Public Health
Agency of Canada, Ottawa, ON
1
National Microbiology
Laboratory, Public Health Agency
of Canada, Winnipeg, MB
2
Office of Chief Science Officer,
Public Health Agency of Canada,
Ottawa, ON
3
Results: Twenty-four studies on the impact of school closures and re-openings on COVID-19
transmission were identified through the seven databases that were searched. Overall the
evidence from these studies was mixed and varied due to several factors such as the time of
implementation of public health measures, research design of included studies and variability
among the levels of schooling examined.
Conclusion: Preliminary findings suggest that school closures have limited impact on reducing
COVID-19 transmission, with other non-pharmaceutical interventions considered much more
effective. However, due to the limitations of the studies, further research is needed to support
the use of this public health measure in response to the COVID-19 pandemic.
*Correspondence:
rojiemiahd.edjoc@phac-aspc.
gc.ca
Suggested citation: El Jaouhari M, Edjoc R, Waddell L, Huston P, Atchessi N, Striha M, Bonti-Ankomah S. Impact
of school closures and re-openings on COVID-19 transmission. Can Commun Dis Rep
2021;47(12):515–23. https://doi.org/10.14745/ccdr.v47i12a02
Keywords: COVID-19, SARS-CoV-2, school closures, school re-opening, non-pharmaceutical intervention
Introduction
As of March 11, 2020, the World Health Organization has
declared the coronavirus disease 2019 (COVID-19) outbreak
a pandemic (1). Globally, jurisdictions started to implement a
variety of non-pharmaceutical interventions (NPIs) to limit the
spread and the impact of COVID-19 disease caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Closing
schools was one of the NPIs implemented; however, these
closures not only disrupted the education and daily routines of
students, but also the lives of teachers and parents.
While school closures have been implemented to combat the
spread of COVID-19, they were also associated with negative
effects on student’s mental health and academic progress and
lead to increased stress in parents and teachers (2). With a lack
of school-based peer interactions and daily routines, it has been
reported that students experience increased distress, loneliness,
anxiety and depressive symptoms (2,3). School routines are
crucial for maintaining the well-being of students, especially
Page 515
CCDR • December 2021 • Vol. 47 No. 12
those with mental health or special education needs (4). In
addition, school closures have been associated with reduced
academic achievement due to delayed educational progress
(3,5,6). It is uncertain whether virtual learning is equally effective
and many students from low-income households lack access to,
and accommodations with, online materials (6).
Given the negative impacts of school closures, it is important to
consider whether they are significantly effective in reducing the
impact of COVID-19. Initially, it was assumed that school closures
would be effective in mitigating the spread of COVID-19 based
on the evidence from both seasonal and epidemic influenza (7,8).
In contrast, modelling studies conducted in Ontario and across
Canada during the first and second waves found that school
closures had limited impact on reducing the transmission of
COVID-19 compared with other NPIs (9–11). Other modelling
studies reported modest effects of school closures in delaying
peak case numbers early in the pandemic (12,13), while some
RAPID COMMUNICATION
studies showed a smaller magnitude of effect when compared
with other NPIs (14,15). Early modelling studies relied on the
underlying assumption that there is a low transmission risk in
children. Although modelling studies are excellent for making
informed predictions, their accuracy is dependent on the
assumptions and the quality of data used. Overall, there was
a need to assess the potential impacts of school closures in
reducing the spread of COVID-19.
This review summarizes empirical studies on the effectiveness
of school closures and the impact of re-opening schools in
reducing community transmission of COVID-19 and decreasing
the incidence of COVID-19 in primary and secondary schools.
The principal focus of this article was the impact of primary and
secondary school closures, although if studies also included data
from other types of schools this was included as well.
Methods
Our research criteria included empirical studies that assessed the
impact of school closures and/or re-openings on COVID-19 that
were published before January 25, 2021. Predictive modelling
studies were excluded. Searches to retrieve relevant articles
were conducted in PubMed, Scopus, BioRxiv, MedRxiv, ArXiv,
SSRN and Research Square, by the Emerging Science Group of
the Public Health Agency of Canada. Search terms included the
following: school AND closure OR re-opening within a database
of COVID-19 literature that is updated daily. References were
also used to search for additional relevant studies. Included
literature was confined to English and French languages.
Articles (n=966) were then screened for relevance. A total of five
observational studies and nineteen ecological studies were found
to be relevant (see Appendix Table A1 and Table A2).
Results
Twenty-four articles published prior to January 25, 2021 on the
impact of school closures and/or re-openings on the spread of
COVID-19, were identified. These included a cross-sectional
study (16), two cohort studies (17,18), two cluster and outbreak
investigations (19,20) and 19 ecological studies. Eleven of
these studies are preprints or studies that have not yet been
peer-reviewed. All studies identified in this review pre-date the
identification of variants of concern.
Most observational studies assessing the impact of school
closures/re-openings on the spread of COVID-19 in schools
reported no significant effects (see Appendix Table A1). Four
studies found no difference in incidence of cases both before
and after closing schools for the holidays, following children
who stayed at home vs those who went to school with strict
surveillance, or following school re-opening (16–19). An outbreak
investigation study reported a large outbreak from a high
school in Israel, but this was confounded by the fact that the
mask mandate was lifted just as there was a heatwave, which
may have affected compliance with other recommended public
health measures (20). Furthermore, it was noted that there was
overcrowding in the high school that limited physical distancing,
and extracurricular activities were not banned.
Of the ecological studies assessing community transmission
(see Appendix Table A2), ten were conducted across multiple
countries, five in the United States, two in Asia and two
in Europe. Five studies reported that school closures and
re-openings were not significantly associated with reduction
in the transmission and incidence of COVID-19 and were
much less effective in reducing transmission when compared
with other NPIs (21–25). Four studies reported a reduction in
the incidence of COVID-19 in the community ranging from
8% to 62% following school closures (26–29). Other studies
reported a significant reduction in the effective reproduction
number (Rt) (30–32). Three studies attributed significant
reductions in mortality to school closures (29,33,34) and
one study reported increased mortality with delayed school
closures (35).
Discussion
Overall, the evidence from these studies was mixed and
varied due to several factors. Based on the findings of the
observational studies assessing the incidence of COVID-19 in
schools, school closures and re-openings did not significantly
contribute to COVID-19 transmission when infection prevention
and control measures (IPAC) were implemented in schools. The
IPAC measures implemented by the schools were similar across
most of the observational studies and included masks, physical
distancing, frequent cleaning, reduced class sizes and improved
hand hygiene. The implementation of these measures in schools
have been reported to act as a mediating variable because
of the reduced transmission and risk of infection with IPAC
measures (36).
The findings from the ecological studies assessing community
transmission were inconsistent, with some studies reporting
that school closures/re-openings were not significantly
associated with reduction in transmission (21–25), and other
studies reporting a significant reduction in Rt (30–32) and
mortality (29,33,34). In several of these ecological studies, it
was reported that other NPIs such as lockdowns, gathering
bans, mask mandates, non-essential business closure and travel
restrictions were more effective than school closures in reducing
the transmission of COVID-19. Ecological studies are considered
a low level of evidence due to the research design, the multiple
confounding factors and the high degree of variability in the
results. All of the ecological studies included in this review
analyzed data on school closures/re-openings early in the
pandemic, between January–August 2020, when multiple NPIs
were implemented simultaneously. Therefore, it was not possible
to isolate the impact of school closures/re-openings on the
CCDR • December 2021 • Vol. 47 No. 12
Page 516
RAPID COMMUNICATION
number of cases of COVID-19 in the community. Additionally,
only one of the ecological studies described if there was
adherence to IPAC measures in the schools (25). These factors
likely contribute to the heterogeneity between studies.
An important limitation of this review was the inconsistencies in
the levels of schooling that were included in each study, which
may have increased the variability in measures of how effective
school closures were across studies. Most studies did not provide
information on what schools were included when determining
the impact of school closures on the spread of COVID-19. Some
studies measured primary and secondary school closures alone
and some measured them in combination with post-secondary
schools. The risk of transmission may have varied significantly
between students in primary and secondary schools because
of potential differences in their behaviours and adherence to
IPAC measures with resultant difference in reduction of viral
transmission. Transmission was found to be lower in primary
schools relative to secondary schools, based on the results of one
study in a review that assessed this (19). Although not specifically
stated in the previous study, their results were in line with what
we know about the use of IPAC to limit transmission in these
settings (37). Additionally, the relative impact of school closures
and re-openings have been shown to vary according to the time
of implementation, level of community transmission, and the
structure of populations from different countries.
Based on the empirical evidence summarized in this article,
school closures had a small effect on limiting the spread of
COVID-19 in schools and the community and appeared to
be much less effective than other NPIs. These findings are
also consistent with modelling studies conducted across
Canada (9–15). The implementation of school closures is
currently based on when the transmission of COVID-19 in the
community is high—as dictated by local health jurisdictions;
however, the role of school closures and re-opening in areas with
low community transmission is less clear and should be studied
further.
School closures may be associated with negative effects on
student’s mental health and academic progress (2); thus, public
health decision makers should consider if the apparent low
efficacy of school closures in reducing transmission outweighs
the many negative consequences on students’ well-being.
Overall, the confidence in this evidence is low given that the
studies in this review vary by several factors and were conducted
at different times and in a number of countries. Finally, the study
period of this review is also a limitation, as there are marked
differences in the 3rd and 4th waves compared with the 1st and 2nd
waves of COVID-19 with the introduction of more transmissible
variants of concern. How the present evidence will compare with
that obtained during periods of the spread of more transmissible
Page 517
CCDR • December 2021 • Vol. 47 No. 12
variants of concern is not known at this time and will require
further study.
Conclusion
The findings of this review may have implications for public
health decision making and future research on mitigation
strategies for schools. The preliminary evidence provided in this
review suggests that school closures and re-openings may have
only a limited impact on the transmission of COVID-19 within a
community. However, there is still a high degree of uncertainty
due to the high variation in the methodology and results across
the various studies. Additional research is needed to further
explore more systematically the impacts of school closures and
to determine how and when they may be used most effectively in
controlling the epidemic.
Important knowledge gaps to consider are how 1) the presence
of new variants of concern and 2) the rollout of COVID-19
vaccinations will impact the transmission of COVID-19 within the
schools and communities. The evidence presented in this article
pre-dates the introduction of variants of concern; therefore,
additional research is needed to understand how the emergence
and spread of these variants will impact the effectiveness of
school closures or what the impact of school re-openings will
have on the spread of COVID-19.
Authors’ statement
MEJ — Methodology, investigation, writing–original draft
RE — Conceptualization, writing–review and editing, supervision
LW — Writing–review and editing
PH — Writing–review and editing
NA — Writing–review and editing
MS — Writing–review and editing
SB-A — Writing–review and editing
Competing interests
None.
Acknowledgements
We would like to acknowledge the work of the Emerging Science
Group for allowing us to collaborate with them on this important
issue.
Funding
None.
RAPID COMMUNICATION
References
1.
2.
3.
World Health Organization. WHO Director-General’s
opening remarks at the media briefing on COVID-19
- 11 March 2020. Geneva (CH): WHO; 2020 (accessed
2021-05-27). https://www.who.int/director-general/
speeches/detail/who-director-general-s-opening-remarks-atthe-media-briefing-on-covid-19---11-march-2020
Viner R, Russell S, Saulle R, Croker H, Stansfeld C,
Packer J, Nicholls D, Goddings A-L, Bonell C, Hudson L,
Hope S, Schwalbe N, Morgan A, Minozzi S. Impacts
of school closures on physical and mental health of
children and young people: a systematic review. medRxiv.
2021;2021.02.10.21251526. DOI
Bahn GH. Coronavirus disease 2019, school closures, and
children’s mental health. Soa Chongsonyon Chongsin Uihak
2020;31(2):74–9. DOI PubMed
12. Davies NG, Kucharski AJ, Eggo RM, Gimma A,
Edmunds WJ; Centre for the Mathematical Modelling of
Infectious Diseases COVID-19 working group. Effects of
non-pharmaceutical interventions on COVID-19 cases,
deaths, and demand for hospital services in the UK: a
modelling study. Lancet Public Health 2020;5(7):e375–85.
DOI PubMed
13. Koo JR, Cook AR, Park M, Sun Y, Sun H, Lim JT, Tam C,
Dickens BL. Interventions to mitigate early spread of
SARS-CoV-2 in Singapore: a modelling study. Lancet Infect
Dis 2020;20(6):678–88. DOI PubMed
14. Courtemanche C, Garuccio J, Le A, Pinkston J, Yelowitz A.
Strong social distancing measures in the United States
reduced the covid-19 growth rate. Health Aff (Millwood)
2020;39(7):1237–46. DOI PubMed
4.
Lee J. Mental health effects of school closures during
COVID-19. Lancet Child Adolesc Health 2020;4(6):421.
DOI PubMed
15. Garchitorena A, Gruson H, Cazelles B, Karki T, Sudre B,
Roche B. Integrated packages of non-pharmaceutical
interventions increased public health response efficiency
against COVID-19 during the first European wave:
evidence from 32 European countries. medRxiv. 2020;
2020.08.17.20174821v2. DOI
5.
London School Economics and Polital Science. Eyles A,
Gibbons S, Montebruno P. Covid-19 school shutdowns:
What will they do to our children’s education? LSE; 2020.
http://eprints.lse.ac.uk/104675/3/Eyles_covid_19_school_
shutdowns_published.pdf
16. Kriger O, Lustig Y, Cohen C, Amit S, Biber A, Barkai G,
Talmi L, Gefen-Halevi S, Mechnik B, Regev-Yochay G.
The Sheba Medical Center healthcare workers’ children’s
school: can we open schools safely? Clin Microbiol Infect
2021;27(3):474.e1–3. DOI PubMed
6.
Kuhfeld M, Soland J, Tarasawa B, Johnson A, Ruzek
E, Liu J. Projecting the Potential Impact of COVID-19
School Closures on Academic Achievement. Educ Res
2020;49(8):549–65. DOI
17. Gandini S, Rainisio M, Luisa Iannuzzo M, Bellerba F,
Cecconi F, Scorrano L. No evidence of association between
schools and SARS-CoV-2 second wave in Italy.
med Rxiv. 2020; 2020.12.16.20248134v2. DOI
7.
National Collaborating Centre for Infectious Diseases.
Isfeld-Kiely H, Moghadas S. Effectiveness of School Closure
for the Control of Influenza A Review of Recent Evidence.
NCCID; 2014. https://nccid.ca/publications/effectiveness-ofschool-closure-for-the-control-of-influenza/
8.
World Health Organization. Non-pharmaceutical public
health measures for mitigating the risk and impact of
epidemic and pandemic influenza. Geneva (CH): WHO;
2019 (accessed 2021-04-27). http://www.who.int/influenza/
publications/public_health_measures/publication/en/
18. Fontanet A, Grant R, Tondeur L, Madec Y, Grzelak
L, Cailleau I, Ungeheuer M-N, Renaudat C,
Fernandes Pellerin S, Kuhmel L, Staropoli I, Anna F,
Charneau P, Demeret C, Bruel T, Schwartz O, Hoen B.
SARS-CoV-2 infection in primary schools in northern France:
A retrospective cohort study in an area of high transmission.
medRxiv. 2020;2020.06.25.20140178v2. DOI
9.
Abdollahi E, Haworth-Brockman M, Keynan Y, Langley JM,
Moghadas SM. Simulating the effect of school closure
during COVID-19 outbreaks in Ontario, Canada. BMC Med
2020;18(1):230. DOI PubMed
10. Naimark D, Mishra S, Barrett K, Khan YA, Mac S,
Ximenes R, Sander B. Simulation-Based Estimation of
SARS-CoV-2 Infections Associated With School Closures
and Community-Based Nonpharmaceutical Interventions in
Ontario, Canada. JAMA Netw Open 2021;4(3):e213793.
DOI PubMed
11. Ng V, Fazil A, Waddell LA, Bancej C, Turgeon P,
Otten A, Atchessi N, Ogden NH. Projected effects of
nonpharmaceutical public health interventions to prevent
resurgence of SARS-CoV-2 transmission in Canada. CMAJ
2020;192(37):E1053–64. DOI PubMed
19. Larosa E, Djuric O, Cassinadri M, Cilloni S, Bisaccia E,
Vicentini M, Venturelli F, Giorgi Rossi P, Pezzotti P,
Bedeschi E; Reggio Emilia Covid-19 Working Group.
Secondary transmission of COVID-19 in preschool and
school settings in northern Italy after their reopening in
September 2020: a population-based study. Euro Surveill
2020;25(49):2001911. DOI PubMed
20. Stein-Zamir C, Abramson N, Shoob H, Libal E, Bitan M,
Cardash T, Cayam R, Miskin I. A large COVID-19 outbreak in
a high school 10 days after schools’ reopening, Israel, May
2020. Euro Surveill 2020;25(29):2001352. DOI PubMed
21. An B, Porcher S, Tang SY, Kim E. Effects of Early Mask
Mandates and Other Policy Interventions on COVID-19
Infections. Research Square. 2021. DOI
22. Liu X, Xu X, Li G, Xu X, Sun Y, Wang F, Shi X, Li X, Xie G,
Zhang L. Differential impact of non-pharmaceutical public
health interventions on COVID-19 epidemics in the United
States. BMC Public Health 2021;21(1):965. DOI PubMed
CCDR • December 2021 • Vol. 47 No. 12
Page 518
RAPID COMMUNICATION
23. Iwata K, Doi A, Miyakoshi C. Was school closure effective
in mitigating coronavirus disease 2019 (COVID-19)? Time
series analysis using Bayesian inference. Int J Infect Dis
2020;99:57–61. DOI PubMed
24. Wieland T. A phenomenological approach to assessing
the effectiveness of COVID-19 related nonpharmaceutical
interventions in Germany. Saf Sci 2020;131:104924.
DOI PubMed
25. Ehrhardt J, Ekinci A, Krehl H, Meincke M, Finci I, Klein J,
Geisel B, Wagner-Wiening C, Eichner M, Brockmann SO.
Transmission of SARS-CoV-2 in children aged 0 to 19 years
in childcare facilities and schools after their reopening in
May 2020, Baden-Württemberg, Germany. Euro Surveill
2020;25(36):2001587. DOI PubMed
26. Banholzer N, van Weenen E, Lison A, Cenedese A,
Seeliger A, Kratzwald B, Tschernutter D, Salles JP, Bottrighi P,
Lehtinen S, Feuerriegel S, Vach W. Estimating the effects
of non-pharmaceutical interventions on the number of new
infections with COVID-19 during the first epidemic wave.
PLoS One 2021;16(6):e0252827. DOI PubMed
27. Banholzer N, van Weenen E, Kratzwald B, Seeliger A,
Tschernutter D, Bottrighi P, Cenedese A, Salles JP, Vach W,
Feuerriegel S. Impact of non-pharmaceutical interventions
on documented cases of COVID-19. medRxiv. 2020;
2020.04.16.20062141v3. DOI
28. Brauner JM, Mindermann S, Sharma M, Johnston D,
Salvatier J, Gavenčiak T, Stephenson AB, Leech G, Altman G,
Mikulik V, Norman AJ, Monrad JT, Besiroglu T, Ge H,
Hartwick MA, Teh YW, Chindelevitch L, Gal Y, Kulveit J.
Inferring the effectiveness of government interventions
against COVID-19. Science 2021;371(6531):eabd9338.
DOI PubMed
29. Auger KA, Shah SS, Richardson T, Hartley D, Hall M,
Warniment A, Timmons K, Bosse D, Ferris SA, Brady PW,
Schondelmeyer AC, Thomson JE. Association Between
Statewide School Closure and COVID-19 Incidence and
Mortality in the US. JAMA 2020;324(9):859–70. DOI PubMed
30. Esra R, Jamieson L, Fox MP, Letswalo D, Ngcobo N,
Mngadi S, Estill J, Meyer-Rath G, Keiser O. Evaluating the
impact of non-pharmaceutical interventions for SARS-CoV-2
on a global scale. medRxiv 2020; 2020.07.30.2016439. DOI
31. Dreher N, Spiera Z, Mcauley FM, Kuohn L, Durbin JR,
Marayati NF, Ali M, Li AY, Hannah TC, Gometz A,
Kostman JT, Choudhri TF. Impact of policy interventions and
social distancing on SARS-CoV-2 transmission in the United
States. medRxiv. 2020; 2020.05.01.20088179v1. DOI
Page 519
CCDR • December 2021 • Vol. 47 No. 12
32. Cowling BJ, Ali ST, Ng TW, Tsang TK, Li JC, Fong MW,
Liao Q, Kwan MY, Lee SL, Chiu SS, Wu JT, Wu P, Leung GM.
Impact assessment of non-pharmaceutical interventions
against coronavirus disease 2019 and influenza in Hong
Kong: an observational study. Lancet Public Health
2020;5(5):e279–88. DOI PubMed
33. Stokes, J, Turner AJ, Anselmi L, Morciano M, Hone T. The
relative effects of non-pharmaceutical interventions on early
Covid-19 mortality: natural experiment in 130 countries.
medRxiv.2020; 2020.10.05.20206888v1. DOI
34. Pasdar Z, Pana TA, Ewers KD, Szlachetka WA,
Perdomo-Lampignano JA, Gamble DT, Bhattacharya S,
Carter B, Myint PK. An Ecological Study Assessing the
Relationship between Public Health Policies and Severity of
the COVID-19 Pandemic. SSRN Electron J. 2020.
https://papers.ssrn.com/abstract=3634847
35. Yehya N, Venkataramani A, Harhay MO. Statewide
Interventions and Coronavirus Disease 2019 Mortality in
the United States: An Observational Study. Clin Infect Dis
2021;73(7):e1863–9. DOI PubMed
36. Public Health Ontario. Technical Brief. IPAC
Recommendations for Use of Personal Protective Equipment
for Care of Individuals with Suspect or Confirmed COVID-19.
Toronto (ON): PHO; 2021. https://www.publichealthontario.
ca/-/media/documents/ncov/updated-ipac-measurescovid-19.pdf?la=en
37. National Collaborating Centre for Methods and Tools.
Living Rapid Review Update 17: What is the specific role of
daycares and schools in COVID-19 transmission? Hamilton
(ON): NCCMT; 2021 (accessed 2021-10-28). https://www.
nccmt.ca/covid-19/covid-19-rapid-evidence-service/19
38. Klimek-Tulwin M, Tulwin T. Early school closures can reduce
the first-wave of the COVID-19 pandemic development.
J Public Health (Berl.) 2020. DOI
39. Papadopoulos DI, Donkov I, Charitopoulos K, Bishara S. The
impact of lockdown measures on COVID-19: a worldwide
comparison. medRxiv. 2020; 2020.05.22.20106476v2. DOI
40. Jüni P, Rothenbühler M, Bobos P, Thorpe KE, da Costa BR,
Fisman DN, Slutsky AS, Gesink D. Impact of climate and
public health interventions on the COVID-19 pandemic: a
prospective cohort study. CMAJ 2020;192(21):E566–73.
DOI PubMed
41. Krishnamachari B, Morris A, Zastrow D, Dsida A, Harper B,
Santella AJ. Effects of Government Mandated Social
Distancing Measures on Cumulative Incidence of COVID-19
in the United States and its Most Populated Cities. medRxiv.
2020; 2020.05.22.20110460v1. DOI
RAPID COMMUNICATION
Appendix: Tables
Appendix Table A1: Summary of observational studies assessing the impact of school closures or re-openings on
the transmission of COVID-19 in schools and the community (n=5)
Method
Study
Key outcomes
Cohort studies (n=2)
Gandini (2020) (17)
Prospective cohort study
and cross-sectional
study
Italy
Sep–Nov 2020
Fontanet (2020) (18)
Retrospective cohort
study
France
Feb–Apr 2020
This study analyzed the association between school
re-opening dates and COVID-19 cases across twenty-one
Italian regions by using a database on positive cases in
elementary, middle and high schools and SARS-CoV-2
incidence in the general population. IPAC measures included
temperature control, hand hygiene, mask mandate for
students/staff, physical distancing, ban on sports and music
and reduced duration of school.
There was no evidence that the second SARS-CoV-2
wave was driven by school re-openings across the
regions.
Several COVID-19 outcomes were measured during school
re-openings: growth of incidence, Rt, and secondary
infections.
School closures implemented in two regions did not
affect the decline of Rt.
This retrospective cohort study included primary school
pupils, teachers, non-teaching staff, parents and relatives
exposed to SARS-CoV-2 in February and March from six
schools. IPAC measures were not described.
IAR was 45/510 (8.8%), 3/42 (7.1%), 1/28 (3.6%),
76/641 (11.9%) and 14/119 (11.8%) among primary
school pupils, teachers, non-teaching staff, parents and
relatives, respectively (p=0.29).
A questionnaire covering sociodemographic information and
history of recent symptoms was completed by participants.
Blood samples were also tested for the presence of
anti-SARS-CoV-2 antibodies using a flow-cytometry-based
assay. Three introductions of SARS-CoV-2 occurred prior
to school closures. Spread within schools vs families was
investigated in this sero-epidemiological study. IAR was
compared between school contacts and family contacts to
understand the potential impact of the school closure.
No secondary infections from COVID-19 introductions
in schools was detected among students and teachers.
SARS-CoV-2 incidence among students was lower than
the general population of all but two Italian regions.
The increase in Rt was not associated with the different
school opening dates.
Among pupils who were infected, their parents were
significantly more likely to be infected (61.0% versus
6.9%; p<0.0001), The same was identified among
relatives of infected pupils compared with non-infected
pupils (44.4% versus 9.1%; p=0.002).
Transmission did not appear to be impacted by the
closure of schools.
Cross-sectional studies (n=1)
Kriger (2020) (16)
Cross-sectional study
Israel
Mar–May 2020
During a national lockdown, an alternative school was used
for healthcare workers’ children to attend with strict symptom
surveillance. Families with children who remained at home
were compared with children at this alternative school. IPAC
measures in the school included daily disinfecting, face mask
use by staff and frequent hand washing.
Symptoms were reported in approximately 16% of
children in both groups: those who attended the school
(n=11/70) and those who did not (n=6/36).
Positive serology tests showing previous exposure was
detected in less than 2% of each group and they were
not significantly different from each other.
This cross-sectional study included 70 children who attended
There was no evidence of increased infection in those at
the alternative primary school and 36 who stayed home, along school compared with those at home.
with their 78 parents.
Data was collected through a short questionnaire;
nasopharyngeal and oropharyngeal swabs were obtained and
tested for SARS-CoV-2 by RT-PCR, and blood was collected
for SARS-CoV-2 IgA and IgG titres.
Cluster and outbreak investigations (n=2)
Larosa (2020) (19)
Cluster investigation
Italy
Sep–Oct 2020
Stein-Zamir (2020) (20)
Outbreak investigation
Israel
May–Jun 2020
This cluster investigation analysed the transmission of
COVID-19 in 41 classes of 36 schools upon their re-opening
in northern Italy. The secondary attack rate was measured in
students and teachers in elementary and secondary schools
(middle and high schools). IPAC measures included: mask
mandate for high school students only, physical distancing
and ban of extracurricular activities.
Secondary attack rate for COVID-19 was reported to be
higher in secondary schools (6.6%) than in elementary
schools (0.38%).
This outbreak investigation study assessed the
epidemiological characteristics of a high school outbreak
in Jerusalem that displayed mass COVID-19 transmission
upon school reopening on May 17. The high school included
grades 7–12.
It was reported that the proportion of the 10–19
year-olds was 19.8% (n=938/4,747) of the cases before
May 24th, and then increased to 40.9% (n=316/772)
after May 24th.
An extreme heatwave occurred upon the re-opening of the
school. IPAC measures: face mask use was lifted for three
days during the heatwave, physical distancing was below the
standard in overcrowded classes, and extracurricular activities
were not banned.
Testing of the whole school revealed that 153 students
(attack rate: 13.2%) and 25 staff members (attack rate:
16.6%) were COVID-19 positive.
COVID-19 rates were higher in students in grades 7–9
than in grades 10–12.
Abbreviations: COVID-19, coronavirus disease 2019; IAR, infection attack rate; IgA, immunoglobulin A; IgG, immunoglobulin G; IPAC, infection prevention and control; Rt, effective reproduction
number; RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
CCDR • December 2021 • Vol. 47 No. 12
Page 520
RAPID COMMUNICATION
Appendix Table A2: Summary of ecological studies assessing the effectiveness of school closures or re-openings on
reducing spread of COVID-19 in the community (n=19)
Study
Method
Key outcomes
This study aimed to identify associations between six NPIs and
the number of COVID-19 infections. Using worldwide data on
NPIs and COVID-19 infections between Jan–Jul 2020, analysis was
conducted on the short- and long-term effects of NPIs on new
infection rates five, nine, 12, and 21 days after their adoption. IPAC
measures and level of schooling included in the study were not
described.
School closures took more time than other NPIs to show
efficacy. After a time lag, the impact of school closures on
new case rates was -0.492 (SE=0.16) at 12 days (p<0.01),
-0.722 (SE=0.148) at 21 days (p<0.001), and -0.824
(SE=0.0967) at 30 days (p<0.001).
Global (n=10)
An (2021) (21)
Ecological study
Global
Jan–Jul 2020
NPIs examined included mask mandates, international travel
restrictions, domestic lockdowns, mass gathering bans, restaurant
closures and school closures.
Banholzer (2020) (27)
Ecological study
20 countries
In this study, the impact of NPIs on the relative reduction of
new COVID-19 cases using a Bayesian hierarchical model with
a time-delayed effect for each NPI. IPAC measures were not
described.
Apr 2020
NPIs examined included 1) primary school closures, 2) border
closures, 3) public event bans, 4) gathering bans, 5) venue closures,
6) lockdowns prohibiting public movements without valid reason
and 7) work bans on non-essential business activities.
Banholzer (2021) (26)
Using a semi-mechanistic Bayesian hierarchical model, this study
aimed to measure the effectiveness of seven NPIs in reducing the
number of new infections. IPAC measures were not described.
Ecological study
20 countries
NPIs examined included 1) primary school closures, 2) border
closures, 3) public event bans, 4) gathering bans, 5) venue closures,
6) lockdowns prohibiting public movements without valid reason
and 7) work bans on non-essential business activities.
Feb–May 2020
Brauner (2021) (28)
This study estimated the effectiveness of NPIs in 41 countries
using a Bayesian hierarchical model by linking intervention
implementation dates to national case and death counts.
Ecological study
41 countries
Intervention effect sizes were categorized by the median
reductions in the Rt of less than 17.5% (small), between 17.5 and
35% (moderate) and at least 35% (large). NPIs examined included:
limiting gatherings to fewer than 1,000 or fewer than 100 or fewer
than 10, closing some businesses, closing most businesses, closing
schools and universities, and stay at home orders. IPAC measures
were not described.
Jan–May 2020
Klimek-Tulwin (2020) (38)
Ecological study
Global
Mar 2020
This study aimed to assess the effect of school closures on
COVID-19 cases globally by measuring correlation between the
incidence rate on the day of school closure and the incidence
rate in the following days. IPAC measures and level of schooling
included in the study were not described.
School closures were not found to have significant effects
on population-adjusted infections in the long-term (90th to
120th day).
The mean reduction of new COVID-19 cases with primary
school closures was 8% (95% CI: 0%–23%).
Compared with other NPIs examined, school closures
appeared to be one of the least effective NPIs.
The relative reduction of new COVID-19 cases with
primary school closures was 17% (95% CI: 2%–36%).
This reduction was lower than two other NPIs (event bans
and venue closures).
The percentage reduction in Rt associated with closing
both schools and universities in conjunction was 38% (95%
CI: 16%–54%), which was categorized as a large effect
size.
The individual effects of school closures was not
measured.
The results indicate that there was a strong correlation
between the day of educational facilities closure and
the incidence rate in the following days (16th (p=0.004),
30th (p=0.002) and 60th (p=0.031) days since the 100th
confirmed case in each country).
Early closure of schools is statistically significantly
correlated with lower incidence rates further on during the
different phases of the epidemic.
Papadopoulos (2020) (39)
Ecological study
Global
Jan–Apr 2020
Pasdar (2020) (34)
Ecological study
22 countries
May 2020
Esra (2020) (30)
Ecological study
Global
Jan–May 2020
Page 521
The impact of lockdown measures was assessed globally using
publicly available data. The timing and association of early NPIs
with log10 national deaths (LogD) and log10 national cases (LogC)
was compared between nations. IPAC measures and level of
schooling included in the study were not described.
Early generalized school closure (p=0.050, regression
coefficient ß=-0.012, 95% CI: 0%–-0.024%) was associated
with reduced LogC (log10 national cases).
The aim of this study was to determine the associations between
NPIs and COVID-19 outcomes.
School closures were effective against all outcomes,
except time to reaching the peak of the epidemic curve.
Associations with NPIs were assessed with their respective
stringency index on several outcomes that form the epidemic
curve: mean mortality rate, time to peak, peak deaths per 100,000
population, cumulative deaths after peak per 100,000 population
and ratio of the mean slope of the descending curve to the
mean slope of the ascending curve. IPAC measures and level of
schooling included in the study were not described.
The strongest association was seen in cumulative deaths
after peak, per 100,000 (rs=-0.744, p=0.009).
This study used globally reported data on SARS-CoV-2 cases to fit
a Bayesian model framework to estimate the association with NPIs
and transmission.
There was an estimated mean reduction in Rt of 12% (95%
CI: 5%–19%) with school closures (primary, secondary and
tertiary educational institutions).
NPIs examined include stay home mandates, gathering limits,
school closures (primary, secondary and tertiary educational
institutions) and mask policies. IPAC measures were not described.
CCDR • December 2021 • Vol. 47 No. 12
In non-European countries, school closures were most
effective against mean mortality rate (rs=-0.757, p=0.049).
RAPID COMMUNICATION
Appendix Table A2: Summary of ecological studies assessing the effectiveness of school closures or re-openings on
reducing spread of COVID-19 in the community (n=19) (continued)
Study
Method
Key outcomes
Global (n=10) (continued)
Jüni (2020) (40)
Ecological study
Global
Mar 2020
Stokes (2020) (33)
Ecological study
Global
Jun 2020
This prospective study of geopolitical areas aimed to determine
whether climate or public health interventions are associated with
reducing transmission of COVID-19.
A weighted random effects regression was used to determine the
association between epidemic growth RRR and climate measures
and public health interventions such as school closures, restrictions
of mass gatherings and measures of social distancing during an
exposure period 14 days previously. IPAC measures and level of
schooling included in the study were not described.
This study examined the variation of NPIs in 130 countries in two
periods: 1) prior to first COVID-19 death and 2) 14-days-post first
COVID-19 death.
This study examined associations with daily COVID-19 deaths per
million and each 24 day period (time between virus transmission
and mortality). IPAC measures and level of schooling included in
the study were not described.
Strong negative associations with epidemic growth were
found for school closures (RRR - 0.63, 95%
CI: 0.52%–0.78%).
This association was more pronounced in areas that
implemented two or three NPIs compared with one NPI.
Stricter/earlier school closures were associated with the
largest reductions in COVID-19 deaths (-1.23 per million
[95% CI: -2.20%–-0.27%]) compared with other NPIs.
North America (n=5)
Auger (2020) (29)
Ecological study
US
Mar–May 2020
Dreher (2020) (31)
Ecological study
US
Apr 2020
This study aimed to determine if school closures were associated
with a decrease in the cumulative incidence of COVID-19 and
mortality.
The impact of primary and secondary school closures was assessed
using publicly available data from all 50 states. IPAC measures
were not described.
This study aimed to measure the impact of NPIs on the effective Rt
of COVID-19 in US states.
The average Rt was measured during the weeks after each state
reached 500 cases. Rt was measured at the week immediately
following 500th case (days +1 to +7) and at a one-week delay from
500th case (days +8 to +14).
NPIs examined included stay at home order, educational facilities
closure and non-essential business closure. IPAC measures and
level of schooling included in the study were not described.
Krishnamachari (2020) (41)
Ecological study
US
May 2020
This study aimed to examine the effects of NPIs on the cumulative
incidence rates of COVID-19 in the US on a state-level in the 25
most populated cities, while adjusting for socio-demographic risk
factors.
A negative binomial regression was used to calculate adjusted rate
ratios by comparing two levels of a binary variable: “above median
value,” and “median value and below” for days to implementing
an NPI.
Results showed that school closures were associated with
a significant decline in incidence of COVID-19 (-62% [95%
CI: -71%–-49%]) and in mortality (-58% [95%
CI: -68%–-46%]).
These associations were stronger in states with a low
cumulative incidence of COVID-19 at the time of the
school closure.
Educational facilities closure was associated with a
significant reduction in Rt compared with states without
this policy the week following 500 cases
(ß=-0.17, 95% CI: -0.30%–-0.05%, p=0.009).
From days 8 to 14 after the 500th case date, educational
facilities closure was associated with a significant
reduction in Rt compared with controls
(ß=-0.12, 95% CI: -0.21%–-0.04%, p=0.006).
Days to school closing was associated with cumulative
incidence on days 35 and 42, with an adjusted rate ratio
of 1.59 (95% CI: 1.03%–2.44%, p=0.04) at 35 days, and
adjusted rate ratio of 1.64 (95%
CI: 1.07%–2.52%, p=0.04) at 42 days.
Delays in closing schools was positively associated with
cumulative incidence at the state level.
NPIs assessed in this study included: days to closing of nonessential businesses, days to stay home orders, days to restrictions
on gatherings, days to restaurant closings and days to schools
closing. IPAC measures and level of schooling included in the study
were not described.
Liu (2020) (22)
Ecological study
US
Feb–Apr 2020
Yehya (2020) (35)
Ecological study
US
Jan–Apr 2020
This study estimated the impact of nine different NPIs on
reduction of the effective Rt by using the daily number of
reported new cases and inferred infections in 50 states. IPAC
measures and level of schooling included in the study were not
described.
Closing schools was found to moderately reduce Rt by
about 10% (95% CI: 7%–14%).
In this study, a state-level analysis was conducted to determine
association between later implemented NPIs with higher
mortality rates.
Later school closure was associated with more deaths
(adjusted mortality rate ratio 1.05; 95% CI:
1.01%–1.09%; p=0.008).
This reduction was smaller than six other NPIs
assessed (stay-at-home order, face masks, gathering
ban, non-essential business closure, declaration of
state of emergency and interstate travel restriction).
Using a multivariable negative binomial regression, the
association was tested between timing of emergency
declarations and school closures with 28-day mortality. Day 1
for each state was set to when they recorded 10 or more
deaths. IPAC measures and level of schooling included in the
study were not described.
CCDR • December 2021 • Vol. 47 No. 12
Page 522
RAPID COMMUNICATION
Appendix Table A2: Summary of ecological studies assessing the effectiveness of school closures or re-openings on
reducing spread of COVID-19 in the community (n=19) (continued)
Study
Method
Key outcomes
Asia (n=2)
Cowling (2020) (32)
Ecological study
This study examined the effect of public health interventions
on the incidence of COVID-19 and on the daily effective Rt.
Laboratory-confirmed COVID-19 cases and the daily effective
Rt were estimated to determine changes in transmissibility
over time. School closures included kindergartens up to
tertiary and post-tertiary institutions, and tutorial centres. IPAC
measures were not described.
Hong Kong
Jan–Feb 2020
Kentaro (2020) (23)
Ecological study
Japan
This study aimed to assess the effectiveness of primary and
secondary school closures on COVID-19 incidence nine days
after implementation. IPAC measures were not described.
Using a Bayesian method, time-series analyses were
conducted, and local linear trend models were developed for
the number of newly reported cases of COVID-19.
Mar 2020
The estimated Rt was 1.28 (95% CI: 1.26%–1.30%)
during the 2-week period before the start of the
school closures and 0.72 (95% CI: 0.70%–0.74%)
during the first two weeks of school closures,
corresponding to a 44% (95% CI: 34%–53%) reduction
in transmissibility.
Rt calculated from hospitalization data was 1.10
(1.06–1.12) before the start of the school closures
and reduced to 0.73 (0.68–0.77) after school closures,
corresponding to a 33% (95% CI: 24%–43%) reduction
in transmissibility.
The school closure intervention was not effective in
decreasing the incidence of COVID-19.
The newly reported COVID-19 cases continued to rise
(α - 0.08, 95% CI: -0.36%–0.65%).
Europe (n=2)
Wieland (2020) (24)
Ecological study
Germany
The aim of this study was to assess the effectiveness of
different NPIs against the spread of COVID-19 over time.
School closures included day-care closures as well. IPAC
measures were not described.
Mar–Apr 2020
Using publicly available data on daily reported German
cases, exponential growth models for infections and Rt were
estimated and investigated with respect to change points in
the time series.
Ehrhardt (2020) (25)
This study aimed to assess the transmission of SARS-CoV-2
among children in primary schools, secondary schools and
childcare facilities in Baden-Württemberg, Germany after
school re-openings in May 2020. IPAC measures included:
reduced class size, disinfecting, hand hygiene and banning of
sports and music in primary and secondary schools.
Ecological study
Germany
Feb–Aug 2020
An epidemic curve was used to show daily new cases after the
schools reopened.
No significant effect was found on COVID-19
infections that could be attributed to school and
day-care closures.
Child-to-child transmission in schools was low.
The study estimated that one secondary case
originates per 25 infectious school days (days that
cases spent at school during infectious period).
School re-openings were not associated with a change
in transmission of SARS-CoV-2.
Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; IPAC, infection prevention and control; NPI, non-pharmaceutical intervention; RRR, ratios of rate ratios;
rs, respective stringency index; Rt, effective reproduction number; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SE; standard error; US, United States
Page 523
CCDR • December 2021 • Vol. 47 No. 12
QUALITATIVE STUDY
Among sheeples and antivaxxers: Social
media responses to COVID-19 vaccine news
posted by Canadian news organizations, and
recommendations to counter vaccine hesitancy
Lisa Tang1*, Sabrina Douglas1, Amar Laila1
Abstract
This work is licensed under a Creative
Commons Attribution 4.0 International
License.
Background: To create a successful public health initiative that counters vaccine hesitancy
and promotes vaccine acceptance, it is essential to gain a strong understanding of the beliefs,
attitudes and subjective risk perceptions of the population.
Affiliation
Methods: A qualitative analysis of coronavirus disease 2019 (COVID-19) vaccine discourse
from 3,731 social media posts on the Twitter and Facebook accounts of six Canadian news
organizations was used to identify the perceptions, attitudes, beliefs and intentions of Canadian
news organizations' social media commenters toward taking a COVID-19 vaccine.
Department of Family Relations
and Applied Nutrition, University
of Guelph, Guelph, ON
1
*Correspondence:
Results: Four main themes were identified: 1) COVID-19 vaccine safety and efficacy concerns;
2) conspiracy theories stemming from mistrust in government and other organizations; 3) a
COVID-19 vaccine is unnecessary because the virus is not dangerous; and 4) trust in COVID-19
vaccines as a safe solution. Based on themes and subthemes, several key communication
recommendations were developed for promotion of COVID-19 vaccine acceptance, including
infographics championed by Public Health that highlight the benefits of the vaccine for those
who have received it, public education about the contents and safety of the vaccine and
eliciting an emotional connection through personal stories of those impacted by COVID-19.
lisa.tang@uoguelph.ca
Conclusion: Specific considerations, such as leveraging the public's trust in healthcare
professionals to act as a liaison between Public Health and the Canadian public to communicate
the benefits of the vaccine against COVID-19 and its variants, may help reduce COVID-19
vaccine hesitancy.
Suggested citation: Tang L, Douglas S, Laila A. Among sheeples and antivaxxers: Social media responses to
COVID-19 vaccine news posted by Canadian news organizations, and recommendations to counter vaccine
hesitancy. Can Commun Dis Rep 2021;47(12):524–33. https://doi.org/10.14745/ccdr.v47i12a03
Keywords: vaccine hesitancy, social media, health communication, COVID-19, vaccines
Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
is an infectious respiratory pathogen responsible for coronavirus
disease 2019 (COVID-19) (1). To slow the spread of COVID-19,
many regions within Canada instituted indoor mask use and
physical distancing. On March 23, 2020, Prime Minister Justin
Trudeau urged Canadians to "go home and stay home" and
adhere to physical distancing recommendations. Following
increasing evidence of asymptomatic spread, on April 6, 2020,
Canada’s Chief Public Health Officer recommended Canadians
wear non-medical masks (2). Even with these mitigation
measures, as of September 2021 there were more than
27,000 deaths in Canada—and over 4.6 million deaths
worldwide (3,4). Given that vaccines are the most successful
and important public health intervention to prevent spread
of infectious disease (5), it has become well accepted that a
COVID-19 vaccine is the best way to develop both personal
and population-level immunity (6,7). In September 2020,
the expedited process of approving COVID-19 vaccines was
authorized in Canada (8), which allowed for approval of PfizerBioNTech, Moderna, AstraZeneca and Janssen vaccines between
the end of 2020 and early 2021 (9).
CCDR • December 2021 • Vol. 47 No. 12
Page 524
QUALITATIVE STUDY
Research has shown that public confidence in vaccines has
remained low in recent years and continues to be a dynamic
and complex issue (10–12). Lack of vaccine confidence has
resulted in vaccine hesitancy, identified by the World Health
Organization as one of the top 10 threats to global health (13).
Vaccine hesitancy is defined as refusal or delay in acceptance
of an available vaccine and is context specific, meaning that an
individual may refuse some vaccines and accept others (14).
Digital communication technology, such as social media (SM),
has been found to propagate the spread of vaccine-related
misinformation (15) that contributes to vaccine hesitancy (16).
Opportunities exist to leverage SM use for public health
initiatives that counter vaccine misinformation and increase
vaccination rates (16,17). This is an important consideration as
the Canadian Community Health Survey shows 75% of Canadians
aged 12 years and older would be somewhat or very likely to
get the COVID-19 vaccine (18). Results from Angus Reid Institute
showed that 48% of Canadians said that they would receive a
COVID-19 vaccine when available, 38% would eventually but
not immediately, 14% would not and 7% were unsure (19).
These attitudes towards COVID-19 vaccinations are important to
consider given a large proportion of the population needs to be
vaccinated to achieve herd immunity (20).
To create successful public health initiatives that counter vaccine
hesitancy and promote vaccine acceptance, it is necessary to
gain an understanding of the beliefs, attitudes and subjective
risk perceptions of the population (21). A recent study examining
COVID-19 vaccine intention found that perceived benefits and
barriers played a role in intention to receive the COVID-19
vaccine (22). Neubaum and Krämern stated that SM may serve
as "a window to the public", providing insight into public
perception and opinion. Research has shown that SM users may
feel empowered to share their thoughts and opinions when they
see posts espousing similar beliefs (23,24) and when they can do
so anonymously (25). These online comments act as an accurate
and reliable source of information on public attitudes and
perceptions that surface during a health crisis (26). For example,
a recent study used English-language Twitter posts to examine
public perceptions of COVID-19 social distancing measures (27)
and found their results reflected the attitudes and opinions of
a large United States public opinion poll taken during the same
timeframe (28,29). Taken together, SM could be used to gain
an understanding of perspectives of the Canadian population
towards public health issues, including perceptions, beliefs,
attitudes and intentions toward receiving a COVID-19 vaccine.
In recent months, perceptions and attitudes toward taking
a COVID-19 vaccine (30–32) have been investigated, and a
growing body of research has focused on those perceptions
and attitudes expressed on SM (33–36). To better inform
public health recommendations to counter vaccine hesitancy in
Canada, further research that examines SM discourse on Twitter
and Facebook in response to Canadian news organizations’
Page 525
CCDR • December 2021 • Vol. 47 No. 12
COVID-19 vaccine reporting may help provide a more
comprehensive understanding of the attitudes, beliefs and
intentions toward taking a COVID-19 vaccine among Canadians.
Methods
Data collection
Six popular Canadian national news organizations were
selected; specifically, Global News, Canadian Broadcasting
Corporation (CBC), Canadian Television Network (CTV), The
Globe and Mail, Maclean’s and The National Post to identify
the perceptions, attitudes, beliefs and intentions of Canadian
news organizations’ SM commenters toward taking a COVID-19
vaccine. These are the predominant national news content
providers in Canada that report the news through television
broadcast (Global News, CBC, CTV) or print (The Globe and
Mail, Maclean’s, The National Post), as well as online. Compared
with a quantitative analysis, which provides information on
vaccine of hesitancy patterns among populations, a qualitative
approach offers a deeper analysis of the socio-cultural aspects of
vaccine hesitancy (37). Thus, a qualitative approach was selected
to allow for an in-depth exploration into the nuances and
complexities of vaccine hesitancy among Canadians.
Social media posts from the Twitter and Facebook accounts
of the six Canadian news organizations listed above were
monitored for when a COVID-19 vaccine-related article was
shared on their Twitter and Facebook account. Twitter and
Facebook were chosen because comments on these platforms
have been used to answer vaccine hesitancy research questions
in previous studies (33,38,39) and both platforms allow news
organizations to link back to articles on their website. All data
were gathered between July and September 2020, and only
English posts were collected for analysis. Each SM post included
a link to their respective news article and often included a
comment inviting SM engagement. These news organizations
were selected because they are nationally representative
organizations with credible reporting practices and represent
a range in political leanings. All commenters are users of SM
with accounts on Twitter and/or Facebook. Authors looked
for news articles that included information on development or
procurement of COVID-19 vaccines or reported on vaccination
survey results. Seven days after the COVID-19 related news
article was shared on the organizations’ SM account, all posted
comments were collected. A seven-day timeframe was sufficient
to collect SM comments made on that article, as few comments
were posted after this time.
A total of six articles (one article per new organization posted on
both Twitter and Facebook) and 4,095 comments were collected
for analysis. The data were then scanned for spam, which was
defined as insults toward other commenters, comments that
were not on the topic of the COVID-19 vaccine, comments that
were not legible (e.g. used only characters) and images (e.g.
QUALITATIVE STUDY
GIFS). A total of 364 posts that included spam and irrelevant
comments were deleted and images that contained text, if
related to COVID-19, were transcribed verbatim. Once data
cleaning was complete, a total of 3,731 posts remained for
analysis. The number of posts per news organization and links to
each original article are shown in Table 1.
Table 1: Total number of combined Twitter and
Facebook posts for each news organization used in
analysis and links to each news organizations' original
COVID-19 vaccine related article posted on their
respective social media accounts
News
Number of
organization
posts
Link to original article
National Post
https://nationalpost.com/health/which308 canadians-get-the-covid-19-vaccinefirst-experts-are-struggling-to-decide
Maclean's
https://www.macleans.ca/society/
642 health/how-anti-vaxxers-could-disruptthe-cure-for-the-covid-19-pandemic/
The Globe
and Mail
70
https://www.theglobeandmail.com/
canada/article-moderna-inc-saysits-covid-19-vaccine-shows-positiveresults-among/
Global News
https://globalnews.ca/news/7251593/
745
canada-pfizer-coronavirus-vaccine/
CBC
498
CTV
https://www.cbc.ca/news/world/
coronavirus-covid19-worldsept4-1.5712020
https://www.ctvnews.ca/health/
coronavirus/feds-sign-deals-with1,468 novavax-and-johnson-johnsonto-secure-millions-of-vaccinedoses-1.5085911
Abbreviations: CBC, Canadian Broadcasting Corporation; COVID-19, coronavirus disease 2019;
CTV, Canadian Television Network
This research study relied exclusively on publicly available data
with some sources as anonymous or unidentifiable; therefore,
ethical approval was not required. This is consistent with
similar Canadian-based research using publicly available SM
content (33).
Analysis
Original posts from each news organizations’ Twitter and
Facebook account, along with accompanying comments, were
imported into NVivo-12 (QSR International, 2019). Using Clarke
and Braun (40) as a guide, each of this study’s researchers
conducted thematic analysis to identify themes as the unit of
analysis. Analysis involved each researcher independently coding
each comment and reply over a 10-week period. Researchers
met bi-weekly to examine and discuss differences in the codes,
which became the building blocks of the themes (40). Based
on previous vaccine hesitancy literature, perceptions, attitudes,
beliefs and intentions were used as sensitizing concepts
to approach qualitative analysis. Sensitizing concepts refer
to general ideas that act as starting points for researchers
approaching a qualitative research question (41). Using these
sensitizing concepts as guide for analysis, the authors then used
inductive analysis to allow themes and patterns to emerge from
the data (41). All three researchers noticed similar themes among
the data, and once coding was complete, all researchers met to
finalize the list of agreed themes and subthemes.
Results
Four themes emerged from comments gathered in response
to news organizations’ SM posts. For each theme, subthemes
were also identified. Most SM comments and replies expressed
negative attitudes and opinions toward the COVID-19 vaccine,
while some expressed positive beliefs and attitudes. Each theme
is described in the following pages, where illustrative quotes
were used to contextualize themes. A summary of themes with
supplementary quotes can be found in Table 2.
Theme 1: COVID-19 vaccine safety and
efficacy concerns
Theme 1 captured concerns about perceived factors that may
influence the safety and efficacy of the vaccine including political
pressures, development speed and testing, ingredients and
potential immune-escaping variants.
Political pressures influencing vaccine production: Concerns
were expressed around the perceived influence of political
pressures rushing vaccine production. For example, one
commenter noted "Would I get the Russian vaccine or Trump’s
vaccine to win an election[?] .. not a chance." - CTV, Twitter.
Another commenter, referring to the influence of politicians
wrote, "Medical experts are dictated what to do by politicians.
Trust them at your peril" - Globe and Mail, Facebook.
Others first to prove safety: A common concern referred
to safety of vaccine and the belief that they lacked adequate
testing. Many commenters remarked that politicians should
receive the vaccine first to prove its safety: "I want the whole
House of Commons, the Senate, the Governor-General and a
special vaccine for the Prime Minister! Then we wait a month and
see what happens!" - CTV, Facebook. Another wrote, "I will let
the masses be the control group and see what happens. It may
be good or not. Time and trial will tell" - CBC, Facebook.
Rushed vaccine: Many commenters expressed concern about
the short timeframe for COVID-19 vaccine development. One
commenter who characterized themselves as not being an
"anti-vaxxer", a word that describes someone who is opposed
to vaccines, noted, "There will be a lot of people like me who
are not anti-vaxxers but will refuse this until a reasonable amount
of time for proper testing and data goes by." - National Post,
Facebook.
CCDR • December 2021 • Vol. 47 No. 12
Page 526
QUALITATIVE STUDY
Table 2: Supplementary quotes from social media commenters in response to Canadian news organizations'
COVID-19 vaccine related Twitter and Facebook posts organized by theme and subtheme
Theme
Subtheme
Quote
Political pressures "These scientists are under a tremendous amount of pressure for governments to push though and get a
vaccine up and running and that's how we end up with oppsys" - CTV, Facebook
influencing
vaccine
"Would you take a vaccine that did not undergo full trials? DJT [Donald J Trump] is proposing forgoing phase 3
production
trials in order to rush a vaccine to production" - CBC, Twitter
"I'll wait for all the heroes to go first, if they survive maybe" - CTV, Twitter
"Nope. Not until I see what happens to all the eager beavers. I'm no guinea pig" - CTV, Twitter
Others first to
prove safety
"The yes voters can line up to be guinea pigs while the intelligent people wait and see what happens." - Global
News, Twitter
"I think all our lovely politicians should be the first to get it and we can all wait 6 months to see how that turns
out." - CTV, Facebook
"I wont be a Guinea pig. I'll wait 5-10 years for a long term study to be peer reviewed and make sure the side
effects of the vaccine arent worse than the effort it takes to avoid covid." - CBC, Facebook
"Anybody dumb enough to get injected by a rushed and undertested vaccine deserves every side effect from
it." - CTV, Facebook
COVID-19
Rushed vaccine
vaccine safety
and efficacy
concerns
"Nope...and I am not anti vaxx.....I am anti being a guinea pig for a rushed vaccine that hasn't been properly
tested" - CTV, Facebook
"I am not against vaccines but I will not be getting this. It's just too fast and not tested enough for me to want
to take this." - Maclean's, Facebook
"You do know it takes roughly 10 years to develop and properly test a vaccine right? Go ahead and trust
something developed in 4 months with zero long term effects results but if you value yourself you'd wait until
you had irrefutable evidence that this vaccine is 100% safe with only a SMALL chance of complications taking
place like every other rigorously tested and proven to be safe vaccine." - National Post, Facebook
"go ahead and have and have mine too but don't judge others that have no desire to put unknown chemicals in
their body" - CTV, Facebook
Ingredient
concern
Vaccine versus
variants
"…check what is in vaccines and what they really do and they don't want chemicals like formaldehyde, mercury
and aluminum in their bodies" - Maclean's, Facebook
"Read the insert and see what is in it. Fetal DNA. Yes, aborted fetus cells. Toxic chemicals beyond
comprehension. You demand a mask for your health and then BLINDLY inject these toxins directly into your
bloodstream. RESEARCH what's in them!" - Global News, Twitter
"We don't yet know, or at least aren't told the mutation rate of Covid … vaccination may be a frequent
undertaking and possibly with no real effect." - National Post, Facebook
"covid is already mutating so good luck with that" - CBC, Facebook
"Think of how many times the virus will have morphed by the time they actually get the vaccine out..." - CBC,
Facebook
"I don't trust our government anymore and won't be used as a guinea pig." - Global News, Twitter
General mistrust
in government
Conspiracy
theories
stemming
from
mistrust in
government
and other
organizations
"Who wants to take a shot in the arm, from a gov. that has had 3 ethics investigations, is so very far from
anything resembling "transparency" it should really be criminal. JT [Justin Trudeau] - fancy socks mr. word salad
has been sticking it up our Cdn. butts long enough, no don't touch my arm. Clearly you are Not to be trusted."
- CTV, Facebook
"… Just because the government says it's okay and pushes thru the creation and testing does not make me feel
confident about it." - Global News, Facebook
"0% trust in the Canadian Healthcare system to provide a safe version of CV19 vaccination." - Global News,
Twitter
"Scientists can be bought just like politicians. Stop being naive thinking the government wants what's best for
us". - CTV, Facebook
COVID-19
vaccine will alter
your DNA
"Do you realize that the new mRNA vaccine which BigPharma is touting as the savior from COVID is in fact
altering your DNA? No wonder they put Gates in the forefront to sell it. They're labeling it as The "Software of
Life." - Global News, Twitter
"Enjoy having your DNA altered for the rest of your life and your children's life." - Global News, Twitter
"Why would I take it knowing it was DNA chipped. Meaning changing your genomes and DNA ... Should have
been asking why are they are rushing to inject the population with it." - CTV, Facebook
"I don't want to be microchipped from Bill Gates, it's a mind control device which can simply make you walk off
the edge of the flat Earth Face with hand over mouth." - Global News, Twitter
Microchips and
nanotechnology
"Those of us with a strong immune system will survive just fine without Gatesfromhell vaccine that he has
admitted will kill over 700 000 people. You go get yourself microchipped like a cow." - Maclean's, Facebook
"There's a huge difference between a chip in a phone or electronic and one in your body! At least you can leave
your phone home." - CTV, Facebook
Page 527
CCDR • December 2021 • Vol. 47 No. 12
QUALITATIVE STUDY
Table 2: Supplementary quotes from social media commenters in response to Canadian news organizations'
COVID-19 vaccine related Twitter and Facebook posts organized by theme and subtheme (continued)
Theme
Subtheme
Quote
"I'm sure we could go back to pre-plandemic life if the media just quit the fear mongering" - CTV, Facebook
It is just "fear
mongering"
"your fear propaganda is a farce. your mask mandates are a farce. your inflated statistics are a farce." - CTV,
Facebook
"Just some more fear mongering by our ridiculous government have a great day." - CTV, Facebook
"You had better chance dying of cancer or car fatalities any other health reason on a daily basis then getting
infected with COVID or dying from it." - CTV, Facebook
COVID-19
vaccine is
unnecessary
because the
virus is not
dangerous
COVID-19 is not
that serious
"Is a vaccine really required for a disease so deadly one has to get tested to see if they have it" - CTV, Facebook
"my wife and I both had it (we are both immunodeficient) No hospital stay the cough lasted about 3 weeks and
we have 0 long term affects." - CTV, Facebook
"A vaccine for a virus with a 0.03% mortality rate? I'll pass thanks!" - The Globe and Mail, Facebook
"I'm not immune compromised, I'm not a senior, I'm healthy, and every flu I've had, my bodies own defenses
have overcome it in the normal anticipated time of infection." - Global News, Facebook
Strong immune
systems and a
healthy lifestyle is
sufficient to beat
COVID-19
"just eat, sleep and exercise and you will be fine. if everyone did that then 80 percent of the healthcare system
wouldn't be needed."- Global News, Facebook
"I would like to be immune to it with my natural bodies antibodies." - Global News, Facebook
"Eating healthy: Non processed, non GMO, organic foods, exercise, get a good amount of sleep, take vitamins,
get lots of vitamin d from sun, the list goes and on and on of what you can do to stay healthy. I don't need
chemicals to keep me healthy. Let the body do its thing and if I catch a cold, flu or covid then i will deal with it."
- Global News, Facebook
"I've seen the ingredients, and unlike some people, I don't misinterpret them. Some ingredients might look
sketchy to anyone who doesn't understand chemistry." - Global News, Twitter
"id say testing on over 50,000 people is good enough" - Global News, Facebook
Trust in science
and medical
professionals
Trust in
COVID-19
vaccines as a
safe solution
"no one is going to be distributing an untested vaccine. It may not be possible to test for long-term protection,
but it will definitely be tested for both safety and effectiveness." - CTV, Facebook
"As I said, my risk management plan involves listening to my family doctor, and to my wife who is a retired
infection control nurse. Those two women have never led me astray. I wish you good luck with your alternate
plan." - Maclean's, Facebook
"The reason it can be made so fast is because it is a virus we are familiar with. Also not sure if you realize this
but research and technology has progressed" - CBC, Facebook
Concern about
long term effects
of COVID-19
"The issue is not only the mortality of covid, but the seriousness of the illness and the long term effects. But
for now, you may not die from covid, but you may die waiting for help in an overcrowded hospital full of covid
patients." - Globe and Mail, Facebook
"almost everyone interviewed in media, old and young, who have had it are saying they're still not feeling 100%
... some have memory loss, loss of energy etc." - CTV, Facebook
"Healthy people can still suffer permanent damage and death" - Global News, Twitter
Intent to get
the COVID-19
vaccine to
protect others
and return to
"normal"
"Thank you for one of the few voices of reason in a crowd of howling anti-vaxxers. As someone with loved ones
with health concerns, I will be first in line to get my shot." - CTV, Facebook
"Maybe if everyone got vaccinated, used masks, and social distance then maybe life would get back to normal
10 times faster than predicted." - CTV, Facebook
Abbreviations: CBC, Canadian Broadcasting Corporation; COVID-19, coronavirus disease 2019; CTV, Canadian Television Network
Ingredient concern: Safety concerns related to the ingredients
used to develop the COVID-19 vaccine. "You go ahead fill your
veins with fetus tissue and mercy and formaldehyde and then
get back to ya and see how great you feel!" - Global News,
Facebook.
Vaccine versus variants: Commenters were concerned about
vaccine efficacy once the COVID-19 virus mutates. One
commenter wrote, "There is the distinct possibility that covid
mutates and renders any vaccine useless" - Maclean’s, Facebook,
while another noted, "Think of how many times the virus will
have morphed by the time they actually get the vaccine out...". CBC, Facebook.
Theme 2: Conspiracy theories stemming
from mistrust in government and other
organizations
Theme 2 characterized the conspiracy theories, including
microchips and changes to DNA, expressed on SM rooted in a
general mistrust of government and organizations involved in
COVID-19 vaccine development.
CCDR • December 2021 • Vol. 47 No. 12
Page 528
QUALITATIVE STUDY
General mistrust in government: All six news organizations’
article posts on SM contained comments pointing toward
mistrust of foreign and domestic government and health
organizations. One commenter when speaking about the
government wrote, "No one iota of trust. I am not a guinea pig
for government vaccine tests" - Global News, Twitter.
The COVID-19 vaccine will alter DNA: Comments about the
vaccine altering DNA were common on all news organizations’
SM platforms: "Insane! Do these people have any idea what this
vaccine entails?! It will literally alter your DNA. Forever." - Global
News, Facebook. Another commenter wrote, "I don’t need nor
do I want anyone altering my DNA" - Global, News, Twitter.
Microchips and nanotechnology: Discourse focused on
microchips and nanotechnology was common. One commenter
wrote, "I dont wanna get chipped" - CTV, Facebook, while
another responded, "Bill Gates can keep his nanobot juice, lol." Global News, Facebook.
Theme 3: A COVID-19 vaccine is unnecessary
because the virus is not dangerous
Theme 3 captured the level of concern related to the perceived
seriousness of becoming infected with COVID-19 expressed on
SM. Commenters felt that severity was being overexaggerated
and a healthy immune system was sufficient to overcome the
virus.
It’s just "fear mongering": Many commenters felt the virus
is not as serious as the media was reporting. In response to a
question posed by a news agency asking whether people will get
the vaccine, one commenter responded, "Just some more fear
mongering by our ridiculous government". - CTV, Facebook.
COVID-19 is not that serious: Many commenters noted that a
COVID-19 vaccine was unnecessary because the virus was not
dangerous. For example, "It’s already hit my house, both my wife
and I at very high risk, no hospital for either of us and yet here
we are!!" - CTV, Facebook, while another commenter wrote, "I’m
more likely to die walking down my stairs than die of Covid." Global News, Twitter.
Strong immune systems and a healthy lifestyle is sufficient
to beat COVID-19: Commenters discussed how being in good
health was sufficient to overcome the virus, "Maybe it’s the
world’s way of weeding out the weak. Most have underlying
conditions and we are in perfect health so covid is not a concern
for us." - CBC, Facebook. Another commenter wrote, "eat
healthy vitamins that’s the best vaccine we can get it". - CTV,
Facebook.
Page 529
CCDR • December 2021 • Vol. 47 No. 12
Theme 4: Trust in COVID-19 vaccines as a safe
solution
A minority of commenters expressed confidence in COVID-19
vaccines to prevent infection. Those with confidence in
the vaccine conveyed trust in science and their healthcare
professional, expressed concerns about potential long-term
COVID-19 effects and felt that the vaccine was necessary to
return to normal.
Trust in science and medical professionals: Commenters
expressed trust in the science behind the vaccines: "If health
Canada approves a vaccine, I’ll be in the first available
line" - CTV, Twitter. Another commenter wrote, "Sign me up,
Surprisingly I trust science and the medical safeguards in place.
I know completely unheard of." - National Post, Facebook.
Other commenters expressed trust in medical professionals:
"If my Dr. Recommends it I would." - Global News, Twitter.
Another wrote, "I will follow my doctors advice as I dont have a
spleen." - Global News, Twitter.
Concern about long-term effects of COVID-19: Several
commenters noted concern about potential long-term effects
of being infected with the COVID-19 virus. One commenter
wrote, "the issue is not just those who have died but those who
have survived, what they went through and the longer lasting
effects..." - CTV, Facebook. Another wrote, "I’m more then
willing to take it, the long-term effects from getting Covid are
the driving force for me" - CTV, Facebook.
Intent to get the COVID-19 vaccine to protect others and
return to "normal": Commenters expressed intention to get the
COVID-19 vaccine so that they are able to return to their normal
life, "Will be first in line so we can go back to normal" - CTV,
Facebook. Another wrote, "As soon as it’s available! Definitely
plan on doing my part to protect the vulnerable" - Global News,
Facebook.
In contrast, those expressing intention to receive the COVID-19
vaccine were met with ridicule. Comments such as "Yup…all the
scared sheeple will be lining up dutifully and shaming anyone
who resists" - CBC, Twitter, were common.
Discussion
The aim of this study was to examine SM discourse on Canadian
news organizations’ SM accounts in response to posted articles
reporting on the COVID-19 vaccine. Comments on article posts
were analyzed to identify perceptions, attitudes, beliefs, and
intentions toward taking a COVID-19 vaccine. Our analysis
identified four themes and a number of sub-themes.
QUALITATIVE STUDY
Comments expressing concern about safety and efficacy of
a COVID-19 vaccine were common. This is consistent with
previous research that examined reasons for vaccine hesitancy,
with safety and efficacy concerns as the main driver for vaccine
hesitancy (42,43). The common concern about a "rushed"
vaccine is not unique to COVID-19. Research examining
responses to the H1N1 vaccine found that people were
concerned about seemingly rushed vaccine development (44).
These findings are consistent with our analysis and are troubling
as research has found that COVID-19 vaccine acceptance is
strongly related to perceived safety (45).
Commenters were concerned about ingredients in the COVID-19
vaccine. These findings are consistent with previous research
by Björkman and Sanner (46) that examined the experiences
and beliefs of taking the H1N1 vaccine in Sweden. This study
determined that participants were concerned about putting
"unknown substances" contained within the vaccine into their
body (46). Taken together, it appears a lack of understanding
regarding vaccine contents has been a consistent barrier to
vaccine uptake.
Social media commenters were concerned about COVID-19
viral mutations rendering the vaccine ineffective against the
virus. Research has shown that speed of vaccination can offset
the harm of more easily transmissible variants (47). Thus, Public
Health messaging that addresses concerns about COVID-19 viral
variants and encourages uptake of the vaccine is needed.
Our analysis found that a reason for supporting a COVID-19
vaccine was concern about potential long-term effects of the
virus. This is consistent with previous research that identified
that perceptions of disease severity were associated with
willingness to receive a COVID-19 vaccine (43,48,49). One
suggestion to increase vaccine uptake could be the sharing of
local data through clear infographics to illustrate the success of
the COVID-19 vaccine for those who been vaccinated. This may
positively influence those who are hesitant on efficacy grounds,
with messaging emphasis shifted toward the risk of developing
long-haul COVID-19 symptoms. Additionally, it is clear from our
results and previous research (43,48,50) that healthcare providers
are effective participants in vaccine communication, as several
commenters mentioned that they would get the vaccine if it was
recommended by their doctor.
Limitations
Study limitations should be considered when interpreting results.
First, it is likely that readers who comment on vaccine-related
posts have strong negative feelings toward the vaccine. Research
has shown that anti-vaccine content on SM leads to more user
engagement than pro-vaccine content (16). Second, we did not
investigate each commenter to identify non-human accounts,
specifically "bots". Bots are defined as automated accounts that
can be designed to spread misinformation and anti-vaccination
content (51). Yuan et al. found 1.45% of accounts participating in
vaccine discourse on SM were bots (52). Third, only English posts
were included in analysis and therefore not representative of the
broader non-English speaking population. Although data were
independently coded by each of the three researchers to reduce
bias (53), we only used social media posts and therefore could
not triangulate findings from multiple sources of information.
Finally, we could not collect demographic information from
commenters and therefore could not make conclusions about
generalizability of results to the Canadian population. Future
research in this area should consider multiple methods of data
collection to test validity through analysis of information from
several sources, examine SM discourse in languages other than
English and on additional SM platforms.
Future directions
Results from this study can help inform Canadian Public Health
COVID-19 vaccine messaging. Previous research has shown that
Public Health communications can positively impact vaccine
intention (22), and themes found in this study are consistent
with previous research that aimed to identify effective vaccine
messaging. Indeed, increasing public knowledge of COVID-19
disease severity and vaccine safety is imperative since these
were primary concerns from commenters in this study and
from participants in previous research (42,49,54,55). Further,
our results are consistent with published literature (43,48,50)
demonstrating healthcare providers can be an effective mode
for reliable vaccine communications. Taken together, successful
efforts can be made toward improving vaccine messaging on SM
to reduce vaccine hesitancy.
A renewed public information drive is required to promote public
urgency in vaccination as an important tool in fighting COVID-19
and its variants. Our analysis points to key recommendations
that may help increase vaccine uptake and decrease hesitancy.
This includes the following: 1) Public Health messaging
focused on increasing the public’s understanding of COVID-19
vaccine contents; 2) leveraging the public’s trust in healthcare
professionals to act as a liaison between Public Health and the
Canadian public to communicate benefits of the vaccine against
COVID-19 and its variants; 3) clear infographics championed
by Public Health that highlight benefits of the vaccine for those
who have received it; and 4) sharing easily understood, poignant
stories of local community members experiencing long-COVID
symptoms, which may illicit an emotional connection.
Conclusion
An analysis of COVID-19 vaccine discourse on SM identified
four themes related to the perceptions, attitudes, beliefs, and
intentions toward taking a COVID-19 vaccine. These included
both negative (concerns about COVID-19 vaccine necessity,
safety and efficacy) and positive (trust in COVID-19 vaccines
as a safe solution) themes. Based on these findings, specific
recommendations to reduce vaccine hesitancy were developed.
CCDR • December 2021 • Vol. 47 No. 12
Page 530
QUALITATIVE STUDY
Authors’ statement
8.
LT — Led the project, conceptualization and study design,
methodology, data collection, formal analysis, and interpretation
of data, writing, editing, and creating final draft
SD — Conceptualization and study design, methodology, data
collection, formal analysis, and interpretation of data, writing,
editing, and creating final draft
AL — Methodology, formal analysis and interpretation of data,
writing, editing, and creating final draft
Ministry of Health (Ontario). COVID-19 Vaccine Approval
Process and Safety. Version 3.0 - March 11, 2021. Toronto,
ON: MHLTC; 2021. https://www.health.gov.on.ca/en/pro/
programs/publichealth/coronavirus/docs/vaccine/COVID-19_
vaccine_approval_process_safety.pdf
9.
Health Canada. Approved COVID-19 Vaccines. Ottawa (ON):
HC; 2021 (accessed 2021-08- 28). https://www.canada.ca/
en/health-canada/services/drugs-health-products/covid19industry/drugs-vaccines-treatments/vaccines.html
All authors have reviewed and approved the final article.
The content and view expressed in this article are those of the
authors and do not necessarily reflect those of the Government
of Canada.
Competing interests
The authors declare no conflict of interest.
Funding
10. Lin C, Tu P, Beitsch LM. Confidence and Receptivity for
COVID-19 Vaccines: A Rapid Systematic Review. Vaccines
(Basel) 2020;9(1):16. DOI PubMed
11. McGregor S, Goldman RD. Determinants of parental
vaccine hesitancy. Can Fam Physician 2021;67(5):339–41.
DOI PubMed
12. Vallis M, Glazer S. Protecting individuals living with
overweight and obesity: attitudes and concerns toward
COVID-19 vaccination in Canada. Obesity (Silver Spring)
2021;29(7):1128–37. DOI PubMed
L Tang is supported in part by funding from the Social Sciences
and Humanities Research Council.
13. World Health Organization. Top ten threats to global
health in 2019. Geneva, Switzerland: WHO; 2019 (accessed
2021-01-18). https://www.who.int/news-room/spotlight/tenthreats-to-global-health-in-2019
References
14. MacDonald NE; SAGE Working Group on Vaccine Hesitancy.
Vaccine hesitancy: Definition, scope and determinants.
Vaccine 2015;33(34):4161–4. DOI PubMed
1.
World Health Organization. Naming the coronavirus disease
(COVID-19) and the virus that causes it. Geneva, Switzerland:
WHO; 2020 (accessed 2021-01-18). https://www.who.int/
emergencies/diseases/novel-coronavirus-2019/technicalguidance/naming-the-coronavirus-disease-(covid-2019)-andthe-virus-that-causes-it
2.
Vogel L, Eggertson L. COVID-19: A timeline of Canada’s
first-wave response. CMAJ; 2020 (accessed 2021-08-26).
https://cmajnews.com/2020/06/12/coronavirus-1095847/
3.
World Health Organization. WHO Coronavirus (COVID-19)
Dashboard. Geneva, Switzerland: WHO; 2021 (accessed
2021-01-18). https://covid19.who.int/
4.
Health Canada. COVID-19 daily epidemiology update.
Ottawa (ON): HC; 2021. https://health-infobase.canada.ca/
covid-19/epidemiological-summary-covid-19-cases.html
5.
Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ,
Lee BW, Lolekha S, Peltola H, Ruff TA, Santosham M,
Schmitt HJ. Vaccination greatly reduces disease, disability,
death and inequity worldwide. Bull World Health Organ
2008;86(2):140–6. DOI PubMed
6.
Frederiksen LSF, Zhang Y, Foged C, Thakur A. The Long
Road Toward COVID-19 Herd Immunity: Vaccine Platform
Technologies and Mass Immunization Strategies. Front
Immunol 2020;11:1817. DOI PubMed
7.
Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines
for COVID-19: the current state of play. Paediatr Respir Rev
2020;35:43–9. DOI PubMed
Page 531
CCDR • December 2021 • Vol. 47 No. 12
15. Dredze M, Broniatowski DA, Hilyard KM. Zika vaccine
misconceptions: A social media analysis. Vaccine
2016;34(30):3441–2. DOI PubMed
16. Puri N, Coomes EA, Haghbayan H, Gunaratne K. Social
media and vaccine hesitancy: new updates for the era of
COVID-19 and globalized infectious diseases. Hum Vaccin
Immunother 2020;16(11):2586–93. DOI PubMed
17. Ahmed N, Quinn SC, Hancock GR, Freimuth VS, Jamison A.
Social media use and influenza vaccine uptake among White
and African American adults. Vaccine 2018;36(49):7556–61.
DOI PubMed
18. Statistics Canada. Majority of Canadians intend to get the
COVID-19 vaccine, September 2020. Ottawa, ON: StatCan;
2020 (accessed 2021-01-18). https://www150.statcan.gc.ca/
n1/daily-quotidien/201217/dq201217c-eng.htm
19. Angus Reid Institute. More Canadians willing to roll up their
sleeves right away as national COVID-19 vaccine rollout
begins. Angus Reid; 2020. https://angusreid.org/canadacovid-vaccine-december/
20. World Health Organization. Coronavirus disease (COVID-19):
Herd immunity, lockdowns and COVID-19. Geneva,
Switzerland: WHO; 2020 (accessed 2021-08-28). https://
www.who.int/emergencies/diseases/novel-coronavirus-2019/
question-and-answers-hub/q-a-detail/herd-immunitylockdowns-and-covid-19
QUALITATIVE STUDY
21. Bond L, Nolan T. Making sense of perceptions of risk of
diseases and vaccinations: a qualitative study combining
models of health beliefs, decision-making and risk
perception. BMC Public Health 2011;11(1):943–56.
DOI PubMed
22. Mercadante AR, Law AV. Will they, or Won’t they?
Examining patients’ vaccine intention for flu and COVID-19
using the Health Belief Model. Res Social Adm Pharm
2021;17(9):1596–605. DOI PubMed
23. Neubaum G, Krämer NC. Monitoring the Opinion of the
Crowd: Psychological Mechanisms Underlying Public
Opinion Perceptions on Social Media. Media Psychol
2017;20(3):502–31. DOI
24. Chun JW, Lee MJ. When does individuals’ willingness to
speak out increase on social media? Perceived social support
and perceived power/control. Comput Human Behav
2017;74:120–9. DOI
33. Griffith J, Marani H, Monkman H. COVID-19 Vaccine
Hesitancy in Canada: Content Analysis of Tweets Using
the Theoretical Domains Framework. J Med Internet Res
2021;23(4):e26874-e. DOI
34. Zhang S, Pian W, Ma F, Ni Z, Liu Y. Characterizing the
COVID-19 Infodemic on Chinese Social Media: exploratory
Study. JMIR Public Health Surveill 2021;7(2):e26090.
DOI PubMed
35. Bonnevie E, Gallegos-Jeffrey A, Goldbarg J, Byrd B,
Smyser J. Quantifying the rise of vaccine opposition on
Twitter during the COVID-19 pandemic. J Commun Healthc
2021;14(1):12–9. DOI
36. Guntuku SC, Buttenheim AM, Sherman G, Merchant RM.
Twitter discourse reveals geographical and temporal
variation in concerns about COVID-19 vaccines in the United
States. Vaccine 2021;39(30):4034–8. DOI PubMed
25. Wu TY, Atkin DJ. To comment or not to comment: examining
the influences of anonymity and social support on one’s
willingness to express in online news discussions. New
Media Soc 2018;20(12):4512–32. DOI
37. Dubé E, Gagnon D, MacDonald N, Bocquier A,
Peretti-Watel P, Verger P. Underlying factors impacting
vaccine hesitancy in high income countries: a
review of qualitative studies. Expert Rev Vaccines
2018;17(11):989–1004. DOI PubMed
26. Henrich N, Holmes B. What the public was saying about the
H1N1 vaccine: perceptions and issues discussed in on-line
comments during the 2009 H1N1 pandemic. PLoS One
2011;6(4):e18479. DOI PubMed
38. Ahmed W, Vidal-Alaball J, Downing J, López Seguí F.
COVID-19 and the 5G Conspiracy Theory: Social
Network Analysis of Twitter Data. J Med Internet Res
2020;22(5):e19458. DOI PubMed
27. Saleh SN, Lehmann CU, McDonald SA, Basit MA,
Medford RJ. Understanding public perception of coronavirus
disease 2019 (COVID-19) social distancing on Twitter. Infect
Control Hosp Epidemiol 2021;42(2):131–8. DOI PubMed
39. Kim H, Han JY, Seo Y. Effects of Facebook Comments
on Attitude Toward Vaccines: The Roles of Perceived
Distributions of Public Opinion and Perceived Vaccine
Efficacy. J Health Commun 2020;25(2):159–69. DOI PubMed
28. Kirzinger A, Kearney A, Hamel L, Brodie M. KFF health
tracking poll—early April 2020: The impact of coronavirus
on life in America. Kaiser Family Foundation; 2020 (accessed
2021-08-26). https://www.kff.org/coronavirus-covid-19/
report/kff-health-tracking-poll-early-april-2020/
40. Clarke V, Braun V. Thematic analysis. J Posit Psychol
2017;12(3):297–8. DOI
29. Epstein K. Just 14% of Americans support ending social
distancing in order to reopen the economy, according
to a new poll. Business Insider; 2020. https://www.
businessinsider.com/poll-most-americans-supportcoronavirus-social-distancing-measures-2020-4
42. Sweileh WM. Bibliometric analysis of global scientific
literature on vaccine hesitancy in peer-reviewed journals
(1990-2019). BMC Public Health 2020;20(1):1252.
DOI PubMed
30. Williams L, Gallant AJ, Rasmussen S, Brown Nicholls LA,
Cogan N, Deakin K, Young D, Flowers P. Towards
intervention development to increase the uptake
of COVID-19 vaccination among those at high risk:
outlining evidence-based and theoretically informed
future intervention content. Br J Health Psychol
2020;25(4):1039–54. DOI PubMed
31. Riad A, Abdulqader H, Morgado M, Domnori S, Koš�ík
M, Mendes JJ, Klugar M, Kateeb E, IADS-Score. Global
Prevalence and Drivers of Dental Students’ COVID-19
Vaccine Hesitancy. Vaccines (Basel) 2021;9(6):566.
DOI PubMed
32. Coe AB, Elliott MH, Gatewood SB, Goode JV,
Moczygemba LR. Perceptions and predictors of intention
to receive the COVID-19 vaccine. Res Social Admin Pharm
2021;s1551-7411(21):000164-09. DOI PubMed
41. Bowen GA. Grounded Theory and Sensitizing Concepts.
Int J Qual Methods 2006;5(3):12–23. DOI
43. Yaqub O, Castle-Clarke S, Sevdalis N, Chataway J. Attitudes
to vaccination: a critical review. Soc Sci Med 2014;112:1–11.
DOI PubMed
44. Carlsen B, Glenton C. The swine flu vaccine, public attitudes,
and researcher interpretations: a systematic review of
qualitative research. BMC Health Serv Res 2016;16:203.
DOI PubMed
45. Karlsson LC, Soveri A, Lewandowsky S, Karlsson L,
Karlsson H, Nolvi S, Karukivi M, Lindfelt M, Antfolk J.
Fearing the disease or the vaccine: the case of COVID-19.
Pers Individ Dif 2021;172:110590. DOI PubMed
46. Björkman I, Sanner MA. The Swedish A(H1N1) vaccination
campaign--why did not all Swedes take the vaccination?
Health Policy 2013;109(1):63–70. DOI PubMed
CCDR • December 2021 • Vol. 47 No. 12
Page 532
QUALITATIVE STUDY
47. Kim H-Y, Bershteyn A, McGillen JB, Braithwaite RS. Under
what circumstances could vaccination offset the harm
from a more transmissible variant of SARS-COV-2 in NYC?
Trade-offs regarding prioritization and speed of vaccination.
medRxiv. 2021:2021.01.29.21250710. DOI
48. Jennings W, Stoker G, Willis H, Valgardsson V, Gaskell J,
Devine D, McKay L, Mills MC. Lack of trust and social
media echo chambers predict COVID-19 vaccine hesitancy.
medRxiv. 2021:2021.01.26.21250246. DOI
49. Driedger SM, Maier R, Furgal C, Jardine C. Factors
influencing H1N1 vaccine behavior among Manitoba
Metis in Canada: a qualitative study. BMC Public Health
2015;15(1):128. DOI PubMed
50. Kowal SP, Jardine CG, Bubela TM. "If they tell me to get
it, I’ll get it. If they don’t...": immunization decision-making
processes of immigrant mothers. Can J Public Health
2015;106(4):e230–5. DOI PubMed
52. Yuan X, Schuchard RJ, Crooks AT. Examining Emergent
Communities and Social Bots Within the Polarized
Online Vaccination Debate in Twitter. Soc Media Soc.
2019;5(3):2056305119865465. DOI
53. Archibald MM. Investigator Triangulation: A Collaborative
Strategy With Potential for Mixed Methods Research.
J Mixed Methods Res 2015;10(3):228–50. DOI
54. Hidiroglu S, Ay P, Topuzoglu A, Kalafat C, Karavus M.
Resistance to vaccination: the attitudes and practices of
primary healthcare workers confronting the H1N1 pandemic.
Vaccine 2010;28(51):8120–4. DOI PubMed
55. Nowak GJ, Sheedy K, Bursey K, Smith TM, Basket
M. Promoting influenza vaccination: insights from a
qualitative meta-analysis of 14 years of influenza-related
communications research by U.S. Centers for Disease
Control and Prevention (CDC). Vaccine 2015;33(24):2741–56.
DOI PubMed
51. Broniatowski DA, Jamison AM, Qi S, AlKulaib L, Chen T,
Benton A, Quinn SC, Dredze M. Weaponized Health
Communication: Twitter Bots and Russian Trolls Amplify the
Vaccine Debate. Am J Public Health 2018;108(10):1378–84.
DOI PubMed
Get CCDR delivered
to your inbox
Know the trends
Get the testing guidelines
Stay current on new vaccines
Learn about emerging infections
Get the table of contents
straight to your inbox
SUBSCRIBE TODAY
Web search: CCDR+Subscribe
Page 533
CCDR • December 2021 • Vol. 47 No. 12
IMPLEMENTATION SCIENCE
The PRONTO study: Clinical performance of
ID NOW in individuals with compatible
SARS-CoV-2 symptoms in walk-in centres—
accelerated turnaround time for contact tracing
Isabelle Goupil-Sormany1,2, Jean Longtin3,4, Jeannot Dumaresq4,5, Marieve Jacob-Wagner3,
Frédéric Bouchard6, Liliana Romero7, Julie Harvey8, Julie Bestman-Smith3,4, Mathieu Provençal9,
Stéphanie Beauchemin9, Valérie Richard2, Annie-Claude Labbé9,10,11*
This work is licensed under a Creative
Commons Attribution 4.0 International
License.
Abstract
Background: This PRONTO study investigated the clinical performance of the Abbott ID
NOWTM (IDN) COVID-19 diagnostic assay used at point of care and its impact on turnaround
time for divulgation of test results.
Affiliations
Direction de la vigie sanitaire,
Ministère de la Santé et des Services
sociaux du Québec, QC
1
Methods: Prospective study conducted from December 2020 to February 2021 in acute
symptomatic participants presenting in three walk-in centres in the province of Québec.
Département de médecine sociale
et préventive, Faculté de Médecine,
Université Laval, Québec, QC
2
Results: Valid paired samples were obtained from 2,372 participants. A positive result on either
the IDN or the standard-of-care nucleic acid amplification test (SOC-NAAT) was obtained in
423 participants (prevalence of 17.8%). Overall sensitivity of IDN and SOC-NAAT were 96.4%
(95% CI: 94.2–98.0%) and 99.1% (95% CI: 97.6–99.8), respectively; negative predictive values
were 99.2% (95% CI: 98.7–99.6%) and 99.8% (95% CI: 99.5–100%), respectively. Turnaround
time for positive results was significantly faster on IDN.
Conclusion: In our experience, IDN use in symptomatic individuals in walk-in centres is a
reliable sensitive alternative to SOC-NAAT without the need for subsequent confirmation
of negative results. Such deployment can accelerate contact tracing, reduce the burden on
laboratories and increase access to testing.
Suggested citation: Goupil-Sormany I, Longtin J, Dumaresq J, Jacob-Wagner M, Bouchard F, Romero L, Harvey J,
Bestman-Smith J, Provençal M, Beauchemin S, Richard V, Labbé A-C. The PRONTO study: Clinical performance of
ID NOW in individuals with compatible SARS-CoV-2 symptoms in walk-in centres—accelerated turnaround time for
contact tracing. Can Commun Dis Rep 2021;47(12):534–42. https://doi.org/10.14745/ccdr.v47i12a04
Keywords: COVID-19, SARS-CoV-2, nucleic acid amplification tests, rapid tests, Abbott ID NOW, sensitivity and
specificity, predictive value, diagnostic performance, point-of-care testing, Canada
Département de microbiologie et
d'infectiologie du centre hospitalier
universitaire (CHU) de Québec –
Université Laval, Québec, QC
3
Département de
microbiologie-infectiologie
et d’immunologie, Faculté de
Médecine, Université Laval,
Québec, QC
4
Département de microbiologie
et d'infectiologie, CISSS de
Chaudière-Appalaches, Lévis, QC
5
Laboratoire de biochimie
médicale, CISSS de
Chaudière-Appalaches, Lévis, QC
6
Direction de la Santé publique,
CISSS de Chaudière-Appalaches,
Lévis, QC
7
Direction de la Santé publique,
CIUSSS de la Capitale-Nationale,
Québec, QC
8
Département des laboratoires
de biologie médicale, Grappe
Optilab-CHUM, Centre hospitalier
de l’Université de Montréal,
Montréal, QC
9
Introduction
Currently, the most reliable methodologies for coronavirus disease 2019 (COVID-19) testing are
standard laboratory-based nucleic acid amplification tests (NAAT). However, over the first waves
of the pandemic, reagent shortages and high demand have challenged our public health capacity
and reactivity (1–4). The long turnaround time (TAT) required to produce a test result has also
compromised search and contact tracing strategies (5–7). Stand alone rapid tests in specific settings
are expected to accelerate case and contact tracing, along with improving public health
actions (8–10).
The Abbott ID NOWTM (IDN) COVID-19 assay, an isothermal NAAT targeting a RdRp segment
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was granted Health Canada
emergency use authorization on September 30, 2020. It is authorized as a lab-based and
Département de microbiologie,
infectiologie et immunologie,
Université de Montréal, Montréal,
QC
10
Service de maladies infectieuses,
Hôpital Maisonneuve-Rosemont,
CIUSSS de l’Est-de-l’Île-de-Montréal,
Montréal, QC
11
*Correspondence:
ac.labbe@umontreal.ca
CCDR • December 2021 • Vol. 47 No. 12
Page 534
IMPLEMENTATION SCIENCE
point-of-care diagnostic assay for the detection of SARS-CoV-2
in individuals with COVID-19 symptoms for fewer than or
equal to seven days at time of testing. Early published studies
established a lower analytical sensitivity compared with many
laboratory-based NAAT assays (11–15). According to the
product insert, negative results are to be treated as presumptive
and be confirmed with a cleared NAAT. The Canadian Public
Health Laboratory Network and the Canadian Society of
Clinical Chemist subsequently recommended certain clinical
use scenarios to balance expected limited sensitivity with other
considerations (16).
Published literature demonstrated that the clinical sensitivity of
IDN was linked to corresponding viral loads, with false negative
results tending to occur when the standard laboratory-based
NAAT cycle thresholds (Ct) are 32 or higher, reflecting lower
viral loads (12,13,17). As shown by others, the highest viral
loads were found in symptomatic participants presenting in
community walk-in centres (9–11). The present study aimed
to assess whether IDN could be used as a reliable stand-alone
test (without subsequent confirmation) as a means to intervene
more quickly on transmission chains, relieve laboratory human
and material resources and give more autonomy to front-line
healthcare providers. As such, we are reporting the agreement
and clinical performance of the IDN, compared to a standardof-care NAAT (SOC-NAAT) assay, among prospectively recruited
symptomatic individuals presenting in community walk-in centres
in the province of Québec, Canada.
Methods
In December 2020, IDN instruments were implemented in three
walk-in centres in the province of Québec. Volunteer participants
were asked to confirm that symptom onset was fewer than or
equal to seven days prior to testing and to provide two samples
simultaneously, as detailed in Table 1.
The oropharyngeal and bilateral nasal swab (OBNS) for the
IDN assay was collected with the foam swab provided with
the Abbott ID NOW COVID-19 kit as follows: after swabbing
the posterior pharynx, tonsils and other inflamed areas for a
few seconds each, the swab was inserted in one nostril until a
resistance was met at the level of the turbinates (approximatively
2 cm), rotated five times against the nasal wall and slowly
removed from the nostril; the same swab was then used for the
other nostril. The OBNS for IDN was collected after the oral and
nasopharyngeal swab (ONPS) for SOC-NAAT in Québec City and
Montréal (18), but performed prior to the gargle for SOC-NAAT
in Lévis (19), since the gargle procedure could dilute any virus
present when swabbing for IDN.
The IDN test was performed on-site, within one hour of
collection, by professionals from diverse training and experience
backgrounds who were trained by our teams on using the IDN
instrument as per the package insert.
Page 535
CCDR • December 2021 • Vol. 47 No. 12
Table 1: Characteristics of the participating centres:
Type of clinic, sampling and testing methodologies
Characteristics
Québec City
and Montréal
Lévis
Type of centre
Walk-in clinic
Drive-thru clinica
SOC-NAAT
sampling
ONPS
ONPS (when gargle
not feasible)
SOC-NAAT
method
Laboratory-developed
PCR
AllplexTM 2019-nCoV
(Seegene) direct PCR
Sampling
sequence
SOC-NAAT followed by
IDN
IDN followed by
SOC-NAAT
IDN sampling
OBNS
OBNS
Gargle
Abbreviations: IDN, ID NOWTM; OBNS, oropharyngeal and bilateral nasal swab; ONPS, oral and
nasopharyngeal swab; PCR, polymerase chain reaction; SOC-NAAT, standard of care-nucleic acid
amplification testing
a
For text simplification, all three centres were considered as walk-in clinics
The SOC-NAAT in Montréal (Hôpital Maisonneuve-Rosemont;
HMR) and Québec City (CHU de Québec) was a real-time
polymerase chain reaction (PCR) assay targeting the structural
protein envelope E gene (18,20). Inactivation and thermal
lysis, rather than chemical extraction, were performed prior to
PCR testing, as previously described (18). The SOC-NAAT in
Lévis (Centre intégré de santé et de services sociaux [CISSS]
de Chaudière-Appalaches) was based on Seegene AllplexTM
technology as previously described (19).
No personal data were collected outside of the information
available on the standard COVID-19 laboratory form (gender,
age, duration of symptoms, COVID-19 contact history). The
duration of symptoms and contact history, combined with
supplemental NAAT when applicable, were used to classify
infection stages of participants for whom discordant results were
obtained. Acute infection was defined as at least having one
symptom among fever, cough, runny nose, dyspnea, sore throat,
anosmia and ageusia, or a combination of two of the following:
headache, fatigue, muscle pain, anorexia, nausea or vomiting,
abdominal cramps or diarrhea within seven days of onset. When
the collected data revealed misclassification, erroneous data
collected by staff or by participant mistake, the case remained
included in the study since representing a real-life situation.
For each study site, TAT was defined as the time between
sample collection and the availability of the laboratory report for
concordantly positive pairs (both the IDN and the SOC-NAAT
results were reported). In Lévis, the time between sample
collection and completion of public health questionnaire with the
case and household contacts was also calculated. The TAT for
negative results was not monitored since negative IDN results
were not reported during the study period.
This PRONTO study was undertaken in the midst of the
second wave of the COVID-19 in Québec, with thousands of
samples being received on a daily basis. There was a context of
emergency (with public, administrative and media pressure) to
implement rapid testing. Formal Ethical Review Board approval
IMPLEMENTATION SCIENCE
was lifted since the study was mandated by the directeur
national de santé publique as part of the Public Health response
during the sanitary emergency state. Explicit verbal consent was
obtained from all participants after receiving a verbal description
of the project.
Statistical analysis
Samples producing invalid results in either arm were excluded
from the calculations.
Data were analyzed using a contingency table. In the absence
of a gold standard for SARS-CoV-2 ribonucleic acid (RNA)
detection, the reference method used for positive percent
agreement and negative percent agreement was the SOC-NAAT.
In addition to computing the overall rates of agreement,
the level of agreement was assessed using kappa statistics
(STATA V16.1). By definition, kappa values above 0.75 indicate
excellent agreement, values between 0.40 and 0.75 indicate
fair to good agreement, and values below 0.40 represent poor
agreement beyond chance (21). To evaluate the clinical sensitivity
and negative predictive value of IDN and SOC-NAAT, a
participant was considered infected if at least one result from the
paired samples was positive, assuming 100% specificity of both
assays. The 95% confidence intervals (95% CI) were obtained
with STATA V16.1.
Outcomes
Table 3: Prevalence of SARS-CoV-2 infection and
distribution of Abbott ID NOWTM and standard-of-care
nucleic acid amplification test results in symptomatic
individuals (n=2,372)
Prevalencea
Location
Québec
City
Table 2: Participant characteristics and number of valid
pairs included (N=2,395)
Québec City
Lévis
Montréal
Total
Participant
characteristics
n
%
n
%
n
%
n
%
Symptomatic
participants
recruited
1,246
N/A
790
N/A
359
N/A
2,395
N/A
Invalid results
12
1.0
9
1.1
2
0.6
23a
1.0
Valid paired
samples
1,234
99.0
781
98.9
357
99.4
2,372
99.0
Male gender
544
44.1
370
47.4
154
43.1
1,068
45.0
Mean age
40
N/A
32
N/A
38
N/A
37
N/A
Age range
(years)
1–88
N/A
1–83
N/A
1–80
N/A
1–88
N/A
118
9.6
109
14.0
33
9.2
260
11.0
Abbreviation: N/A, not applicable
a
Among the 23 excluded pairs, 22 invalid results were obtained with Abbott ID NOWTM and one
with standard-of-care nucleic acid amplification test
n/N
Results
%
193/1,234
15.6
Lévis
114/781
14.6
Montréal
116/357
32.5
423/2,372
17.8
Total
Between December 6 and February 22, 2020, paired samples
were obtained from 2,395 individuals. After exclusion of 23
pairs associated with an invalid result with either method, the
performance analysis was based on 2,372 participants (Table 2).
Younger than 18
years of age
As shown in Table 3, a total of 423 participants (17.8%) were
considered infected (at least one positive result by IDN or
SOC-NAAT). Positive concordant results were obtained on
404 pairs (95.5%); among the 19 discordant pairs, four were
positive with IDN only and 15 with SOC-NAAT only. Agreement
was excellent, as reflected by a kappa coefficient value of
0.97. Overall, IDN sensitivity and negative predictive value
were respectively estimated at 96.4% (95% CI 94.2–98.0) and
99.2% (95% CI 98.7–99.6), with little (not statistically significant)
variation across centres (Table 4).
IDN
SOC-NAAT
POS
NEG
POS
187
2
NEG
4
1,041
POS
109
1
NEG
4
667
POS
108
1
NEG
7
241
POS
404
4
NEG
15
1,949
Abbreviations: IDN, ID NOWTM; NEG, negative; POS, positive; SOC-NAAT, standard of
care-nucleic acid amplification testing
a
A participant was considered infected if at least one result from the paired samples was positive,
assuming 100% specificity of IDN and SOC-NAAT
Characteristics of the 19 participants for whom discordant
results were obtained are presented in Table 5. For the 15
negative IDN, the mean Ct value of the corresponding positive
SOC-NAAT was 33.5 (range 30.9–35.0). The mean Ct values for
the concordantly positive pairs, available for the Québec City site
(26.0) and the Montréal site (23.5), were clearly lower, reflecting
a higher viral load. Among the 15 participants for whom the
discordant profile was SOC-NAAT positive/IDN negative, two
were asymptomatic, four were considered as late presentation
and nine as acutely infected. Among the four participants for
whom the discordant profile was SOC-NAAT negative/IDN
positive, two had an acute infection and two could not be staged
nor confirmed by supplementary testing.
The TAT between sampling and availability of laboratory report
of positive results was on average 20.1 hours for SOC-NAAT
and 1.2 hours for IDN. In Lévis, TAT between sampling and
end of public health tracing was on average 36.0 hours for the
symptomatic individuals who either had SOC-NAAT positive/
IDN negative results or did not participate in this study but
were assessed at the same drive-through clinic during the same
period, and for whom testing was performed by SOC-NAAT
CCDR • December 2021 • Vol. 47 No. 12
Page 536
IMPLEMENTATION SCIENCE
Table 4: Agreement between Abbott ID NOWTM and standard-of-care nucleic acid amplification testing results and
clinical performance (n=2,372)
Test
Statistics
Assessment center
Lévis
Montréal
Québec City
Total
Agreement
%
PPAa
95% CI
98.9
99.1
99.1
99.0
96.2–99.9
95.0–100
95.0–100
97.5–99.7
99.6
99.4
97.2
99.2
99.0–100
98.5–99.8
94.3–98.9
98.7–99.6
%
NPAa
95% CI
%
ORA
95% CI
99.5
99.4
97.8
99.2
98.9–99.8
98.5–99.8
95.6–99.0
98.8–99.5
0.98
0.97
0.95
0.97
0.97–1.00
0.95–1.00
0.91–0.98
0.96–0.98
97.9
96.5
94.0
96.4
94.8–99.4
91.3–99.0
88.0–97.5
94.2–98.0
99.0
99.1
99.1
99.1
96.3–99.9
95.2–100
95.3–100
97.6–99.7
Κ
Cohen’s kappa
95% CI
Clinical performanceb
%
IDN sensitivity
95% CI
%
SOC-NAAT sensitivity
95% CI
99.6
99.4
97.1
99.2
99.0–99.9
98.5–99.8
94.1–98.8
98.7–99.6
99.8
99.9
99.6
99.8
99.3–100
99.2–100
97.7–100
99.5–100
%
IDN NPV
95% CI
%
SOC-NAAT NPV
95% CI
Abbreviations: CI, Confidence Interval; IDN, ID NOWTM; NPA, negative percent agreement; NPV, negative predictive value; ORA, overall rates of agreement; PPA, positive percent agreement;
SOC-NAAT, standard of care-nucleic acid amplification test
a
PPA and NPA were computed by considering the SOC-NAAT as the reference method
b
A participant was considered infected if at least one result from the paired samples was positive, assuming 100% specificity of IDN and SOC-NAAT
Table 5: Laboratory and clinical information of participants in whom discrepant results were obtained (n=19)
Assessment
center
SOC-NAATa
Ct value
Symptoms
durationb,c
Contact with
a known
caseb
Supplementary testingd
Clinical stage
IDN negative and SOC-NAAT positive (IDN false negative), n=15
Québec City
34.2
Unknown
34.8
N/A
Yes, but not
detailed
Initial SOC-NAAT sample retested after chemical
extraction: positive result with Ct value of 32.4
Asymptomatic
34.0
Less than 24
hours
Unknown
Initial SOC-NAAT sample retested after chemical
extraction: positive result with Ct value of 32.9
Acute presentation
31.5
More than 7 days
Unknown
ND
Late presentatione
N/A
Yes, but not
detailed
2 days
Home
ND
Acute presentation
1 day
Workplace
IDN swabf retested by two other assaysg: weakly
positive with one assay
Acute presentation
1 day
Home
IDN swabf retested by two other assaysg: weakly
positive with one assay
Acute presentation
34.0
(2/3 genes)
32.0
Lévis
(3/3 genes)
30.9
(3/3 genes)
34.4
(3/3 genes)
Page 537
Initial SOC-NAAT sample retested after chemical
extraction: positive result with Ct value of 33.4
Symptoms
resolved 6 days
earlier
CCDR • December 2021 • Vol. 47 No. 12
Resampled 72 hours later and tested by IDN and
SOC-NAAT with a Ct value of 35
Resampled 2 days later: negative on IDN and SOCNAAT
IDN swabf retested by two other assaysf: negative
results
Late presentatione
(post-symptomatic)
Asymptomatic
IMPLEMENTATION SCIENCE
Table 5: Laboratory and clinical information of participants in whom discrepant results were obtained (n=19)
(continued)
Assessment
center
SOC-NAATa
Ct value
Symptoms
durationb,c
Contact with
a known
caseb
Supplementary testingd
Clinical stage
IDN negative and SOC-NAAT positive (IDN false negative), n=15 (continued)
Montréal
34.2
More than 7 days
Home
ND
Late presentatione
33.5
1 day
Workplace
ND
Acute presentation
31.6
3 days
Home
ND
Acute presentation
35.0
7 days
Unknown
ND
Late presentatione
34.2
2 days
No
ND
Acute presentation
34.9
4 days
Unknown
ND
Acute presentation
33.3
Less than 24
hours
School
Initial SOC-NAAT sample retested after chemical
extraction: positive with Ct value of 33.7
Acute presentation
IDN positive and SOC-NAAT negative (SOC-NAAT false negative), n=4
2 hours
School
Québec City
Unknown
Unknown
N/A
Lévis
1 day
Unknown
Montréal
5 days
Home
IDN swabf tested by NAAT after chemical extraction:
positive result with a Ct value of 25.5
Initial SOC-NAAT sample retested after chemical
extraction: positive result with a Ct value of 33.8
IDN swabf tested by NAAT after chemical extraction:
positive result with a Ct value of 30.8
Initial SOC-NAAT sample retested after chemical
extraction: positive result with a Ct value of 35.2
IDN swabf tested by two other assays: negative
results
Initial SOC-NAAT sample retested by two commercial
assaysg: negative results
ND
Acute presentation
Unknown
Acute
presentation;
possible falsepositive IDN
Acute presentation
vs. possible falsepositive IDN
Abbreviations: Ct, cycle threshold; IDN, ID NOWTM; N/A, not applicable; ND, not done; SOC-NAAT, standard of care-nucleic acid amplification test
a
In Québec City and Montréal, the SOC-NAAT was a laboratory-developed test targeting the E gene. In Lévis, the Allplex™ 2019-nCoV assay (Seegene) includes three gene targets (E, RdRp and N);
the Ct values shown are the mean of the two or three positive results obtained
b
The duration of symptoms before testing and COVID-19 contact history were obtained through the standard routine questionnaire form. Missing information occurs frequently
c
Some individuals were included in this study based on the assertion that they were symptomatic. The questionnaire form—revised only for discordant pairs—revealed that some participants were
asymptomatic. It was decided not to exclude the latter a posteriori
d
The alternate NAAT was the laboratory-developed test preceded by chemical RNA extraction using the NucliSens easyMAG platform (bioMérieux; Saint-Laurent, Canada)
e
Presentation was considered late when symptoms started more than seven days before sampling as IDN is currently Health Canada-approved for participants tested within the first seven days of
symptoms
f
In Québec City and Lévis, after elution in the IDN Sample Receiver buffer, the swab sample was transported into a dry 15 mL Falcon tube and frozen for possible subsequent testing by NAAT to
resolve discrepancies between IDN and SOC-NAAT results or for retesting of the SOC-NAAT sample with a more sensitive laboratory platform
g
Simplexa COVID-19 (DiaSorin) and FilmArray RP 2.0 (bioMérieux)
(n=283); it was 13.6 hours for the 110 participants for whom the
IDN was positive, representing a difference of 22.4 hours (95% CI
18.8–26.1, p<0.0001).
Discussion
In this PRONTO study, the clinical performance of IDN was
compared to SOC-NAAT among a large number of symptomatic
individuals in community-based walk-in centres. Agreement
between the two testing strategies was nearly perfect.
Although the sensitivity of IDN (96.4%) was slightly lower than
for SOC-NAAT (99.1%), the difference was not statistically
significant. Very few false negative results were observed in
both arms, resulting in excellent negative predictive value of
99.5% and 99.8% for IDN and SOC-NAAT, respectively. Thus,
our results differ from earlier studies that demonstrated lower
sensitivity (55%–84%) (22,23). Some recent studies suggest a
better performance (86%–100%), although the 95% CI in these
latter studies were wider, due to a smaller sample size (22–28).
This discrepancy in sensitivity might be explained by variation
in pre-test probability in the target population (29) and by our
optimized swabbing methodology (30). The current study was
performed in a group with probable higher viral titers and
higher pre-test probability, during a high prevalence wave. A
multi-compartment swabbing protocol was also used herein,
which included three throat areas and both nostrils, which
has been previously shown to be a sensitive alternative to
nasopharyngeal swabbing (31). Another possible explanation
is that the SOC-NAAT comparators used in our study are
associated with lower analytical sensitivity than other commercial
NAATs currently used for the detection of SARS-CoV-2 (18).
CCDR • December 2021 • Vol. 47 No. 12
Page 538
IMPLEMENTATION SCIENCE
Indeed, at the Montréal site (data not shown), during the same
period, 127 similar individuals (with COVID-19 compatible
symptoms) had their ONPS tested by a commercial NAAT: 38
had concordant positive results; 85 had concordant negative
results; and four had negative IDN but positive commercial NAAT
results (sensitivity of the IDN 90.5%; 95% CI 77.4–97.3).
The discrepant pairs were classified according to their probable
clinical stage since later infections with higher Ct values might
not represent contagiousness (32–34). We presumed, as a
hypothesis for our study, that false negative results would be
associated with a lower viral load, with the infected individual
being less infectious. Although the timing of the test is important
to monitor dynamic viral load, our data confirmed discordant
results to be associated with higher Ct, an indirect indicator of
viral load (35,36).
The risk of not detecting all cases (or risk of false negative
results) can be mitigated by appropriate counselling:
automated messages sent with negative results invite people
to get retested and seek medical attention if symptoms do
not resolve by themselves after 48 hours (37,38). It could
also be counterbalanced by the timeliness of the results and
the possibility of increasing access to testing by increasing
overall laboratory capacity. Although lower IDN sensitivity and
missed cases could be deemed obstacles for promoting the
technology, we believe otherwise, especially in the context of
high vaccination uptake. Clinical sensitivity of a strategy should
include analytical sensitivity but also TAT and access to testing.
IDN use accelerated contact tracing, and we feel it increased
access to testing by offering a less intrusive OBNS sampling and
by delocalizing to the point-of-care. In fact, a Québec survey
poll showed that half of the eligible population with COVID-19
compatible symptoms did not get tested during the study period
(39). Rapid testing or more comfortable sampling methods could
represent a valuable solution (18,19).
The optimal approach for the diagnosis of COVID-19 remains
under debate. Some experts focus on test sensitivity and neglect
the public health and population impacts of accelerated contact
tracing (7,8). Although SOC-NAAT processes are now optimised
for high testing volume, laboratory resources are profoundly
stretched, particularly with the return to “normal” of healthcare
activities. An attractive scenario would be to supply IDN directly
to first-line clinics, with clear guidance on whom to test with
this strategy (for example, symptomatic individuals and close
contacts of positive cases). Cost-effective analysis should be
undertaken to better guide Canadian public health specialists,
microbiologists, administrators and clinicians.
In our study, results were available faster if samples were tested
with IDN vs. SOC-NAAT in all assessment centres, with a faster
public health inquiry in Lévis for IDN compared to SOC-NAAT.
Although representing different indicators, both are proxies
for public health intervention, and congruent in showing a net
Page 539
CCDR • December 2021 • Vol. 47 No. 12
advantage for IDN. Current public health recommendations
are that people with COVID-19 symptoms (and their household
contacts in certain high-prevalence regions) should self-isolate
from the onset of symptoms. However, no interventions have
been made to possible contacts until symptomatic participants
have a confirmed diagnosis of COVID-19. Without rapid results,
public health loses a valuable window of opportunity, particularly
if these contacts do not express a typical disease presentation.
We can also postulate that adherence to self-isolation is
increased when the diagnosis is confirmed.
Strengths and limitations
Among all the similar studies published to date, this PRONTO
study has the largest number of participants, even exceeding the
total number of participants included in the systematic review by
Tu et al. (24). Being a multi-site study and performed in a real-life
setting (e.g. the personnel performing the IDN testing stemmed
from diverse training and experience backgrounds), external
validity is increased. We were able to collect comparative data
as part of the implementation process in overwhelmed walk-in
centres and laboratories. We also aimed to document, in two of
the sites, the impact of rapid testing on public health. Although
a cause-and-effect relationship between IDN use and the impact
on transmission to contacts cannot be established, we postulate
that faster tracing will benefit public health containment
strategies (9,10).
Our study has certain limitations. First, SOC-NAAT differed
between laboratories, although adhered to the same validation
panels provided by the provincial Public Health Laboratory.
Second, very little participant-level data were collected from
participating institutions. As such, IDN could not be correlated
with the indications for testing, the appropriateness of the
test, and the clinical evolution of participants with positive test
results. Third, differences in practices within and between walkin centres (for example different personnel, rapidly changing
recommendations over time) may represent confounding
variables; for example, by including some asymptomatic
participants. Fourth, our diagnostic definition (at least one
positive result from the paired samples), which implies 100%
specificity of both assays, may have lead to slight overestimation
of the sensitivity for both assays. While false positive IDN results
are considered unlikely (28) compared with the well described
false positive laboratory PCR results (40), we suspect two false
positive results in our study (Table 5), and we witnessed some
infrequent confirmed false positive IDN results in routine care
after the end of the study.
Conclusion
Based on our large experience, IDN use in walk-in centres with
an optimized sampling method in acute symptomatic participants
can be achieved safely without the need for laboratory
confirmation of negative results. In this context, IDN can be
considered a stand-alone testing option. Such deployment
IMPLEMENTATION SCIENCE
accelerates contact tracing of positive cases and reduces the
burden on laboratories, while increasing access to testing.
Authors’ statement
IGS — Conceived the original idea, acquired the financial
support, performed literature searches, drafted the manuscript,
review and editing
JL — Conceived the original idea and statistical analysis,
performed initial literature searches, wrote the first draft,
supervised the project
JD — Conceived the original idea and statistical analysis,
performed additional literature searches, drafted the manuscript,
performed additional literature searches, performed data
curation and statistical analyses, supervised the project
MJW — Collected the data and contributed to laboratory
content of the manuscript
FB — Collected the data and contributed to the analysis and
data curation
LR — Provided resources, validated methodology and feasibility,
supervised the project
JH — Collected the data and contributed to laboratory content
of the manuscript
JBS — Collected the data and contributed to laboratory content
of the manuscript
MP — Collected the data and contributed to laboratory content
of the manuscript
SB — Collected the data and contributed to laboratory content
of the manuscript
VD — Collected the data and contributed to laboratory content
of the manuscript
ACL — Performed data curation and statistical analyses,
performed additional literature searches, drafted the manuscript,
visualized data presentation, review and editing, supervised the
project
All authors approved the final version to be published and
agreed to be accountable for all aspects of the work.
The content and view expressed in this article are those of the
authors and do not necessarily reflect those of the Government
of Canada.
Funding
This PRONTO study received no private funding. The ID NOW
kits were provided in-kind from Health Canada, and human
resources were funded by the Ministère de la Santé et des
Services sociaux through the budget of each of the three
participating institutions.
References
1.
Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X,
Tjian R. Overcoming the bottleneck to widespread testing:
a rapid review of nucleic acid testing approaches for
COVID-19 detection. RNA 2020;26(7):771–83. DOI PubMed
2.
European Centre for Disease Prevention and Control.
Diagnostic testing and screening for SARS-CoV-2.
Stockholm, Sweden; ECDC: (updated 2021-05-21;
accessed 2021-07-21). https://www.ecdc.europa.eu/en/
covid-19/latest-evidence/diagnostic-testing
3.
World Health Organization. Laboratory testing for
coronavirus disease 2019 (COVID-19) in suspected human
cases: interim guidance, 2 March 2020. Geneva (CH): WHO;
2020 (accessed 2021-07-21). https://apps.who.int/iris/
handle/10665/331329
4.
Centers for Disease Control and Prevention. Interim
Guidelines for Collecting and Handling of Clinical Specimens
for COVID-19 Testing. Atlanta, GA: CDC; (updated
2021-02-26; accessed 2021-07-21). https://www.cdc.gov/
coronavirus/2019-ncov/lab/guidelines-clinical-specimens.
html
5.
Pettengill MA, McAdam AJ. Can We Test Our Way
Out of the COVID-19 Pandemic? J Clin Microbiol
2020;58(11):e02225–20. DOI PubMed
6.
Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics
in context. Sci Transl Med 2020;12(546):eabc1931. DOI
7.
Larremore DB, Wilder B, Lester E, Shehata S, Burke JM,
Hay JA, Tambe M, Mina MJ, Parker R. Test sensitivity is
secondary to frequency and turnaround time for COVID-19
screening. Sci Adv 2021;7(1):eabd5393. DOI PubMed
8.
Mina MJ, Parker R, Larremore DB. Rethinking Covid-19
Test Sensitivity - A Strategy for Containment. N Engl J Med
2020;383(22):e120. DOI PubMed
9.
Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ,
Sun C, Sylvia S, Rozelle S, Raat H, Zhou H. Epidemiology,
causes, clinical manifestation and diagnosis, prevention
and control of coronavirus disease (COVID-19) during the
early outbreak period: a scoping review. Infect Dis Poverty
2020;9(1):29. DOI PubMed
Competing interests
None.
Acknowledgments
We thank all participants, the administrators and personnel of the
walk-in centres who took care of them and performed the IDN,
and the laboratory technologists who performed the SOC-NAATs
for this study.
CCDR • December 2021 • Vol. 47 No. 12
Page 540
IMPLEMENTATION SCIENCE
10. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI,
Russell TW, Munday JD, Kucharski AJ, Edmunds WJ,
Funk S, Eggo RM; Centre for the Mathematical Modelling
of Infectious Diseases COVID-19 Working Group. Feasibility
of controlling COVID-19 outbreaks by isolation of cases and
contacts. Lancet Glob Health 2020;8(4):e488–96.
DOI PubMed
11. Harrington A, Cox B, Snowdon J, Bakst J, Ley E,
Grajales P,Maggiore J, Kahn S. Comparison of Abbott ID
Now and Abbott m2000 Methods for the Detection of
SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from
Symptomatic Patients. J Clin Microbiol 2020;58(8):e00798–
20. DOI PubMed
12. Smithgall MC, Scherberkova I, Whittier S, Green DA.
Comparison of Cepheid Xpert Xpress and Abbott ID Now to
Roche cobas for the Rapid Detection of SARS-CoV-2. J Clin
Virol 2020;128:104428. DOI PubMed
13. Basu A, Zinger T, Inglima K, Woo KM, Atie O, Yurasits L,
See B, Aguero-Rosenfeld ME. Performance of Abbott ID
Now COVID-19 Rapid Nucleic Acid Amplification Test
Using Nasopharyngeal Swabs Transported in Viral Transport
Media and Dry Nasal Swabs in a New York City Academic
Institution. J Clin Microbiol 2020;58(8):e01136–20.
DOI PubMed
14. Lephart PR, Bachman MA, LeBar W, McClellan S, Barron K,
Schroeder L, Newton DW. Comparative study of four
SARS-CoV-2 Nucleic Acid Amplification Test (NAAT)
platforms demonstrates that ID NOW performance is
impaired substantially by patient and specimen type. Diagn
Microbiol Infect Dis 2021;99(1):115200. DOI PubMed
15. Mitchell SL, George KS. Evaluation of the COVID19 ID NOW
EUA assay. J Clin Virol 2020;128:104429. DOI PubMed
16. Canadian Public Health Laboratory Network and the
Canadian Society of Clinical Chemists. Interim guidance on
the use of the Abbott ID NOW™ instrument and COVID-19
assay. Can Commun Dis Rep 2020;46(11-12):422–6.
DOI PubMed
17. Rhoads DD, Cherian SS, Roman K, Stempak LM,
Schmotzer CL, Sadri N. Comparison of Abbott ID
Now, DiaSorin Simplexa, and CDC FDA Emergency
Use Authorization Methods for the Detection of
SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from
Individuals Diagnosed with COVID-19. J Clin Microbiol
2020;58(8):e00760–20. DOI PubMed
18. Gobeille Paré S, Bestman-Smith J, Fafard J, Doualla-Bell F,
Jacob-Wagner M, Lavallée C, Charest H, Beauchemin S,
Coutlée F, Dumaresq J, Busque L, St-Hilaire M, Lépine G,
Boucher V, Desforges M, Goupil-Sormany I, Labbé AC;
G-SPIT study group. Natural spring water gargle samples
as an alternative to nasopharyngeal swabs for SARS-CoV-2
detection using a laboratory-developed test. J Med Virol
2021. DOI PubMed
19. Dumaresq J, Coutlée F, Dufresne PJ, Longtin J, Fafard J,
Bestman-Smith J, Bergevin M, Vallières E, Desforges M,
Labbé AC. Natural spring water gargle and direct RT-PCR for
the diagnosis of COVID-19 (COVID-SPRING study).
J Clin Virol 2021;144:104995. DOI PubMed
Page 541
CCDR • December 2021 • Vol. 47 No. 12
20. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A,
Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML,
Mulders DG, Haagmans BL, van der Veer B, van den Brink S,
Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M,
Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C.
Detection of 2019 novel coronavirus (2019-nCoV) by
real-time RT-PCR. Euro Surveill 2020;25(3):2000045.
DOI PubMed
21. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd
ed. New York: John Wiley & Sons; 1981.
22. Lee J, Song JU. Diagnostic accuracy of the Cepheid Xpert
Xpress and the Abbott ID NOW assay for rapid detection
of SARS-CoV-2: A systematic review and meta-analysis.
J Med Virol 2021;93(7):4523–31. DOI PubMed
23. Subsoontorn P, Lohitnavy M, Kongkaew C. The diagnostic
accuracy of isothermal nucleic acid point-of-care tests for
human coronaviruses: A systematic review and meta-analysis.
Sci Rep 2020;10(1):22349. DOI PubMed
24. Tu YP, Iqbal J, O’Leary T. Sensitivity of ID NOW and RT-PCR
for detection of SARS-CoV-2 in an ambulatory population.
eLife 2021;10:e65726. DOI PubMed
25. Ghofrani M, Casas MT, Pelz RK, Kroll C, Blum N, Foster SD.
Performance characteristics of the ID NOW COVID-19 assay:
A regional health care system experience. medRxiv. 2020;
2020.06.03.20116327v1. https://www.medrxiv.org/content/
medrxiv/early/2020/06/05/2020.06.03.20116327.full.pdf
26. Leong KW, Law TL, Saiful AS. Kang, Woo, Chow, Yong ZL.
Excellent negative predictive value (99.8%) of two rapid
molecular COVID-19 tests compared to conventional RT-PCR
for SARS-CoV-2 (COVID-19) in 2,011 tests performed in
a single centre. medRxiv. 2021; 2021.06.20.21258392v1.
https://www.medrxiv.org/content/medrxiv/ear
ly/2021/06/21/2021.06.20.21258392.full.pdf
27. Comer S, Fisk D. An Extended Laboratory Validation Study
and Comparative Performance Evaluation of the Abbott
ID NOW™ COVID-19 Assay in a Coastal California Tertiary
Care Medical Center. medRxiv. 2020; 2020.06.14.20130518.
https://www.medrxiv.org/content/medrxiv/ear
ly/2020/06/16/2020.06.14.20130518.full.pdf
28. Stokes W, Berenger BM, Singh T, Adeghe I, Schneider A,
Portnoy D, King T, Scott B, Pabbaraju K. shokoples S,
Wong AA, Gill K, Turnbull L, Hu J, Tipples G. Acceptable
Performance of the Abbott ID NOW Among Symptomatic
Individuals with Confirmed COVID-19. medRxiv. 2020;
2020.12.24.20248786. https://www.medrxiv.org/content/
medrxiv/early/2020/12/30/2020.12.24.20248786.full.pdf
29. Balayla J, Lasry A, Gil Y, Volodarsky-Perel A. Prevalence
Threshold and Temporal Interpretation of Screening
Tests: The Example of the SARS-CoV-2 (COVID-19)
Pandemic. medRxiv. 2020; 2020.05.17.20104927.
https://www.medrxiv.org/content/medrxiv/ear
ly/2020/05/22/2020.05.17.20104927.full.pdf
IMPLEMENTATION SCIENCE
30. Burnes LE, Clark ST, Sheldrake E, Faheem A, Poon BP,
Christie-Holmes N, Finlay L, Kandel C, Phan M, Frankland C,
Lau T, Gubbay JB, Corbeil A, Katz K, Kozak RA. One swab,
two tests: validation of dual SARS-CoV-2 testing on the
Abbott ID NOW™. J Clin Virol 2021;141:104896.
DOI PubMed
31. LeBlanc JJ, Heinstein C, MacDonald J, Pettipas J,
Hatchette TF, Patriquin G. A combined oropharyngeal/nares
swab is a suitable alternative to nasopharyngeal swabs for
the detection of SARS-CoV-2. J Clin Virol 2020;128:104442.
DOI PubMed
32. Longtin Y, Charest H, Quach C, Savard P, Baz M, Boivin G,
Farfard J, Villeneuve J, Roger M, De Serres G. Infectivity of
healthcare workers diagnosed with coronavirus disease 2019
(COVID-19) approximately 2 weeks after onset of symptoms:
A cross-sectional study. Infect Control Hosp Epidemiol
2021;11:1–3. DOI PubMed
33. Manzulli V, Scioscia G, Giganti G, Capobianchi MR,
Lacedonia D, Pace L, Cipolletta D, Tondo P, De Nittis R,
Rondinone V, Serrecchia L, Parisi A, Galante D, Lo Caputo S,
Santantonio TA, Moschetta D, Dattoli V, Fasanella A,
Foschino Barbaro MP. Real Time PCR and Culture-Based
Virus Isolation Test in Clinically Recovered Patients: Is
the Subject Still Infectious for SARS-CoV2? J Clin Med
2021;10(2):309. DOI PubMed
34. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L,
Boodman C, Bello A, Hedley A, Schiffman Z, Doan K, Bastien
N, Li Y, Van Caeseele PG, Poliquin G. Predicting infectious
SARS-CoV-2 from diagnostic samples. Clin Infect Dis
2020;1(10):2663–6. DOI PubMed
35. Krause E, Puyskens A, Bourquain D, Brinkmann A, Biere B,
Schaade L, Michel J, Nitsche A. Sensitive on-site detection
of SARS-CoV-2 by ID NOW COVID-19. Mol Cell Probes
2021;58:101742. DOI PubMed
36. Sepulveda JL, Abdulbaki R, Sands Z, Codoy M, Mendoza S,
Isaacson N, Kochar O, Keiser J, Haile-Mariam T, Meltzer AC,
Mores CN, Sepulveda AR. Performance of the Abbott
ID NOW rapid SARS-CoV-2 amplification assay in
relation to nasopharyngeal viral RNA loads. J Clin Virol
2021;140:104843. DOI PubMed
37. Zimmer R. Delays in testing as a source of
COVID-19 false-negative results. Can Fam Physician
2020;66(12):e298–301. DOI PubMed
38. Woloshin S, Patel N, Kesselheim AS. False Negative Tests
for SARS-CoV-2 Infection - Challenges and Implications.
N Engl J Med 2020;383(6):e38. DOI PubMed
39. Paré I. 41% of people with symptoms don’t get tested. Le
Devoir. 2021, 29 January; Sect. Health. https://www.ledevoir.
com/societe/sante/594260/coronavirus-les-quebecois-pas-sienclins-au-depistage
40. Layfield LJ, Camp S, Bowers K, Miller DC. SARS-CoV-2
detection by reverse transcriptase polymerase chain
reaction testing: analysis of false positive results
and recommendations for quality control measures.
Pathol Res Pract 2021;225:153579. DOI PubMed
CCDR • December 2021 • Vol. 47 No. 12
Page 542
OUTBREAK
COVID-19 outbreak in a long-term care facility
in Kelowna, British Columbia after rollout of
COVID-19 vaccine in March 2021
Fatemeh Sabet1,2, Barbara Gauthier3, Muddassir Siddiqui3, Amanda Wilmer4, Natalie Prystajecky4,5,
Pamela Rydings3, Michele Andrews3, Sue Pollock3,6*
This work is licensed under a Creative
Commons Attribution 4.0 International
License.
Abstract
Background: In March 2021, a coronavirus disease 2019 (COVID-19) outbreak was declared at a
large long-term care and short stay facility in British Columbia, Canada—well after introduction
of the vaccination program in long-term care facilities that resulted in a dramatic decline in
the number of outbreaks in this type of setting. The objective of this study is to provide the
descriptive epidemiology of this outbreak, in the context of partial immunization of both
residents and staff at the facility.
Affiliations
Public Health and Preventive
Medicine Residency Program,
University of Calgary, Calgary, AB
1
Alberta Health Services, Calgary,
AB
2
Methods: The cases’ information was extracted from a provincial information system
(Panorama). Descriptive analysis was performed using Microsoft Excel and SAS. Outbreak
management controls included, but were not limited to, asymptomatic testing and efforts to
increase vaccination.
Results: Twenty-six cases among the 241 resident and three cases among the 418 staff
(corresponding to attack rates of 10% and less than 1%, respectively) were identified. The
attack rate in residents was considerably lower than the average attack rate for COVID-19
outbreaks in long-term care facilities before the vaccine rollout. Seventeen resident cases were
either partially or fully immunized. Four of the eight hospitalized cases and two of the three
deceased cases were partially immunized. Seventeen cases were temporary stay residents.
The three staff cases were not vaccinated. Ten cases were identified as part of asymptomatic
testing.
Conclusion: Introduction of vaccination at facilities contributed to lower attack rates and higher
numbers of asymptomatic cases in this outbreak. Screening asymptomatic individuals identified
additional cases among vaccinated residents. Findings underscore the importance of achieving
high vaccine coverage, including among temporary stay residents, to prevent virus introduction
and subsequent unrecognized transmission opportunities.
Population Health, Interior
Health Authority Kelowna, BC
3
Pathology and Laboratory
Medicine, University of British
Columbia, Vancouver, BC
4
British Columbia Centre for
Disease Control Public Health
Laboratory, Vancouver, BC
5
School of Population and Public
Health, University of British
Columbia, Vancouver, BC
6
*Correspondence:
sue.pollock@interiorhealth.ca
Suggested citation: Sabet FA, Gauthier B, Siddiqui M, Wilmer A, Prystajecky N, Rydings P, Andrews M, Pollock SL.
COVID-19 outbreak in a long-term care facility in Kelowna, British Columbia after rollout of COVID-19 vaccine in
March 2021. Can Commun Dis Rep 2021;47(12):543–52. https://doi.org/10.14745/ccdr.v47i12a05
Keywords: long-term care, outbreak, COVID-19 vaccine, descriptive epidemiology
Introduction
The coronavirus disease 2019 (COVID-19) pandemic, declared
in March 2020, has physically and mentally affected many
lives, especially seniors and individuals living with underlying
medical conditions. Long-term care (LTC) facilities experienced
an increase in outbreaks, as well as increased morbidity and
mortality amongst staff and residents (1,2).
Page 543
CCDR • December 2021 • Vol. 47 No. 12
Vaccination of frontline staff has been found to be highly
effective in preventing COVID-19 infection (3); however, older
adults with multiple underlying comorbidities were one of the
groups not included in the preauthorization vaccine effectiveness
clinical trials and are expected to have lower immunogenicity
from vaccination (4). Other studies in this population have
focused on vaccine effectiveness in the post-marketing phase
in individuals with partial versus complete immunization (3,5). A
OUTBREAK
recent publication on vaccine effectiveness among residents of
nursing homes in the United States showed a reduction in the
number of infections and milder symptoms among individuals
who were partially or fully vaccinated (6). In addition, the
emergence of new variants of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has raised questions about vaccine
effectiveness against novel strains of the virus (7–9).
In March 2021, Interior Health (IH; a regional health authority in
British Columbia, Canada) reported the end of the third wave
of the pandemic. Although the incidence rate of COVID-19
infection in IH was decreasing at that time, the prevalence
of variants of concern was starting to increase, particularly
the Alpha (B.1.1.7) variant. Providing the COVID-19 vaccine
to seniors in LTC facilities in British Columbia resulted in a
significant decrease in the number of COVID-19 outbreaks and
deaths at these facilities (10). However, a COVID-19 outbreak
occurred at a large LTC facility three months after the start of
vaccination program. On March 5, 2021, IH Communicable
Disease Unit and Infection Prevention and Control (IPAC) were
notified of a positive COVID-19 result in a resident of a LTC
facility who had been admitted in December 2020 to the short
stay unit (SSU) from a nearby acute care site for rehabilitation.
The resident, who had hypothyroidism and hypertension as their
underlying medical condition and who had received their second
dose of the Pfizer-BioNTech COVID-19 vaccine eight days prior
to symptom onset, was isolated in a private room with mild
symptoms, including sore throat, cough, congestion and fatigue.
The same day, it was discovered that another resident, who
was unknowingly exposed to a COVID-19-positive roommate in
an acute care setting outbreak, had recently been transferred
back to a different unit in the same LTC facility. This resident
underwent testing on March 6, 2021, and was found to be
COVID-19 positive. This resident had been admitted to the acute
care site for renal failure and sepsis secondary to urinary tract
infection and the only COVID-19 infection symptom was fatigue.
The acute care setting outbreak included five staff and five
patients and was declared over on April 7, 2021.
The LTC facility was unique in that it comprised 181 beds
divided between four LTC units and included a 60-bed SSU as
well. Resident rooms were a mix of private, semi-private and
multi-bedrooms. There were approximately 418 staff working at
the facility during the outbreak: approximately 70 SSU staff and
208 LTC staff, plus 140 staff working in both areas of the facility.
The IPAC measures at the facility before the outbreak began
included the restrictions that were in place for LTC facilities in
British Columbia as per the provincial guidelines (11). These
measures included but were not limited to daily screening of staff
and residents, use of appropriate personal protective equipment,
regular hand hygiene and frequent environmental cleaning.
Social visits were restricted to one designated visitor, subject
to strict symptom screening, at two meters of distance with
personal protective equipment in place. Staff were restricted to
work at a single LTC site. The facility was required to perform
daily reports of any symptomatic residents or staff.
Outbreak control measures
A subgroup of the Communicable Disease Unit called the
Adult Care Facility COVID-19 Response Team was created as
a pandemic response to oversee COVID-19 outbreaks related
to LTC facilities in early 2020. The Adult Care Facility Team
assembled an outbreak management team including the local
Medical Health Officer, IPAC, Environmental Public Health,
Epidemiology, Community Care Licensing, Clinical Operations,
Workplace Health and Safety, Emergency Response Team,
Communications and representatives of the facility. Introduction
of outbreak management measures started within a day of the
identification of the index case.
After the initial outbreak management team assessment, an
outbreak was declared and ongoing daily meetings occurred.
Residents were isolated to their private rooms or beds from
the start of the outbreak until a cohorting plan was developed.
Ongoing screening occurred daily to identify newly symptomatic
staff or residents who were then placed in isolation, tested for
COVID-19 and reported as soon as possible. New positive cases
were added to an outbreak line list. Symptomatic staff were
excluded from work. Staff were cohorted and started to work
exclusively at designated units within the facility. Contact tracing
was performed as positive cases were identified, with exposed
individuals cohorted and pre-emptively placed in isolation.
The IPAC support provided education and direction on infection
control practices. Resident activities were cancelled and meals
were served only at resident rooms. Unimmunized residents
and staff were immediately offered the vaccine. Vaccination of
the recently infected residents and staff was delayed due to
natural immunity following infection. Asymptomatic testing was
performed to detect cases and prevent unrecognized facility
transmission.
The objective of this report is to provide descriptive
epidemiology for a COVID-19 outbreak in a large LTC facility,
which was more open to movement of residents and staff owing
to the unique co-location of an SSU, in the context of partial
immunization of both residents and staff.
Methods
Case finding and data collection
The IPAC and Communicable Disease Unit staff began an
investigation of residents and staff, under the direction of the
Medical Health Officer. Facility-related cases were defined as
per provincial outbreak guidelines (12). Cases were defined as
individuals with a positive COVID-19 polymerase chain reaction
test result, regardless of symptoms and standardized information
was collected on any confirmed cases (13). Investigation was
completed for any additional case starting February 18, 2021—
CCDR • December 2021 • Vol. 47 No. 12
Page 544
OUTBREAK
Results
Unvaccinated cases are defined as individuals who either
had not received a vaccine or had received only one dose of
vaccine within 21 days of episode date (symptom onset when
available, otherwise specimen collection date for first positive
test). Partially vaccinated individuals had received the first
dose of vaccine more than 21 days before their episode date
and either had not received the second dose of vaccine or had
received the second dose within seven days of their onset of
symptoms. Individuals with episode dates more than seven days
after receiving their second dose of vaccine are considered fully
vaccinated. This definition was adapted provincially for partial
and full vaccination at the time that the outbreak happened (14).
Outbreak declared
Figure 1: Epidemic curve of outbreak cases by episode
datea,b, unit and role (resident/staff) (N=29)
8
7
6
5
4
3
2
07-Apr
06-Apr
05-Apr
04-Apr
03-Apr
02-Apr
01-Apr
31-Mar
30-Mar
29-Mar
28-Mar
27-Mar
26-Mar
25-Mar
24-Mar
23-Mar
22-Mar
21-Mar
20-Mar
19-Mar
18-Mar
17-Mar
16-Mar
15-Mar
14-Mar
13-Mar
12-Mar
11-Mar
10-Mar
09-Mar
08-Mar
07-Mar
06-Mar
05-Mar
04-Mar
03-Mar
28-Feb
02-Mar
27-Feb
0
01-Mar
1
26-Feb
Information about reportable cases, including their immunization
records, was available through Panorama, the British Columbia
Public Health Communicable Disease Unit’s integrated records
system (13). Staff immunization records were extracted from
Panorama using Public Health Environment for Integrated data
Extracts (PHENIX). Immunization records for residents that
were not cases were provided by Interior Health’s Strategic
Information team. Descriptive analyses were performed using
Microsoft Excel 2010 and SAS version 9.4.
A resident of SSU was identified as the first case with disease
onset on February 25, 2021. Over the next two weeks, the
disease was spread to staff and two other units in the facility. The
outbreak was declared over on May 5, 2021 (Figure 1).
Number of COVID-19 cases
Specimen collection and testing were undertaken following
provincial guidelines. Flocked nasopharyngeal swabs (residents)
or saline gargles (staff) were collected, then were rapidly
transported to Kelowna General Hospital laboratory for testing
on the Panther Fusion® SARS-CoV-2 Assay (Hologic, San Diego,
California, United States) or the AllplexTM 2019-nCOV Assay
(Seegene, Seoul, South Korea). Positive specimens were referred
to British Columbia Centre for Disease Control Public Health
Laboratory for whole genome sequencing.
25-Feb
one incubation period prior to the first identified case—for likely
linkage to the outbreak.
Episode date (Symptom onset, otherwise test date)
Resident - A (SSU)
Resident - B (LTC)
Staff - B (LTC)
Resident - D (LTC)
Staff - D (LTC)
Staff - Entire facility
Abbreviations: COVID-19, coronavirus disease 2019; LTC, long-term care; SSU, short stay unit
a
Episode date refers to symptom onset date if available otherwise specimen collection date for
earliest positive test
b
There was no additional cases detected after April 2, 2021
When the outbreak was declared, resident immunization rates
were similar for the LTC units and the SSU for COVID-19 vaccine
dose one (91.1% vs 87.7%, respectively) but were different for
vaccine dose two (82.8% of LTC residents and 22.8% of SSU
residents had received their second dose). Staff full vaccination
rate decreased slightly from 58% to 54% during the course of the
outbreak; however, partial vaccination rate increased from 6% to
19% from the date that the outbreak was declared until it was
declared over.
Ten of 29 cases were asymptomatic: all were resident cases and
were identified as part of the asymptomatic testing conducted in
response to the outbreak (Table 1). Six of the ten asymptomatic
cases were fully vaccinated. Eight of the 26 resident cases were
hospitalized and there were three COVID-19-related deaths.
All deaths occurred among cases that were at least partially
vaccinated and four of the eight hospitalizations were also
among partially vaccinated cases (Table 2).
Asymptomatic COVID-19 polymerase chain reaction testing
was performed in a ring screen model, with the highest-risk
asymptomatic resident and staff contacts tested first, and with
subsequent testing in more remote contacts as additional cases
were identified. Asymptomatic testing was performed at five
to seven-day intervals, in multiple rounds based on the level of
COVID-19 activity in the staff and residents on a particular unit.
Table 1: Characteristics of COVID-19 cases included in the outbreak investigation by role (resident/staff) (N=29)
Characteristics of the cases
Total cases
Residents
Number
Staff
%
Number
Total
%
Number
%
26
100.0%
3
100.0%
29
100.0%
4
15.4%
1
33.3%
3
10.3%
16
61.5%
2
66.7%
10
34.5%
Younger than 30 years
0
0.0%
0
0.0%
0
0.0%
30–39 years
0
0.0%
1
33.3%
1
3.4%
Sex
Males
Females
Age group
Page 545
CCDR • December 2021 • Vol. 47 No. 12
OUTBREAK
Table 1: Characteristics of COVID-19 cases included in the outbreak investigation by role (resident/staff) (N=29)
(continued)
Characteristics of the cases
Residents
Number
Staff
%
Number
Total
%
Number
%
40–49 years
1
3.8%
0
0.0%
1
3.4%
50–59 years
0
0.0%
2
66.7%
2
6.9%
60–69 years
0
0.0%
0
0.0%
0
0.0%
70–79 years
5
19.2%
0
0.0%
5
17.2%
80–89 years
11
42.3%
0
0.0%
11
37.9%
9
34.6%
0
0.0%
9
31.0%
90+ years
Unit
A (SSU)
17
65.4%
0
0.0%
17
58.6%
B (LTC)
7
26.9%
1
33.3%
8
27.6%
D (LTC)
2
7.7%
1
33.3%
3
10.3%
Entire facility
0
0.0%
1
33.3%
0
0.0%
Unvaccinated
9
34.6%
3
100.0%
11
37.9%
Partially vaccinated
9
34.6%
0
0.0%
10
34.5%
Fully vaccinated
8
30.8%
0
0.0%
8
27.6%
Any (total)
17
65.4%
0
0.0%
17
58.6%
Cardiac disease
13
50.0%
0
0.0%
14
48.3%
Pulmonary disease
5
19.2%
0
0.0%
7
24.1%
Kidney disease
2
7.7%
0
0.0%
5
17.2%
Other
6
23.1%
0
0.0%
10
34.5%
None
9
34.6%
3
100.0%
12
41.4%
Asymptomatic
10
38.5%
0
0.0%
10
34.5%
Symptomatic
5
19.2%
3
100.0%
8
27.6%
Hospitalized
8
30.8%
0
0.0%
8
27.6%
ICU
0
0.0%
0
0.0%
0
0.0%
Death
3
11.5%
0
0.0%
3
10.3%
B.1.160
16
61.5%
2
66.7%
18
62.1%
B.1.36
1
3.8%
0
0.0%
1
3.4%
Insufficient nucleic acid for WGS
9
34.6%
1
33.3%
10
34.5%
Less than 30.0
17
65.4%
2
66.7%
19
65.5%
30.0 or higher
9
34.6%
1
33.3%
10
34.5%
Vaccination status
Chronic medical conditionsa
Disease status
SARS-CoV-2 lineage
Ct value
Abbreviations: COVID-19, coronavirus disease 2019; Ct value, cycle threshold value; ICU, intensive care unit; LTC, long-term care; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2;
SSU, short stay unit; WGS, whole genome sequencing
a
Breakdown of type chronic medical conditions may add to more than 100% as it was possible for cases to have more than one condition
CCDR • December 2021 • Vol. 47 No. 12
Page 546
OUTBREAK
Table 2: Characteristics of COVID-19 cases included in the outbreak investigation by vaccination status (N=29)
Characteristics of the cases
Total cases
Unimmunized
Number
Partially vaccinated
%
Number
%
Fully vaccinated
Number
%
12
100.0%
9
100.0%
8
100.0%
Males
3
25.0%
2
20.2%
1
12.5%
Females
9
75.0%
8
88.9%
7
87.5%
Younger than 30 years
0
0.0%
0
0.0%
0
0.0%
30–39 years
1
8.3%
0
0.0%
0
0.0%
40–49 years
1
8.3%
0
0.0%
0
0.0%
50–59 years
2
16.7%
0
0.0%
0
0.0%
60–69 years
0
0.0%
0
0.0%
0
0.0%
70–79 years
2
16.7%
1
11.1%
2
25.0%
80–89 years
5
41.7%
3
33.3%
3
37.5%
90+ years
1
8.3%
5
55.6%
3
37.5%
Resident
9
75.0%
9
100.0%
8
100.0%
Staff
3
25.0%
0
0.0%
0
0.0%
A (SSU)
8
66.7%
7
77.8%
2
25.0%
B (LTC)
1
8.3%
1
11.1%
6
75.0%
D (LTC)
2
16.7%
1
11.1%
0
0.0%
Entire facility
1
8.3%
0
0.0%
0
0.0%
Any (total)
5
41.7%
7
77.8%
5
62.5%
Cardiac disease
3
25.0%
5
55.6%
5
62.5%
Pulmonary disease
2
16.7%
2
22.2%
1
12.5%
Kidney disease
1
8.3%
0
0.0%
1
12.5%
Other
4
33.3%
1
11.1%
1
12.5%
None
7
58.3%
2
22.2%
3
37.5%
Asymptomatic
4
33.3%
0
0.0%
6
75.0%
Symptomatic
4
33.3%
3
33.3%
1
12.5%
Hospitalized
4
33.3%
4
44.4%
0
0.0%
ICU
0
0.0%
0
0.0%
0
0.0%
Death
0
0.0%
2
22.2%
1
12.5%
8
66.7%
6
66.7%
4
50.0%
Sex
Age group
Role
Unit
Chronic medical conditionsa
Disease status
SARS-CoV-2 lineage
B.1.160
B.1.36
1
8.3%
0
0.0%
0
0.0%
Insufficient nucleic acid for WGS
3
25.0%
3
33.3%
4
50.0%
Less than 30.0
10
83.3%
6
66.7%
3
37.5%
30.0 or higher
2
16.7%
3
33.3%
5
62.5%
Ct value
Abbreviations: COVID-19, coronavirus disease 2019; Ct value, cycle threshold value; ICU, intensive care unit; LTC, long-term care; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2;
SSU, short stay unit; WGS, whole genome sequencing
a
Breakdown of type chronic medical conditions may add to more than 100% as it was possible for cases to have more than one condition
Page 547
CCDR • December 2021 • Vol. 47 No. 12
OUTBREAK
Of the 26 resident cases, 17 were fully or partially vaccinated
(Table 1). All three staff cases within this outbreak were
unvaccinated. The majority of cases that were considered fully
vaccinated break through cases was from Unit B, where residents
had higher opportunity to get their second dose of vaccine
compared with other units. The majority of cases that were
considered unvaccinated was from the SSU (Table 2).
All the samples from resident cases that were successfully
sequenced at SSU and Unit B were identified as the SARS-CoV-2
lineage B.1.160 (n=13). All thirteen B.1.160 cases cluster
together within three mutations. However, one resident case at
Unit D was successfully sequenced and was genetically different,
identified as B.1.136 lineage (Figure 2). Ten cases had cycle
threshold (Ct) values over 30.0, nine of whom were asymptomatic
cases. Eight of ten cases with higher Ct values were among those
considered at least partially vaccinated (Table 1 and Table 2).
Despite its smaller bed capacity compared with the other facility
units, 17 of the 26 cases were from the SSU where the index case
occurred. The attack rate at SSU was 28%. A higher proportion
of resident cases were females with ages above 80 years that
reflected the demographic profile in the facility. Seventeen of
26 resident cases (65%) had some underlying chronic medical
condition, and this proportion was higher among residents
from the LTC unit (Table 3). The disease outcomes were more
prominent amongst the resident of SSU as there were higher
proportion of severe outcomes that occurred in this unit
compared with the other two units.
The average attack rate at the facility was 10% in residents and
less than 1% in staff. The resident attack rate in the short stay
unit of the facility was 22% compared with 4% in the LTC units.
Clinical Operations was able to arrange on site vaccination for
residents. Staff were provided with educational material about
vaccination and were strongly encouraged to access vaccine
through local public health facilities. The proportion of resident
vaccination rate did not change significantly during the course
of the outbreak. Staff immunization with at least one dose of
vaccine increased from 63.8% to 72.5%.
Table 3: Characteristics of COVID-19 resident cases included in the outbreak investigation by unit (N=26)
Characteristics of the cases
Total resident cases
Unit A (SSU)
Number
Unit B (LTC)
%
Number
Unit D (LTC)
%
Number
%
17
100.0%
7
100.0%
2
100.0%
Sex
Males
2
11.8%
1
14.3%
0
0.0%
15
88.2%
6
85.7%
2
100.0%
Younger than 70 years
0
0.0%
0
0.0%
1
50.0%
70–79 years
4
23.5%
1
14.3%
0
0.0%
80–89 years
9
52.9%
2
28.6%
0
0.0%
90+ years
4
23.5%
4
57.1%
1
50.0%
Unvaccinated
8
47.1%
0
0.0%
1
50.0%
Partially vaccinated
7
41.2%
1
14.3%
1
50.0%
Fully vaccinated
2
11.8%
6
85.7%
0
0.0%
Females
Age group
Vaccination status
Chronic medical conditionsa
Any (total)
10
58.8%
5
71.4%
2
100.0%
Cardiac disease
7
41.2%
5
71.4%
1
50.0%
Pulmonary disease
4
23.5%
1
14.3%
0
0.0%
Kidney disease
1
5.9%
1
14.3%
0
0.0%
Other
4
23.5%
1
14.3%
1
50.0%
None
7
41.2%
2
28.6%
0
0.0%
Asymptomatic
4
23.5%
5
71.4%
1
50.0%
Symptomatic
4
23.5%
0
0.0%
1
50.0%
Hospitalized
7
41.2%
1
14.3%
0
0.0%
ICU
0
0.0%
0
0.0%
0
0.0%
Death
2
11.8%
1
14.3%
0
0.0%
Disease status
CCDR • December 2021 • Vol. 47 No. 12
Page 548
OUTBREAK
Table 3: Characteristics of COVID-19 resident cases included in the outbreak investigation by unit (N=26)
(continued)
Characteristics of the cases
Unit A (SSU)
Number
Unit B (LTC)
%
Number
Unit D (LTC)
%
Number
%
SARS-CoV-2 lineage
B.1.160
12
70.6%
4
57.1%
0
0.0%
B.1.36
0
0.0%
0
0.0%
1
50.0%
Insufficient nucleic acid for WGS
5
29.4%
3
42.9%
1
50.0%
Less than 30.0
13
76.5%
3
42.9%
1
50.0%
30.0 or higher
4
23.5%
4
57.1%
1
50.0%
Ct value
Abbreviations: COVID-19, coronavirus disease 2019; Ct value, cycle threshold value; ICU, intensive care unit; LTC, long-term care; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SSU,
short stay unit; WGS, whole genome sequencing
a
Breakdown of type chronic medical conditions may add to more than 100% as it was possible for cases to have more than one condition
Figure 2: Phylogenetic tree demonstrating severe acute respiratory syndrome coronavirus 2 genetic diversity of
the cases linked to the outbreaka
Abbreviation: SSU, short stay unit
a
This tree is rooted to the original Wuhan reference strain, and displays sequences based on the number of mutations that differ from this reference strain (x-axis). Cases belonging to the outbreak are
displayed as light blue and green dots on the tree tips
Discussion
An outbreak in a LTC Facility in Kelowna represented one of
the few LTC outbreaks after introduction of vaccination to this
population in British Columbia. The attack rate in residents at the
facility was considerably lower than the average attack rate for
COVID-19 outbreaks in LTC facilities before the vaccine rollout
and the number of asymptomatic cases was relatively higher. To
compare the numbers, the average attack rate for COVID-19
outbreaks in LTC facilities before the vaccine rollout was 45%
(ranging from 5% to 90%). The average attack rate of the facility
outbreaks is calculated based on the information on declared
outbreaks and total cases available on British Columbia Centre
for Disease Control website (15).
Page 549
CCDR • December 2021 • Vol. 47 No. 12
In this outbreak, most of the breakthrough cases were among the
partially vaccinated residents. This finding is consistent with two
cohort studies that show lower antibody response to first dose
of vaccination in population older than 80 years of age (16,17).
Six of 10 cases that were identified among the fully vaccinated
residents were detected by asymptomatic testing with high
Ct values. Similarly, another study demonstrated complete
vaccination with messenger ribonucleic acid (mRNA) vaccines to
be 94% effective against hospitalization for adults, while partial
vaccination was 65% effective against hospitalization for adults
older than 65 years of age (18).
The LTC facilities in IH had an overall low vaccination rate (68%)
at the time of this outbreak, which contributed to the ongoing
transmission. Shared dietary and housekeeping staff between
OUTBREAK
the LTC units and SSU was another factor that likely facilitated
introduction of the infection to different units. Despite efforts
to increase staff vaccination rate, the rate of full vaccination
decreased slightly during the outbreak (from 58% to 54%). The
slight decrease was due to staff movement in and out of the
facility during the course of outbreak management. Outbreak
protocols were successful in increasing the partial vaccination
rate among staff. In addition, the structural characteristics of
the facility (a large, aging building and multi-bed rooms) likely
contributed to the outbreak.
Unit A (short stay unit)
The attack rate was higher in the SSU than in the LTC units. The
residents were not required to be vaccinated prior to arrival at
SSU and due to the transient nature of resident’s visit at this
unit, complete immunization rate was lower than LTC side. High
turnover at the facility and high volume of traffic through the
facility due to rehabilitation services were other factors that
likely facilitated transmission within the unit. Recurrent transfers
between this unit and a nearby acute care setting increased the
need for vigilant screening of the admissions.
The resident partial vaccination rate at this unit was high before
the outbreak and did not have a meaningful change during the
course of the outbreak; however, staff vaccination rate increased
by 10%. The strict outbreak measures and the improved
vaccination rate and/or acquisition of natural immunity following
infection facilitated outbreak management. However, due to
the limited vaccine supply and to accelerate the initiation of
vaccination in the population, a decision was made provincially
to extend the interval between the first and second dose of
vaccination at the beginning of March 2021 (19,20). Therefore,
full vaccination of some of the residents and staff was delayed.
All of the cases that required hospitalization at this unit were
partially or fully vaccinated and had chronic medical conditions.
Two deaths were reported in partially or fully vaccinated
individuals with multiple underlying chronic medical conditions.
Their deaths were primarily related to their underlying conditions
and COVID-19 infection was a contributory factor.
Unit B (long-term care)
The cases at this unit were linked to the SSU (Figure 2). While all
the confirmed cases were considered partially or fully vaccinated,
these definitions rely on an assessment of status at episode date.
Most of the cases diagnosed had Ct values in higher ranges and
were asymptomatic. It is possible that the cases may have had
earlier infections that were not detected until they underwent
asymptomatic testing. It is also possible that since most of
these cases were fully vaccinated, they had lower viral load and
decreased severity of infection.
Unit D (long-term care)
The initial case at this unit was transferred to the LTC from an
acute care setting. This resident then transmitted infection to
one other resident on the unit. These two cases identified on this
unit were unvaccinated and were transferred to the SSU early
in the course of the outbreak for cohorting purposes. The viral
lineage identified for these cases was the same as that from the
acute care facility outbreak, demonstrating that these two cases
were unrelated to the outbreak in the rest of the facility.
Strengths and limitations
This is one of the initial studies describing an outbreak in a LTC
setting after the introduction of the COVID-19 vaccination. It
includes a comprehensive assessment of the cases that were
partially or fully vaccinated to contribute to the growing body
of evidence concerning the attack rate and disease outcome in
immunized individuals. In addition, whole genome sequencing
and phylogenetic assessment supplemented the epidemiologic
investigation to clarify the disease transmission patterns. This
study demonstrates the complexity of managing an outbreak
in this setting and can inform outbreak prevention and
management in LTC facilities.
A number of factors limits this study. A proper assessment of
vaccine effectiveness and disease outcome requires a larger
sample size to compare between vaccinated and unvaccinated
groups, in order to adjust for confounding factors that can
contribute to severe symptoms in population with advanced age.
However, the number of cases linked to this outbreak was small
and the cases were heterogeneous and belonged to different
cohorts with distinct lineages of virus, limiting the power of
statistical analysis. In addition, due to the specific characteristics
of the outbreak and the facility, the findings may not be
generalizable to other settings.
Conclusion
This descriptive analysis is consistent with other investigations
demonstrating that partial or complete COVID-19 vaccination
provides protection for residents of LTC facilities, prevents
severe infection and outcomes and highlights the importance of
vaccination in these settings. However, breakthrough infections
occur, and may be more common in elderly individuals due
to their less robust immune response to vaccination (4,18,19).
This highlights the importance of continued vigilance regarding
general IPAC measures, such as use of appropriate personal
protective equipment, routine symptom screening and rapid
isolation and testing of individuals who experience COVID-19
symptoms. In addition, since asymptomatic or mild infection
appears more common in immunized individuals, asymptomatic
testing is a critical tool for identifying and isolating cases before
further transmission occurs.
CCDR • December 2021 • Vol. 47 No. 12
Page 550
OUTBREAK
Authors’ statement
3.
Thompson MG, Burgess JL, Naleway AL, Tyner HL,
Yoon SK, Meece J, Olsho LE, Caban-Martinez AJ,
Fowlkes A, Lutrick K, Kuntz JL, Dunnigan K, Odean MJ,
Hegmann KT, Stefanski E, Edwards LJ, Schaefer-Solle N,
Grant L, Ellingson K, Groom HC, Zunie T, Thiese MS, Ivacic L,
Wesley MG, Lamberte JM, Sun X, Smith ME, Phillips AL,
Groover KD, Yoo YM, Gerald J, Brown RT, Herring MK,
Joseph G, Beitel S, Morrill TC, Mak J, Rivers P, Harris KM,
Hunt DR, Arvay ML, Kutty P, Fry AM, Gaglani M. Interim
Estimates of Vaccine Effectiveness of BNT162b2 and
mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2
Infection Among Health Care Personnel, First Responders,
and Other Essential and Frontline Workers - Eight U.S.
Locations, December 2020-March 2021. MMWR Morb
Mortal Wkly Rep 2021;70(13):495–500. DOI PubMed
4.
Britton A, Jacobs Slifka KM, Edens C, Nanduri SA, Bart SM,
Shang N, Harizaj A, Armstrong J, Xu K, Ehrlich HY, Soda E,
Derado G, Verani JR, Schrag SJ, Jernigan JA, Leung VH,
Parikh S. Effectiveness of the Pfizer-BioNTech COVID-19
Vaccine Among Residents of Two Skilled Nursing Facilities
Experiencing COVID-19 Outbreaks - Connecticut,
December 2020-February 2021. MMWR Morb Mortal Wkly
Rep 2021;70(11):396–401. DOI PubMed
5.
Teran RA, Walblay KA, Shane EL, Xydis S, Gretsch S,
Gagner A, Samala U, Choi H, Zelinski C, Black SR.
Postvaccination SARS-CoV-2 Infections Among Skilled
Nursing Facility Residents and Staff Members - Chicago,
Illinois, December 2020-March 2021. MMWR Morb Mortal
Wkly Rep 2021;70(17):632–8. DOI PubMed
6.
White EM, Yang X, Blackman C, Feifer RA, Gravenstein S,
Mor V. Incident SARS-CoV-2 Infection among
mRNA-Vaccinated and Unvaccinated Nursing Home
Residents. N Engl J Med 2021;385(5):474–6. DOI PubMed
7.
Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL,
Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE,
Briner C, Kwatra G, Ahmed K, Aley P, Bhikha S, Bhiman JN,
Bhorat AE, du Plessis J, Esmail A, Groenewald M, Horne E,
Hwa SH, Jose A, Lambe T, Laubscher M, Malahleha M,
Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A,
Oelofse S, Patel F, Pillay S, Rhead S, Rodel H, Rossouw L,
Taoushanis C, Tegally H, Thombrayil A, van Eck S,
Wibmer CK, Durham NM, Kelly EJ, Villafana TL, Gilbert S,
Pollard AJ, de Oliveira T, Moore PL, Sigal A, Izu A; NGS-SA
Group; Wits-VIDA COVID Group. Efficacy of the ChAdOx1
nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N
Engl J Med 2021;384(20):1885–98. DOI PubMed
8.
Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M,
Caspi I, Levy R, Leshchinsky M, Ken Dror S, Bergerzon G,
Gadban H, Gadban F, Eliassian E, Shimron O, Saleh L,
Ben-Zvi H, Keren Taraday E, Amichay D, Ben-Dor A, Sagas D,
Strauss M, Shemer Avni Y, Huppert A, Kepten E, Balicer RD,
Netzer D, Ben-Shachar S, Stern A. Evidence for increased
breakthrough rates of SARS-CoV-2 variants of concern in
BNT162b2-mRNA-vaccinated individuals.
Nat Med 2021;27(8):1379–84. DOI PubMed
FS — Writing original draft, review and editing, project
administration
BG — Methodology and analysis, writing review and editing
MS — Methodology and analysis, writing review and editing
AW — Conceptualization, investigation and resources, writing
original draft, review and editing
NP — Investigation and resources, writing review and editing
PR — Investigation and resources, writing review and editing
MA — Investigation and resources, writing review and editing
SP — Conceptualization, supervision, writing review and editing
Competing interests
None.
Acknowledgements
The outbreak management team acknowledges all the
individuals at the Interior Health Authority who contributed
to the outbreak investigation and management. In addition,
the authors acknowledge Dr. Danuta Skowronski’s invaluable
contribution to this article.
Funding
This work was supported by the Interior Health Authority.
References
1.
McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M,
Schwartz NG, Lewis J, Baer A, Kawakami V, Lukoff MD,
Ferro J, Brostrom-Smith C, Rea TD, Sayre MR, Riedo FX,
Russell D, Hiatt B, Montgomery P, Rao AK, Chow EJ,
Tobolowsky F, Hughes MJ, Bardossy AC, Oakley LP,
Jacobs JR, Stone ND, Reddy SC, Jernigan JA, Honein
MA, Clark TA, Duchin JS; Public Health–Seattle and King
County, EvergreenHealth, and CDC COVID-19 Investigation
Team. Epidemiology of Covid-19 in a Long-Term Care
Facility in King County, Washington. N Engl J Med
2020;382(21):2005–11. DOI PubMed
2.
Vilches TN, Nourbakhsh S, Zhang K, Juden-Kelly L,
Cipriano LE, Langley JM, Sah P, Galvani AP, Moghadas SM.
Multifaceted strategies for the control of COVID-19
outbreaks in long-term care facilities in Ontario, Canada.
Prev Med 2021;148:106564. DOI PubMed
Page 551
CCDR • December 2021 • Vol. 47 No. 12
OUTBREAK
9.
Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M,
Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F,
Gaebler C, Lifton R, Nussenzweig MC, Hatziioannou T,
Bieniasz PD, Darnell RB. Vaccine Breakthrough
Infections with SARS-CoV-2 Variants. N Engl J Med
2021;384(23):2212–8. DOI PubMed
10. BC Centre for Disease Control. British Columbia (BC)
COVID-19 Situation Report, Week 9: Feb 28-March 6, 2021.
BCCDC; 2021 (accessed 2021-04-30). http://www.bccdc.ca/
Health-Info-Site/Documents/COVID_sitrep/Week_9_2021_
BC_COVID-19_Situation_Report.pdf
11. BC Centre for Disease Control. COVID-19 Infection
prevention and Control: Guidance for Long-term care and
seniors’ assisted living settings. BCCDC; 2021 (accessed
2021-04-30). http://www.bccdc.ca/Health-Info-Site/
Documents/COVID19_LongTermCareAssistedLiving.pdf
12. BC Centre for Disease Control. British Columbia (BC)
COVID-19: Outbreak management protocol for acute
care, long-term care and seniors’ assisted living setting.
BCCDC; 2021 (accessed 2021-04-30). http://www.bccdc.ca/
Health-Professionals-Site/Documents/COVID-19_Provincial_
Outbreak_Management_Protocol_LTC.pdf
13. BC Centre for Disease Control. COVID-19 Case Report
Form. BCCDC; 2021. (accessed 2021-04-31). http://www.
bccdc.ca/Documents/COVID-19_Case_Report_Form.pdf
14. BC Centre for Disease Control. Interim Guidance: Public
health management of cases and contacts associated
with novel coronavirus (COVID-19) in the community.
BCCDC; 2021 (accessed 2021-08-20). http://www.bccdc.
ca/resource-gallery/Documents/Guidelines%20and%20
Forms/Guidelines%20and%20Manuals/Epid/CD%20Manual/
Chapter%201%20-%20CDC/2019-nCoV-Interim_Guidelines.
pdf
17. Collier DA, Ferreira IATM, Kotagiri P, Datir RP, Lim EY,
Touizer E, Meng B, Abdullahi A; CITIID-NIHR BioResource
COVID-19 Collaboration, Elmer A, Kingston N, Graves B,
Le Gresley E, Caputo D, Bergamaschi L, Smith KGC,
Bradley JR, Ceron-Gutierrez L, Cortes-Acevedo P,
Barcenas-Morales G, Linterman MA, McCoy LE, Davis C,
Thomson E, Lyons PA, McKinney E, Doffinger R, Wills M,
Gupta RK. Age-Related immune responses to SARS-CoV-2
vaccine BNT162b2. Nature. 2021;596(7872):417-22.
DOI PubMed
18. Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ,
Steingrub JS, Shapiro NI, Ginde AA, Douin DJ, Prekker ME,
Brown SM, Peltan ID, Gong MN, Mohamed A, Khan A,
Exline MC, Files DC, Gibbs KW, Stubblefield WB, Casey JD,
Rice TW, Grijalva CG, Hager DN, Shehu A, Qadir N,
Chang SY, Wilson JG, Gaglani M, Murthy K, Calhoun N,
Monto AS, Martin ET, Malani A, Zimmerman RK, Silveira FP,
Middleton DB, Zhu Y, Wyatt D, Stephenson M, Baughman A,
Womack KN, Hart KW, Kobayashi M, Verani JR, Patel MM;
IVY Network; HAIVEN Investigators. Effectiveness of
Pfizer-BioNTech and Moderna Vaccines Against COVID-19
Among Hospitalized Adults Aged ≥65 Years - United
States, January-March 2021. MMWR Morb Mortal Wkly Rep
2021;70(18):674–9. DOI PubMed
19. Quach C, Deeks S. COVID-19 vaccination: why extend the
interval between doses? JAMMI 2021;6(2):73–8. DOI
20. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A,
Lockhart S, Perez JL, Pérez Marc G, Moreira ED,
Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury
K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt
LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB,
Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber
WC; C4591001 Clinical Trial Group. Safety and Efficacy
of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med
2020;383(27):2603–15. DOI PubMed
15. BC Centre for Disease Control. Weekly COVID-19 long term
care assisted living & independent living outbreak report.
BCCDC; 2021 (accessed 2021-08-20). http://www.bccdc.
ca/Health-Info-Site/Documents/COVID_sitrep/Weekly_
COVID-19_Outbreak_Report_05062021.pdf
16. Müller L, Andrée M, Moskorz W, Drexler I, Walotka L,
Grothmann R, Ptok J, Hillebrandt J, Ritchie A, Rabl D,
Ostermann PN, Robitzsch R, Hauka S, Walker A, Menne C,
Grutza R, Timm J, Adams O, Schaal H. Age-dependent
immune response to the Biontech/Pfizer BNT162b2
COVID-19 vaccination. Clin Infect Dis. 2021 Apr 27:ciab381.
DOI PubMed
CCDR • December 2021 • Vol. 47 No. 12
Page 552
CCDR
CANADA
COMMUNICABLE
DISEASE REPORT
Public Health Agency of Canada
130 Colonnade Road
Address Locator 6503B
Ottawa, Ontario K1A 0K9
ccdr-rmtc@phac-aspc.gc.ca
To promote and protect the health of Canadians
through leadership, partnership, innovation and action
in public health.
Public Health Agency of Canada
Published by authority of the Minister of Health.
© This work is licensed under a Creative Commons
Attribution 4.0 International License.
This publication is also available online at
https://www.canada.ca/ccdr
Également disponible en français sous le titre :
Relevé des maladies transmissibles au Canada